<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006387" GROUP_ID="ORAL" ID="599306062612513317" MERGED_FROM="" MODIFIED="2010-11-10 15:11:10 +0100" MODIFIED_BY="Luisa Fernandez Mauleffinch" REVIEW_NO="0185" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2010-11-10 12:12:00 +0000" MODIFIED_BY="Luisa Fernandez Mauleffinch">
<TITLE MODIFIED="2010-09-10 10:35:11 +0100" MODIFIED_BY="[Empty name]">Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy</TITLE>
<CONTACT>
<PERSON ID="7514" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Anne-Marie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Glenny</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer in Evidence Based Oral Health Care</POSITION>
<EMAIL_1>a.glenny@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Oral Health Group</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building, Oxford Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 275 7811</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 275 7815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-11-10 12:12:00 +0000" MODIFIED_BY="Luisa Fernandez Mauleffinch">
<PERSON ID="7514" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Anne-Marie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Glenny</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer in Evidence Based Oral Health Care</POSITION>
<EMAIL_1>a.glenny@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Oral Health Group</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building, Oxford Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 275 7811</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 275 7815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="50BB1C5582E26AA20094E4F45CBA083C" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Susan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Furness</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>Susan.Furness@manchester.ac.uk</EMAIL_1>
<EMAIL_2>suefurness@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Oral Health Group, School of Dentistry</DEPARTMENT>
<ORGANISATION>The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Bldg, Oxford Rd</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 275 6877</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 275 7815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8328" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Helen</FIRST_NAME>
<MIDDLE_INITIALS>V</MIDDLE_INITIALS>
<LAST_NAME>Worthington</LAST_NAME>
<SUFFIX/>
<POSITION>Co-ordinating Editor</POSITION>
<EMAIL_1>helen.worthington@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Oral Health Group</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building, Oxford Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 306 0237</PHONE_1>
<PHONE_2>+44 161 275 7819</PHONE_2>
<FAX_1>+44 161 275 7815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="E89644D582E26AA200334BFE73114296" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS>I</MIDDLE_INITIALS>
<LAST_NAME>Conway</LAST_NAME>
<SUFFIX/>
<POSITION>Lecturer in Dental Public Health</POSITION>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Glasgow Dental School</DEPARTMENT>
<ORGANISATION>University of Glasgow</ORGANISATION>
<ADDRESS_1>378 Sauchiehall Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Glasgow</CITY>
<ZIP>G2 3JZ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15545" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Richard</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Oliver</LAST_NAME>
<SUFFIX/>
<POSITION>Specialist in Oral Surgery</POSITION>
<EMAIL_1>richard.oliver@redonline.org</EMAIL_1>
<EMAIL_2>oral.surgeon@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>RED (Research and Education in Dentistry)</ORGANISATION>
<ADDRESS_1>10 Longbow Close, Harlescott Lane</ADDRESS_1>
<ADDRESS_2/>
<CITY>Shrewsbury</CITY>
<ZIP>SY1 3GZ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7294" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jan</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Clarkson</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>j.e.clarkson@chs.dundee.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Dental Health Services &amp; Research Unit, University of Dundee, Dundee</DEPARTMENT>
<ORGANISATION>Cochrane Oral Health Group, The University of Manchester</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="E896463C82E26AA200334BFEA83C1697" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Michaelina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Macluskey</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical Lecturer/ Honorary Specialist Registrar in Oral and Maxillofacial Surgery</POSITION>
<EMAIL_1>m.macluskey@dundee.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Unit of Oral Surgery and Medicine</DEPARTMENT>
<ORGANISATION>University of Dundee</ORGANISATION>
<ADDRESS_1>University of Dundee Dental Hospital and School</ADDRESS_1>
<ADDRESS_2>Park Place</ADDRESS_2>
<CITY>Dundee</CITY>
<ZIP>DD1 4NR</ZIP>
<REGION>Scotland</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>01382660111 ext: 35889</PHONE_1>
<PHONE_2/>
<FAX_1>01382635989</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8E24013282E26AA20024C3AA23CEC3BE" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sue</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pavitt</LAST_NAME>
<SUFFIX/>
<POSITION>Director of the Comprehensive Health Research Division, Senior Lecturer in Clinical Trials Research</POSITION>
<EMAIL_1>S.Pavitt@leeds.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Trials Research Unit</DEPARTMENT>
<ORGANISATION>University of Leeds</ORGANISATION>
<ADDRESS_1>Clinical Trials Research House</ADDRESS_1>
<ADDRESS_2>71-75 Clarendon Road</ADDRESS_2>
<CITY>Leeds</CITY>
<ZIP>LS2 9NP</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 113 343 8609</PHONE_1>
<PHONE_2/>
<FAX_1>+44 113 343 1471</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="67864607554256799237100528122752" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kelvin</FIRST_NAME>
<MIDDLE_INITIALS>KW</MIDDLE_INITIALS>
<LAST_NAME>Chan</LAST_NAME>
<SUFFIX/>
<POSITION>Staff Medical Oncologist</POSITION>
<EMAIL_1>Dr.Kelvin.Chan@uhn.on.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Princess Margaret Hospital</ORGANISATION>
<ADDRESS_1>610 University Avenue</ADDRESS_1>
<ADDRESS_2/>
<CITY>Toronto</CITY>
<ZIP>M5G 2M9</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="06534392732467886944091001154200" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Brocklehurst</LAST_NAME>
<SUFFIX/>
<POSITION>Specialist Registrar &amp; Clinical Teaching Fellow in Dental Public Health</POSITION>
<EMAIL_1>paul.brocklehurst@hotmail.co.uk</EMAIL_1>
<EMAIL_2>paul.brocklehurst@postgrad.manchester.ac.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building</ADDRESS_1>
<ADDRESS_2>Oxford Road</ADDRESS_2>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="3A76016E82E26AA200D5E26B77F1B451" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME/>
<MIDDLE_INITIALS/>
<LAST_NAME>The CSROC Expert Panel</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Oral Health Group</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building, Oxford Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 275 7818</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 275 7815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2010-11-05 11:32:51 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="5" MONTH="11" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="28" MONTH="7" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="10" MONTH="12" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2010-11-05 11:33:00 +0000" MODIFIED_BY="[Empty name]"/>
<HISTORY/>
<SOURCES_OF_SUPPORT MODIFIED="2010-11-05 17:11:44 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-11-05 17:11:44 +0000" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>School of Dentistry, The University of Manchester</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Cochrane Oral Health Group</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>The University of Dundee</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>The University of Glasgow</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2010-11-05 17:11:44 +0000" MODIFIED_BY="[Empty name]">
<NAME>Manchester Academic Health Sciences Centre (MAHSC) and NIHR Manchester Biomedical Research Centre</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>National Institute of Health, National Institute of Dental &amp; Craniofacial Research</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Central Manchester &amp; Manchester Children's University Hospitals NHS Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-11-10 12:22:00 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-11-10 12:20:05 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-09-10 10:35:18 +0100" MODIFIED_BY="[Empty name]">Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy</TITLE>
<SUMMARY_BODY MODIFIED="2010-11-10 12:20:05 +0000" MODIFIED_BY="[Empty name]">
<P>Oral cavity (mouth) cancer is usually detected earlier and treated with surgery and radiotherapy. Oropharyngeal (throat) cancer may be at an advanced stage when it is found and is treated with radiotherapy. Both surgery and radiotherapy may be associated with disfigurement and decreased ability to eat, drink and talk. Recent advances show that by altering how the radiotherapy is given to patients, improvements in overall survival can be achieved. The new methods of giving radiotherapy are called accelerated fractionation or hyperfractionation. However, they may be associated with an increase in side effects.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-11-05 11:35:45 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-09-10 10:14:44 +0100" MODIFIED_BY="[Empty name]">
<P>The management of advanced oral cavity and oropharyngeal cancers is problematic and has traditionally relied on surgery and radiotherapy, both of which are associated with substantial adverse effects. Radiotherapy has been in use since the 1950s and has traditionally been given as single daily doses. This method of dividing up the total dose, or fractionation, has been modified over the years and a variety of approaches have been developed with the aim of improving survival whilst maintaining acceptable toxicity.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-09-10 10:24:01 +0100" MODIFIED_BY="[Empty name]">
<P>To determine which radiotherapy regimens for oral cavity and oropharyngeal cancers result in increased overall survival, disease free survival, progression free survival and locoregional control.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-11-05 11:35:45 +0000" MODIFIED_BY="[Empty name]">
<P>The following electronic databases were searched: the Cochrane Oral Health Group's Trials Register (to 28 July 2010), CENTRAL (<I>The Cochrane Library</I> 2010, Issue 3), MEDLINE via OVID (1950 to 28 July 2010) and EMBASE via OVID (1980 to 28 July 2010). There were no restrictions regarding language or date of publication.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-09-10 10:21:32 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials where more than 50% of participants had primary tumours of the oral cavity or oropharynx, and which compared two or more radiotherapy regimens, radiotherapy versus other treatment modality, or the addition of radiotherapy to other treatment modalities.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-10-08 11:33:21 +0100" MODIFIED_BY="[Empty name]">
<P>Data extraction and assessment of risk of bias was undertaken independently by two or more authors. Study authors were contacted for additional information as required. Adverse events data were collected from published trials.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-11-05 11:34:42 +0000" MODIFIED_BY="[Empty name]">
<P>30 trials involving 6535 participants were included. Seventeen trials compared some form of altered fractionation (hyperfractionation/accelerated) radiotherapy with conventional radiotherapy; three trials compared different altered fractionation regimens; one trial compared timing of radiotherapy, five trials evaluated neutron therapy and four trials evaluated the addition of pre-operative radiotherapy. Pooling trials of any altered fractionation radiotherapy compared to a conventional schedule showed a statistically significant reduction in total mortality (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76 to 0.98). In addition, a statistically significant difference in favour of the altered fractionation was shown for the outcome of locoregional control (HR 0.79, 95% CI 0.70 to 0.89). No statistically significant difference was shown for disease free survival.</P>
<P>No statistically significant difference was shown for any other comparison.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-11-05 11:35:07 +0000" MODIFIED_BY="[Empty name]">
<P>Altered fractionation radiotherapy is associated with an improvement in overall survival and locoregional control in patients with oral cavity and oropharyngeal cancers. More accurate methods of reporting adverse events are needed in order to truly assess the clinical performance of different radiotherapy regimens.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-11-10 12:22:00 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-11-10 12:22:00 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2010-11-10 12:22:00 +0000" MODIFIED_BY="[Empty name]">
<P>Oral cancers are a significant disease group globally with more than 404,000 new cases worldwide in 2002 (<LINK REF="REF-Parkin-2005" TYPE="REFERENCE">Parkin 2005</LINK>; <LINK REF="REF-Warnakulasuriya-2009" TYPE="REFERENCE">Warnakulasuriya 2009</LINK>). Oral cancers are the sixth most common cancer worldwide, accounting for an estimated 4% of all cancers. The incidence and mortality from oral cancers varies geographically; the highest age standardised rates of oral cancers are reported in parts of Europe (France, Hungary), Botswana and south central Asia (Sri Lanka, Pakistan, Bangladesh and India) (<LINK REF="REF-Parkin-2005" TYPE="REFERENCE">Parkin 2005</LINK>). There is overwhelming evidence that tobacco use, alcohol consumption and betel quid chewing are the main risk factors in the aetiology of intraoral cancer (<LINK REF="REF-La-Vecchia-1997" TYPE="REFERENCE">La Vecchia 1997</LINK>; <LINK REF="REF-Macfarlane-1995" TYPE="REFERENCE">Macfarlane 1995</LINK>). There is also strong evidence that low socio-economic status is associated with a higher incidence and poorer survival of oral cancers (<LINK REF="REF-Faggiano-1997" TYPE="REFERENCE">Faggiano 1997</LINK>). There is a higher incidence of oral cancers in men (<LINK REF="REF-Freedman-2007" TYPE="REFERENCE">Freedman 2007</LINK>) that is generally attributed to a greater exposure to the known risk factors and vast majority of cases occur in men over 50 (<LINK REF="REF-Warnakulasuriya-2009" TYPE="REFERENCE">Warnakulasuriya 2009</LINK>) and among low socio-economic groups (<LINK REF="REF-Conway-2008" TYPE="REFERENCE">Conway 2008</LINK>). However, the ratio of males to females diagnosed with oral cancers has declined from approximately 5:1 in the 1960s to less than 2:1 in 2002 (<LINK REF="REF-Parkin-2005" TYPE="REFERENCE">Parkin 2005</LINK>). Another recent trend is the increasing incidence of oral cavity and oropharyngeal cancers in younger adults in the European Union and the United States (<LINK REF="REF-Warnakulasuriya-2009" TYPE="REFERENCE">Warnakulasuriya 2009</LINK>).</P>
<P>The epidemiological data concerning 'oral cancer' obscure the fact that 'oral cancer' includes both oral cavity and oropharyngeal cancers which have clinically different aetiology, are generally diagnosed at different stages and managed in different ways. Patients with oral cavity cancers generally present with early stage disease and the primary treatment is surgery or radiotherapy or both. However, oropharyngeal cancers are likely to be advanced at the time of diagnosis and primary treatment is more likely to be radiation therapy or chemoradiation. It is now recognised that oral infection with human papilloma virus (HPV) is strongly associated with the development of oropharyngeal cancer where HPV infection is found in 40% to 60% of patients (<LINK REF="REF-D_x0027_Souza-2007" TYPE="REFERENCE">D'Souza 2007</LINK>), and HPV is thought to be associated with the increased incidence of oropharyngeal cancer (<LINK REF="REF-Hammarstedt-2006" TYPE="REFERENCE">Hammarstedt 2006</LINK>). The link between oncogenic HPV and oropharyngeal cancer is strong and has been documented in numerous studies, fulfilling the epidemiological criteria for disease causality, especially in the development of oropharyngeal cancer in non-smokers (<LINK REF="REF-Sturgis-2007" TYPE="REFERENCE">Sturgis 2007</LINK>). The proportion of patients with oropharyngeal cancer who are HPV positive has increased dramatically over recent years (<LINK REF="REF-Attner-2010" TYPE="REFERENCE">Attner 2010</LINK>; <LINK REF="REF-Ryerson-2008" TYPE="REFERENCE">Ryerson 2008</LINK>) but it is interesting to note that this group of patients have significantly improved rates of both overall survival and disease free survival (<LINK REF="REF-Fakhry-2006" TYPE="REFERENCE">Fakhry 2006</LINK>; <LINK REF="REF-Fakhry-2008" TYPE="REFERENCE">Fakhry 2008</LINK>; <LINK REF="REF-Licitra-2006" TYPE="REFERENCE">Licitra 2006</LINK>).</P>
<P>The most common cancer of the oral cavity is the squamous cell carcinoma that arises from the lining of the oral cavity; over 95% of all oral cavity cancers are squamous cell carcinomas. Despite significant technical advances in the treatment of oral cancer, it still has a significant mortality with 128,000 deaths recorded, representing nearly half of the incident cases (48%) (<LINK REF="REF-Parkin-2001" TYPE="REFERENCE">Parkin 2001</LINK>). Survival following a diagnosis of oral cavity or oropharyngeal cancer remains poor with 5-year survival around 50% overall, with only limited improvement in the past 3 decades (<LINK REF="REF-Warnakulasuriya-2009" TYPE="REFERENCE">Warnakulasuriya 2009</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-11-05 11:39:01 +0000" MODIFIED_BY="[Empty name]">
<P>Surgery has long been the mainstay for the treatment of oral cancer but radiotherapy can be used alone, in combination (adjuvant) with surgery, or in combination with chemotherapy (<LINK REF="REF-Garg-2004" TYPE="REFERENCE">Garg 2004</LINK>). Radiotherapy (also referred to as radiation therapy) is a localised treatment and thereby affects cells only in the treated area. Radiotherapy is used alone for small tumours or for patients who cannot have surgery. It may be used before surgery to kill cancer cells and shrink the tumour. It also may be used after surgery to destroy cancer cells that may remain in the area.</P>
<P>Radiotherapy works by damaging the deoxyribonucleic acid (DNA) of rapidly dividing cells so that the usual mechanisms of DNA repair (which are usually less effective in cancer cells compared to normal cells) cannot work and the cells die. However, normal cells that proliferate rapidly will inevitably be affected by therapeutic radiation. Therefore tissues such as hair, salivary glands and the mucosa are commonly affected (<LINK REF="REF-CRUK-2009" TYPE="REFERENCE">CRUK 2009</LINK>).</P>
<P>Conventional radiotherapy uses high-energy photons to kill cancer cells. Two types of radiotherapy are commonly used to treat oral and oropharyngeal cancers: teletherapy - where the radiation is produced by a linear accelerator machine (external beam). Patients undergoing this type of therapy have to go to the hospital or clinic daily, usually 5 days a week for several weeks. Alternatively they may receive radiotherapy in the form of brachytherapy (also referred to as implant radiotherapy). Here the radiation comes from a radioactive material placed in seeds, needles, or carried via thin plastic tubes and put directly into the tissue. The patient must stay in hospital for the duration of the implant therapy, typically several days. Some people with oral cancer have both kinds of radiation therapy.</P>
<P>Radiotherapy for the treatment of head and neck cancer has conventionally been given as single daily doses of 1.8 to 2.0 Gy/fraction, 5 days a week to a total dose of 66 to 70 Gy (over 6½ to 7 weeks). This method of dividing up the total dose, or fractionation, has been modified over the years based on the underlying biology of the tumours and normal host tissues and has been recently reviewed by Bernier (<LINK REF="REF-Bernier-2005" TYPE="REFERENCE">Bernier 2005</LINK>; <LINK REF="REF-Bernier-2006" TYPE="REFERENCE">Bernier 2006</LINK>). There are two main types of altered fractionation: hyperfractionation and accelerated fractionation. Hyperfractionation uses smaller, multiple daily doses over a similar duration as conventional fractionation to give a higher total dose. Typically twice daily fractions of 1.1 to 1.2 Gy/fraction to a total dose of 74 to 80 Gy are used. Accelerated fractionation uses similar total doses as conventional treatment in a reduced treatment time. Accelerated radiotherapy schedules have been developed recently to overcome tumour cell repopulation during the course of therapy (squamous cell cancers of the head and neck can double the number of cancerous cells in 3 days) (<LINK REF="STD-Bourhis-2006" TYPE="STUDY">Bourhis 2006</LINK>). Further variations have been attempted: continuous hyperfractionated accelerated radiotherapy (CHART), intensity modulated radiotherapy (IMRT) and image-guided radiotherapy (<LINK REF="REF-CRUK-2009" TYPE="REFERENCE">CRUK 2009</LINK>; <LINK REF="REF-Harari-2005" TYPE="REFERENCE">Harari 2005</LINK>).</P>
<P>When used as an adjuvant to surgery, radiotherapy has traditionally been given post-operatively particularly when there has been incomplete excision or there is extracapsular spread of the tumour out of the cervical lymph nodes. Neoadjuvant radiotherapy (given before surgery) is less common because of the deleterious effects on the tissues making surgery more difficult. Studies have shown improved survival in combination therapy where radiotherapy is given post-operatively rather than pre-operatively (<LINK REF="REF-Fanucchi-2006" TYPE="REFERENCE">Fanucchi 2006</LINK>).</P>
<P>Tumours can be resistant to radiotherapy for a variety of reasons. Very rapidly proliferating tumour cells can repopulate in between treatments (hence the case for hyperfractionation), tumour cells can be intrinsically resistant to radiation or the tumours may be hypoxic (oxygen is required to enhance the DNA damage of the radiotherapy). In view of this, chemotherapy can be added to enhance the action of radiotherapy.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2010-11-05 11:40:12 +0000" MODIFIED_BY="[Empty name]">
<P>The management of advanced oral cavity and oropharyngeal cancers is problematic and has traditionally relied on surgery and radiotherapy, both of which are associated with substantial adverse effects. Although there have been new treatments developed there has been limited improvement in survival over the past 3 decades (<LINK REF="REF-Warnakulasuriya-2009" TYPE="REFERENCE">Warnakulasuriya 2009</LINK>). Oropharyngeal cancers have relatively 'silent' symptoms which may not be present during the early stages of the disease, which is a possible explanation for the fact that stage of disease at diagnosis has not altered in the past 40 years despite public education (<LINK REF="REF-McGurk-2005" TYPE="REFERENCE">McGurk 2005</LINK>). Tumour recurrence and the development of multiple primary tumours are the major causes of treatment failure (<LINK REF="REF-Day-1992" TYPE="REFERENCE">Day 1992</LINK>; <LINK REF="REF-Partridge-2000" TYPE="REFERENCE">Partridge 2000</LINK>; <LINK REF="REF-Woolgar--2003" TYPE="REFERENCE">Woolgar 2003</LINK>). Surgical treatment may be disfiguring and result in a substantially reduced quality of life as patients are socially isolated, due to difficulties with altered appearance, speech, eating and drinking. Developments in the way in which radiotherapy is delivered aim to improve its efficacy and maintain acceptable levels of toxicity.</P>
<P>This review is undertaken as part of a series of reviews looking at the different treatment modalities of oral cancer (<LINK REF="REF-Furness-2010" TYPE="REFERENCE">Furness 2010</LINK>; <LINK REF="REF-Oliver-2007" TYPE="REFERENCE">Oliver 2007</LINK>; <LINK REF="REF-Pavitt-2007" TYPE="REFERENCE">Pavitt 2007</LINK>). These reviews have been categorised into four intervention groups: surgery, chemotherapy, radiotherapy and immunotherapy. For this radiotherapy review we will aim to answer the broad question 'Does treatment with radiotherapy, in addition to chemotherapy and/or surgery, improve the outcomes for patients with oral cavity and oropharyngeal cancers?'.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-09-10 10:23:51 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Primary objective</HEADING>
<P>To determine which radiotherapy regimens for oral cavity and oropharyngeal cancers result in increased overall survival, disease free survival, progression free survival and locoregional control.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Secondary objective</HEADING>
<P>To determine the implication of treatment modalities in terms of morbidity, quality of life, costs, hospital days of treatment, complications and harms.</P>
</SUBSECTION>
</OBJECTIVES>
<METHODS MODIFIED="2010-11-05 11:49:48 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-11-05 11:42:09 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-11-05 11:40:35 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials comparing radiotherapy to an alternative radiotherapy regimen or other treatment modality, or trials evaluating the addition of radiotherapy to other treatment modalities (including surgery and chemotherapy). Trials with a minimum follow-up of 6 months will be included. It is anticipated that there will be no studies comparing radiotherapy with placebo (although if there are such studies they will be included).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-11-05 11:41:00 +0000" MODIFIED_BY="[Empty name]">
<P>Patients with oral cancer as defined by the International Classification of Diseases for Oncology (ICD-O) codes as C01-C02, C03, C04, C05-C06 (oral cavity) and cancer of the oropharynx (ICD-O: C09, C10) will be included but hypopharynx (ICD-O: C13), nasopharynx (ICD-O: C11) and larynx (ICD-O: C32) will be excluded. Cancers of the lip (ICD-O: C00) will also be excluded (<LINK REF="REF-WHO-1992" TYPE="REFERENCE">WHO 1992</LINK>).</P>
<P>Studies of head and neck cancer with cases of oral cancer will be included (so long as at least 50% of participants who have oral cavity or oropharyngeal cancer are included, or data for these cancers alone are available separately).</P>
<P>Cancers will be primary squamous cell carcinomas arising from the oral mucosa. Histological variants of squamous cell carcinomas will be included (adenosquamous, verrucous, basaloid, papillary etc) although they are known to have differing natural history to the majority of conventional squamous cell carcinomas they have a common aetiology, their incidence is low and they are generally managed in the same way. Carcinoma in situ will be included. Epithelial malignancies of the salivary glands, odontogenic tumours, all sarcomas and lymphomas will be excluded as these have a different aetiology and are managed differently.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-11-04 10:23:16 +0000" MODIFIED_BY="[Empty name]">
<P>Radiotherapy: any mode of administration, dose of fractionation and total dose, number of fractions per day and per week, and duration of radiotherapy will be included.</P>
<P>Comparisons were made between different radiotherapy regimens and radiotherapy versus other treatment modalities including surgery and chemotherapy. The addition of radiotherapy to other treatment modalities were also be evaluated.</P>
<P>The intervention under evaluation must be radiotherapy. Trials where all participants receive the same radiotherapy regimen and are randomised to other treatments were excluded. Trials evaluating the role of chemoradiotherapy compared to radiotherapy alone are covered in the chemotherapy review by <LINK REF="REF-Furness-2010" TYPE="REFERENCE">Furness 2010</LINK>.</P>
<P>The treatments received and compared must be the primary treatment for the tumour and patients should not have received any prior intervention other than diagnostic biopsy.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-11-05 11:42:09 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measures</HEADING>
<UL>
<LI>Overall survival/total mortality (disease related mortality will also be studied if possible).</LI>
<LI>Locoregional control.</LI>
<LI>Disease free survival.</LI>
<LI>Progression free survival or time to recurrence.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<UL>
<LI>Quality of life.</LI>
<LI>Harms associated with treatment.</LI>
<LI>Direct and indirect costs to patients and health services.</LI>
<LI>Patient satisfaction.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-11-05 11:44:14 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2010-11-05 11:44:14 +0000" MODIFIED_BY="[Empty name]">
<P>This review is part of a series of Cochrane reviews on the treatment modalities for treating oral cavity and oropharyngeal cancer. The reviews have been broadly divided into four themes concerning surgery, chemotherapy, radiotherapy or immunotherapy/targeted therapies. A search strategy was developed that would encompass three of the four broad themes simultaneously (surgery, chemotherapy, radiotherapy) and further adapted for use in the following databases (date of the most recent searches as indicated):</P>
<UL>
<LI>The Cochrane Oral Health Group's Trials Register (to 28 July 2010) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>)</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2010, Issue 3) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>)</LI>
<LI>MEDLINE via OVID (1950 to 28 July 2010) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)</LI>
<LI>EMBASE via OVID (1980 to 28 July 2010) (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</LI>
</UL>
<P>Current Controlled Trials (<A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A>) was searched for oral cancer or oropharyngeal cancer on 25 January 2010.<BR/>
</P>
<P>Because studies involving oral cancer are often included with those of the head and neck, a broad search was undertaken to include all possible studies. The searches attempted to identify all relevant trials irrespective of language. The reference list of related review articles and articles considered to be potentially relevant were checked for further trials. Authors of identified trials and known specialists in the field were contacted in an attempt to identify any additional published or unpublished trials.</P>
<P>Sensitive search strategies were developed for each database using a combination of free text and MeSH terms; these were based on the search strategy developed for MEDLINE (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) but revised appropriately for each database. The search strategy combined the subject search with the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in MEDLINE: sensitivity maximising version (2009 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> version 5.0.2 (updated September 2009) (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). The search of EMBASE was linked to the Cochrane Oral Health Group filter for identifying randomised controlled trials in this database (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</P>
<P>Handsearching was done as part of the Cochrane Collaboration's worldwide handsearching programme, <I>see</I> the <A HREF="http://apps1.jhsph.edu/cochrane/NSmasterlist.htm">Cochrane Master List</A> of journals being searched for more information. The reference lists of related reviews and all articles obtained were checked for further trials. Authors of trial reports and specialists in the field known to the review authors were written to concerning further published and unpublished trials.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-11-05 11:49:48 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2010-11-05 11:45:43 +0000" MODIFIED_BY="[Empty name]">
<P>The titles and abstracts (when available) of all reports identified through the electronic searches were scanned independently by two review authors. For studies appearing to meet the inclusion criteria, or for which there were insufficient data in the title and abstract to make a clear decision, the full report was obtained. The full reports obtained from all the electronic and other methods of searching were assessed independently by two review authors to establish whether the studies met the inclusion criteria or not. Disagreements were resolved by discussion. Where resolution was not possible, a third review author was consulted. All studies meeting the inclusion criteria underwent a risk of bias assessment and data extraction using a specially designed data extraction form. Studies rejected at this or subsequent stages were recorded in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table, and reasons for exclusion recorded.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-11-05 11:45:52 +0000" MODIFIED_BY="[Empty name]">
<P>Data were extracted by two review authors independently using specially designed data extraction forms. The data extraction forms were piloted on several papers and modified as required before use. Any disagreements were discussed and a third review author consulted where necessary. However, group discussion was often required following data extraction due to the complexity of the data presented. When necessary authors were contacted for clarification or missing information.</P>
<P>For each trial the following data were recorded:</P>
<UL>
<LI>Year of publication, country of origin and source of study funding</LI>
<LI>Details of the participants including demographic characteristics and criteria for inclusion and exclusion, proportion with oral cavity and oropharyngeal cancer</LI>
<LI>Details of the type of intervention, timing and duration</LI>
<LI>Details of the outcomes reported, including method of assessment, and time intervals.</LI>
</UL>
<P>As the majority of trials were for head and neck cancers the proportion of oral/oropharyngeal cancer patients was recorded (Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Head and neck cancer trials with only combined data (i.e. no outcome data available by primary tumour site) where greater than 50% of participants presented with oral/oropharyngeal cancer were included in this review. However, where separate 'pure' oral/oropharyngeal cancer data were available for a trial, these 'pure' data were extracted and analysed and the combined head and neck data ignored.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-11-05 11:47:56 +0000" MODIFIED_BY="[Empty name]">
<P>For the studies included in this review assessment of risk of bias was conducted by two review authors using the Cochrane risk of bias assessment tool. Six domains were assessed for each included study: sequence generation, allocation concealment, blinding, completeness of outcome data, risk of selective outcome reporting and risk of other potential sources of bias.</P>
<P>A description of the domains was tabulated for each included trial, along with a judgement of low, high or unclear risk of bias. For example, criteria for risk of bias judgements regarding allocation concealment are given below as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> 5.0.2 (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>).</P>
<UL>
<LI>Low risk of bias - adequate concealment of the allocation (e.g. sequentially numbered, sealed, opaque envelopes or centralised or pharmacy-controlled randomisation).</LI>
<LI>Unclear risk of bias - unclear about whether the allocation was adequately concealed (e.g. where the method of concealment is not described or not described in sufficient detail to allow a definite judgement).</LI>
<LI>High risk of bias - inadequate allocation concealment (e.g. open random number lists or quasi-randomisation such as alternate days, date of birth, or case record number).</LI>
</UL>
<P>A summary assessment of the risk of bias for the primary outcome (across domains) across studies was undertaken (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). Within a study, a summary assessment of low risk of bias was given when there was a low risk of bias for all key domains, unclear risk of bias when there was an unclear risk of bias for one or more key domains, and high risk of bias when there was a high risk of bias for one or more key domains.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-11-04 17:15:14 +0000" MODIFIED_BY="[Empty name]">
<P>The primary outcome is total mortality expressed as a hazard ratio (it is acknowledged that it is preferable to talk in terms of overall survival, however, statistically the estimate of effect is the hazard ratio of death). If hazard ratios were not quoted in studies, we calculated the log hazard ratio and the standard error (SE) from the available summary statistics or Kaplan-Meier curves, according to the methods proposed by Parmar et al (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>), or these data were requested from authors. A meta-analysis of individual patient data (IPD) for altered fractionation versus conventional fractionation has previously been published (<LINK REF="STD-Bourhis-2006" TYPE="STUDY">Bourhis 2006</LINK>). For trials included in the Bourhis meta-analysis, the IPD were used instead of data presented in the published reports of the individual trials.</P>
<P>For dichotomous outcomes, the estimates of effect of an intervention were expressed as risk ratios together with 95% confidence intervals. Dichotomous data were only used for primary outcomes where hazard ratios were unavailable or could not be calculated.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-11-05 11:49:40 +0000" MODIFIED_BY="[Empty name]">
<P>Meta-analyses were conducted only if there were studies of similar comparisons reporting the same outcome measures. The significance of any discrepancies in the estimates of the treatment effects from the different trials was assessed by means of Cochran's test for heterogeneity and the I<SUP>2</SUP> statistic, and any heterogeneity investigated.<BR/>
</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-11-05 11:49:48 +0000" MODIFIED_BY="[Empty name]">
<P>Risk ratios were combined for dichotomous data, and hazard ratios for survival data, using a fixed-effect model, unless there were more than four trials to be combined, when a random-effects model was used. Hazard ratio data were entered into the meta-analysis using the inverse variance method.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-11-04 17:17:03 +0000" MODIFIED_BY="[Empty name]">
<P>Due to the different natural history and treatment regimens for oral cavity and oropharyngeal cancers we planned to analyse these cancer types separately, if there were sufficient data.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-11-04 17:19:33 +0000" MODIFIED_BY="[Empty name]">
<P>A sensitivity analysis (to examine the effects of randomisation, allocation concealment, blinded outcome assessment (if appropriate) and quality of follow-up/completeness of data set) was planned. </P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-11-05 15:29:04 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-11-05 15:29:04 +0000" MODIFIED_BY="[Empty name]">
<P>Over 5000 research papers were identified through the electronic searching. Screening of the titles and abstracts resulted in the identification of 129 potentially relevant trials for inclusion in the review. Full text copies of these articles were retrieved, where available. Further assessment of the papers resulted in 30 trials (from 68 publications) being included int he review. Forty-one trials (from 63 publications) were excluded, the reasons for which are presented in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>Of the 30 trials included in the review, 19 were multicentred, with the number of centres ranging from 2 to 26. Fourteen trials were undertaken in the US (one linked with centres in Canada and one linked to the UK), four in centres across Europe, two in Italy, two in Germany, two in India, one across Australia and NewZealand and one solely in the UK, France, Japan, Brazil, and Poland.</P>
<P>Participants were recruited over periods ranging from 1 year to 10 years, with the earliest recruitment commencing in 1969 (<LINK REF="STD-Lawrence-1974" TYPE="STUDY">Lawrence 1974</LINK>; <LINK REF="STD-Terz-1981" TYPE="STUDY">Terz 1981</LINK>).</P>
<P>Fifteen of the included trials reported the cancer stage of recruited participants. Five of the trials recruited those with stages II-IV, nine included patients with stages III-IV and one trial recruited those with stages I-IV. Tumour extent (TNM) was reported in 25 of the included trials, 13 of which included patients with T1 to T4 tumours. The remaining 12 included T2 to T4 or T3 to T4.</P>
<P>Of the 30 included trials, only two included recruited participants with oral cavity cancer only and a further four included only those with oropharyngeal cancer. The authors of two trials provided us with separate data (<I>see</I> Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for details) and one trial recruited only those with cancer of either the oral cavity or oropharynx. In the remaining included trials at least 50% of participants had either oral cavity or oropharyngeal cancer.</P>
<P>Trials were grouped into five main categories.</P>
<SUBSECTION>
<HEADING LEVEL="3">Altered fractionation</HEADING>
<UL>
<LI>Hyperfractionated versus conventional (<LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>; <LINK REF="STD-Horiot-1992" TYPE="STUDY">Horiot 1992</LINK>; <LINK REF="STD-Pinto-1991" TYPE="STUDY">Pinto 1991</LINK>).</LI>
<LI>Hyperfractionated/accelerated versus conventional (<LINK REF="STD-Bourhis-2006" TYPE="STUDY">Bourhis 2006</LINK>; <LINK REF="STD-Dobrowsky-2000" TYPE="STUDY">Dobrowsky 2000</LINK>; <LINK REF="STD-Marcial-1987" TYPE="STUDY">Marcial 1987</LINK>; <LINK REF="STD-Poulsen-2001" TYPE="STUDY">Poulsen 2001</LINK>).</LI>
<LI>Hyperfractionated/accelerated/split versus conventional (<LINK REF="STD-Bartelink-2002" TYPE="STUDY">Bartelink 2002</LINK>; <LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>; <LINK REF="STD-Horiot-1997" TYPE="STUDY">Horiot 1997</LINK>; <LINK REF="STD-Olmi-2003" TYPE="STUDY">Olmi 2003</LINK>).</LI>
<LI>Accelerated versus conventional (<LINK REF="STD-Skladowski-2006" TYPE="STUDY">Skladowski 2006</LINK>; <LINK REF="STD-Weissberg-1983" TYPE="STUDY">Weissberg 1983</LINK>).</LI>
<LI>Accelerated/boost versus conventional (<LINK REF="STD-Ang-2001" TYPE="STUDY">Ang 2001</LINK>; <LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>; <LINK REF="STD-Ghoshal-2008" TYPE="STUDY">Ghoshal 2008</LINK>; <LINK REF="STD-Sanguineti-2005" TYPE="STUDY">Sanguineti 2005</LINK>).</LI>
<LI>Accelerated/split versus conventional (<LINK REF="STD-Marcial-1993" TYPE="STUDY">Marcial 1993</LINK>).</LI>
<LI>Hyperfractionated/accelerated split course radiotherapy versus accelerated boost (<LINK REF="STD-Fu-1995" TYPE="STUDY">Fu 1995</LINK>).</LI>
<LI>Split course versus accelerated (<LINK REF="STD-Hukku-1991" TYPE="STUDY">Hukku 1991</LINK>).</LI>
<LI>Variable total dose/duration (<LINK REF="STD-Cox-1990" TYPE="STUDY">Cox 1990</LINK>).</LI>
</UL>
<P>
<I>Note</I>: Conventional radiotherapy was defined as 66-77 Gy in 2 Gy fractions, for 5 days a week.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Neutron therapy</HEADING>
<UL>
<LI>Mixed beam versus photon (<LINK REF="STD-Griffin-1989" TYPE="STUDY">Griffin 1989</LINK>).</LI>
<LI>Neutron versus photon (<LINK REF="STD-Griffin-1984" TYPE="STUDY">Griffin 1984</LINK>; <LINK REF="STD-MacDougall-1990" TYPE="STUDY">MacDougall 1990</LINK>; <LINK REF="STD-Maor-1986" TYPE="STUDY">Maor 1986</LINK>; <LINK REF="STD-Maor-1995" TYPE="STUDY">Maor 1995</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pre-operative radiotherapy</HEADING>
<UL>
<LI>Pre-operative radiotherapy versus surgery alone (<LINK REF="STD-Ketcham-1969" TYPE="STUDY">Ketcham 1969</LINK>; <LINK REF="STD-Lawrence-1974" TYPE="STUDY">Lawrence 1974</LINK>; <LINK REF="STD-Terz-1981" TYPE="STUDY">Terz 1981</LINK>).</LI>
<LI>Pre-operative and post-operative radiotherapy versus post-operative radiotherapy alone (<LINK REF="STD-Bergermann-1992" TYPE="STUDY">Bergermann 1992</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Timing of radiotherapy regimen</HEADING>
<UL>
<LI>Morning radiotherapy versus afternoon radiotherapy (<LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other</HEADING>
<UL>
<LI>Low dose rate interstitial radiotherapy versus high dose rate interstitial radiotherapy (<LINK REF="STD-Inoue-2001" TYPE="STUDY">Inoue 2001</LINK>).</LI>
</UL>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-11-05 11:59:07 +0000" MODIFIED_BY="[Empty name]">
<P>A summary of the risk of bias assessment is presented in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<ALLOCATION MODIFIED="2010-11-05 11:58:02 +0000" MODIFIED_BY="[Empty name]">
<P>Eighteen of the included trials were assessed as having adequate sequence generation. In the remaining 12 trials, the sequence generation was considered to be unclear. Fourteen trials were assessed as having adequate allocation concealment, the remaining trials providing insufficient information on this item.</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-09-09 16:00:11 +0100" MODIFIED_BY="[Empty name]">
<P>In most trials of radiotherapy, blinding of participants and clinicians would be difficult. A decision was made to assess those not explicitly reporting on blinding of outcome assessors as having no blinding. It was felt that for objective outcomes (such as total mortality) the lack of blinding was unlikely to result in bias. However, for more subjective outcomes, lack of blinding was considered to represent a potential risk of bias. Only one trial reported blind outcome assessment (<LINK REF="STD-Ketcham-1969" TYPE="STUDY">Ketcham 1969</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-11-05 11:58:18 +0000" MODIFIED_BY="[Empty name]">
<P>Twelve of the included trials were assessed as being at an unclear risk of bias with regard to incomplete outcome data. All other trials were assessed as low risk with regard to this item, due to no missing outcome data, balanced missing outcome data across groups, missing outcome data unlikely to be related to true outcome, or unlikely to have clinical impact on estimate of effect.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-11-03 22:06:25 +0000" MODIFIED_BY="[Empty name]">
<P>Majority of the included trials (24/30) were assessed as being free of selective reporting bias, reporting on expected, clinically important outcomes. Six trials were assessed as being at unclear risk of bias for this item due to reasons such as lack of information to determine if subgroup analyses were preplanned.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-11-05 11:59:07 +0000" MODIFIED_BY="[Empty name]">
<P>Five trials were assessed as being at high risk of bias with regard to other potential sources of bias (<LINK REF="STD-Bergermann-1992" TYPE="STUDY">Bergermann 1992</LINK>; <LINK REF="STD-Fu-1995" TYPE="STUDY">Fu 1995</LINK>; <LINK REF="STD-Ketcham-1969" TYPE="STUDY">Ketcham 1969</LINK>; <LINK REF="STD-Maor-1986" TYPE="STUDY">Maor 1986</LINK>; <LINK REF="STD-Marcial-1987" TYPE="STUDY">Marcial 1987</LINK>). Fourteen were assessed as being at low risk of bias with regard to other potential sources of bias and 11 trials assessed as unclear risk of bias.</P>
<P>The overall assessment of risk of bias in the included trials is described within the section <LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK>.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-11-05 12:42:43 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Altered fractionation</HEADING>
<P>Within this section trials have been grouped to ensure they are similar in terms of dose/fraction (Gy), fractions/week, total dose (Gy) and duration of radiotherapy. The following definitions have been used.</P>
<UL>
<LI>Conventional - single daily doses of 1.8 to 2.0 Gy/fraction, 5 days a week to a total dose of 66 to 70 Gy (typically over 6½ to 7 weeks).</LI>
<LI>Hyperfractionated - total dose is divided into small doses, with more than 1 fraction/day.</LI>
<LI>Accelerated - total dose given over a shorter period of time (&lt; 6 weeks).</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Hyperfractionated versus conventional radiotherapy</HEADING>
<P>Three trials were included in this comparison (<LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>; <LINK REF="STD-Horiot-1992" TYPE="STUDY">Horiot 1992</LINK>; <LINK REF="STD-Pinto-1991" TYPE="STUDY">Pinto 1991</LINK>), with a total of 966 randomised participants. All three trials were considered to be at unclear risk of bias with regard to total mortality. For less objective outcomes, two trials were considered to be at high risk of bias (<LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>; <LINK REF="STD-Horiot-1992" TYPE="STUDY">Horiot 1992</LINK>) and one trial at unclear risk of bias (<LINK REF="STD-Pinto-1991" TYPE="STUDY">Pinto 1991</LINK>). Two trials included patients with primary tumours of the oropharynx only (<LINK REF="STD-Horiot-1992" TYPE="STUDY">Horiot 1992</LINK>; <LINK REF="STD-Pinto-1991" TYPE="STUDY">Pinto 1991</LINK>). <LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000 </LINK>included patients with head and neck tumours, of which 10% were located in the oral cavity and 60% in the oropharynx. The radiotherapy regimens evaluated in the three trials are presented in the table below.</P>
<SUBSECTION>
<HEADING LEVEL="6">Summary of radiotherapy regimens: hyperfractionated versus conventional radiotherapy</HEADING>
<TABLE COLS="10" ROWS="5">
<TR>
<TD>
<P/>
</TD>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Hyperfractionated</P>
</TH>
<TH>
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Conventional</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>81.6</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>70</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Horiot-1992" TYPE="STUDY">Horiot 1992</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.15</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>80.5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.75-2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>70</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7-8</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pinto-1991" TYPE="STUDY">Pinto 1991</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.1</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>70.4</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>6.4</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>66</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>6.5</P>
</TD>
</TR>
</TABLE>
<P>For all three trials individual patient data (IPD) were available from <LINK REF="REF-Bourhis-2006" TYPE="REFERENCE">Bourhis 2006</LINK> for total mortality and locoregional control. A statistically significant difference was shown in favour of the hyperfractionated radiotherapy for both total mortality (hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.68 to 0.90) and locoregional control (HR 0.74, 95% CI 0.62 to 0.89) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>Disease free survival data were available for one of the trials (<LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>) and showed no statistically significant difference between hyperfractionated and conventional radiotherapy (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hyperfractionated/accelerated versus conventional</HEADING>
<P>Four trials compared a hyperfractionated/accelerated radiotherapy regimen with conventional radiotherapy (<LINK REF="STD-Bourhis-2006" TYPE="STUDY">Bourhis 2006</LINK>; <LINK REF="STD-Dobrowsky-2000" TYPE="STUDY">Dobrowsky 2000</LINK>; <LINK REF="STD-Marcial-1987" TYPE="STUDY">Marcial 1987</LINK>; <LINK REF="STD-Poulsen-2001" TYPE="STUDY">Poulsen 2001</LINK>), with a total of 1071 randomised participants. Three trials were considered to be at low risk of bias with regard to assessment of total mortality (<LINK REF="STD-Bourhis-2006" TYPE="STUDY">Bourhis 2006</LINK>; <LINK REF="STD-Dobrowsky-2000" TYPE="STUDY">Dobrowsky 2000</LINK>; <LINK REF="STD-Poulsen-2001" TYPE="STUDY">Poulsen 2001</LINK>) and high risk of bias for other outcomes. <LINK REF="STD-Marcial-1987" TYPE="STUDY">Marcial 1987</LINK> was considered to be at high risk of bias across all outcomes.</P>
<P>All trials recruited patients with tumours of the head and neck. The percentage of participants with cancer of the oral cavity or oropharynx ranged from 61% (<LINK REF="STD-Marcial-1987" TYPE="STUDY">Marcial 1987</LINK>) to 91% (<LINK REF="STD-Bourhis-2006" TYPE="STUDY">Bourhis 2006</LINK>). The radiotherapy regimens are presented in the table below. Both arms in the trial by <LINK REF="STD-Poulsen-2001" TYPE="STUDY">Poulsen 2001</LINK> received a reduced total dose in comparison to the other three trials.</P>
<SUBSECTION>
<HEADING LEVEL="6">Summary of radiotherapy regimens: hyperfractionated/accelerated versus conventional radiotherapy</HEADING>
<TABLE COLS="10" ROWS="6">
<TR>
<TD>
<P/>
</TD>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Hyperfractionated/accelerated</P>
</TH>
<TH>
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Conventional</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bourhis-2006" TYPE="STUDY">Bourhis 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>62-64</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>70</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dobrowsky-2000" TYPE="STUDY">Dobrowsky 2000</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2.5 on day 1 then 1.65</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>14</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>55.3</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2.4</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>70</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Marcial-1987" TYPE="STUDY">Marcial 1987</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>60</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.8-2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>66-73.8</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7-8</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Poulsen-2001" TYPE="STUDY">Poulsen 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.8</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>14</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>39.6</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2.3</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>50</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
</TR>
</TABLE>
<P>IPD for total mortality and locoregional control were available for all four trials (<LINK REF="REF-Bourhis-2006" TYPE="REFERENCE">Bourhis 2006</LINK>). The pooled HR for total mortality was not statistically significant (HR 0.87, 95% CI 0.75 to 1.00) but the pooled estimate for locoregional control just attained statistical significance (HR 0.84, 95% CI 0.72 to 0.99) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>Only one of the four trials presented data for disease free survival (<LINK REF="STD-Poulsen-2001" TYPE="STUDY">Poulsen 2001</LINK>). No statistically significant difference between treatment groups was shown (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hyperfractionated/accelerated/split versus conventional</HEADING>
<P>Four trials were included in this comparison (<LINK REF="STD-Bartelink-2002" TYPE="STUDY">Bartelink 2002</LINK>; <LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>; <LINK REF="STD-Horiot-1997" TYPE="STUDY">Horiot 1997</LINK>; <LINK REF="STD-Olmi-2003" TYPE="STUDY">Olmi 2003</LINK>), including a total of 1299 randomised participants.</P>
<P>Only one trial was considered to be at low risk of bias with regard to the assessment of total mortality (<LINK REF="STD-Horiot-1997" TYPE="STUDY">Horiot 1997</LINK>); the remaining trials were considered to be at unclear risk of bias. With regard to more subjective outcomes, all trials were considered to be at either high or unclear risk of bias.</P>
<P>One of these trials recruited participants with cancer of the oropharynx only (<LINK REF="STD-Olmi-2003" TYPE="STUDY">Olmi 2003</LINK>). The remaining three trials recruited participants with head and neck cancer with the percentage of those with cancer of the oral cavity or oropharynx ranging from 71% (<LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>) to 80% (<LINK REF="STD-Bartelink-2002" TYPE="STUDY">Bartelink 2002</LINK>; <LINK REF="STD-Horiot-1997" TYPE="STUDY">Horiot 1997</LINK>).</P>
<P>The radiotherapy regimens for the five trials are presented in the table below.</P>
<SUBSECTION>
<HEADING LEVEL="6">Summary of radiotherapy regimens: hyperfractionated/accelerated/split versus conventional radiotherapy</HEADING>
<TABLE COLS="10" ROWS="6">
<TR>
<TD>
<P/>
</TD>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Hyperfractionated/accelerated/split</P>
</TH>
<TH ALIGN="CENTER">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Conventional</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bartelink-2002" TYPE="STUDY">Bartelink 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.6</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>72</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>weeks 1, 4 and 7</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>70</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.6</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>67.2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2.5 weeks, 2 weeks rest then 1.5 weeks</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>70</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Horiot-1997" TYPE="STUDY">Horiot 1997</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.6</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>21 (14 after split)</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>72</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.1 weeks, 2 weeks rest then 2.4 weeks</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>70</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Olmi-2003" TYPE="STUDY">Olmi 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.6</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>64-67.2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2 weeks, 2 weeks rest then 3 weeks</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>66-70</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>6.5-7</P>
</TD>
</TR>
</TABLE>
<P>Total mortality and locoregional control data were available for the calculation of HR in all four the trials; IPD were available for <LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>, <LINK REF="STD-Horiot-1997" TYPE="STUDY">Horiot 1997</LINK> and <LINK REF="STD-Olmi-2003" TYPE="STUDY">Olmi 2003</LINK> and HR data were calculated from a Kaplan-Meier graph for <LINK REF="STD-Bartelink-2002" TYPE="STUDY">Bartelink 2002</LINK>. No statistically significant difference was shown between the two radiotherapy schedules with regard to either total mortality (HR 1.02, 95% CI 0.90 to 1.17) or locoregional control (HR 0.86, 95% CI 0.74 to 1.01) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>Only two of the four trials presented data on disease free survival (<LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>; <LINK REF="STD-Olmi-2003" TYPE="STUDY">Olmi 2003</LINK>). The radiotherapy schedules were similar in both trials. <LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK> recruited 542 participants with head and neck cancers (10% oral cavity, 60% oropharynx) to the two radiotherapy regimens, and <LINK REF="STD-Olmi-2003" TYPE="STUDY">Olmi 2003</LINK> recruited 192 participants with cancer of the oropharynx. The results with regard to disease free survival are contradictory, with substantial statistical heterogeneity (P = 0.02, I<SUP>2 </SUP>= 82%) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Accelerated versus conventional</HEADING>
<P>Two trials compared an accelerated regimen (with no split, boost or hyperfractionation) with conventional radiotherapy (<LINK REF="STD-Skladowski-2006" TYPE="STUDY">Skladowski 2006</LINK>; <LINK REF="STD-Weissberg-1983" TYPE="STUDY">Weissberg 1983</LINK>), including a total of 164 randomised participants.</P>
<P>Both trials were considered to be at unclear risk of bias for the assessment of total mortality and high risk of bias for subjective outcomes.</P>
<P>Both trials recruited participants with head and neck cancer; 64% of those recruited by <LINK REF="STD-Weissberg-1983" TYPE="STUDY">Weissberg 1983</LINK> and 50% of those recruited by <LINK REF="STD-Skladowski-2006" TYPE="STUDY">Skladowski 2006</LINK> had tumours of the oral cavity or oropharynx.</P>
<P>The radiotherapy regimens for the two trials are presented in the table below, and differ substantially. The accelerated course used by <LINK REF="STD-Skladowski-2006" TYPE="STUDY">Skladowski 2006</LINK> was of longer duration with a higher total dose than <LINK REF="STD-Weissberg-1983" TYPE="STUDY">Weissberg 1983</LINK>. Also, <LINK REF="STD-Skladowski-2006" TYPE="STUDY">Skladowski 2006</LINK> gave a lower dose/fraction for 7 fractions/week (rather than 5 fractions/week). The conventional radiotherapy schedules were similar.</P>
<SUBSECTION>
<HEADING LEVEL="6">Summary of radiotherapy regimens: accelerated versus conventional radiotherapy</HEADING>
<TABLE COLS="10" ROWS="4">
<TR>
<TD>
<P/>
</TD>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Accelerated</P>
</TH>
<TH ALIGN="CENTER">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Conventional</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Weissberg-1983" TYPE="STUDY">Weissberg 1983</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>40-48</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2-3</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>60-70</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>6-7</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Skladowski-2006" TYPE="STUDY">Skladowski 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
<TD ALIGN="CENTER">
<P>66+/-2 (T2)</P>
<P>70+/-2 (T3-4)</P>
</TD>
<TD ALIGN="CENTER">
<P>4.7-5.1</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>66+/-2 (T2) </P>
<P>70+/-2 (T3-4)</P>
</TD>
<TD ALIGN="CENTER">
<P>6.7-7.1</P>
</TD>
</TR>
</TABLE>
<P>Only one trial reported data for total mortality and locoregional control (<LINK REF="STD-Skladowski-2006" TYPE="STUDY">Skladowski 2006</LINK>), for which IPD were also available (<LINK REF="STD-Bourhis-2006" TYPE="STUDY">Bourhis 2006</LINK>). A statistically significant difference in favour of the altered fractionation was shown (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). Both trials reported on disease free survival, however, given the substantial clinical and statistical heterogeneity between the trials' results (P = 0.0004, I<SUP>2 </SUP>= 92%) a pooled analysis is not reported here (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Accelerated/boost versus conventional</HEADING>
<P>Four trials compared an accelerated regimen incorporating a radiotherapy boost with conventional radiotherapy (<LINK REF="STD-Ang-2001" TYPE="STUDY">Ang 2001</LINK>; <LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>; <LINK REF="STD-Ghoshal-2008" TYPE="STUDY">Ghoshal 2008</LINK>; <LINK REF="STD-Sanguineti-2005" TYPE="STUDY">Sanguineti 2005</LINK>), with a total of 1203 randomised participants.</P>
<P>One trial was assessed as being at low risk of bias with regard to total mortality (<LINK REF="STD-Ang-2001" TYPE="STUDY">Ang 2001</LINK>) and three were assessed as being at unclear risk of bias with regard to total mortality (<LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>; <LINK REF="STD-Ghoshal-2008" TYPE="STUDY">Ghoshal 2008</LINK>; <LINK REF="STD-Sanguineti-2005" TYPE="STUDY">Sanguineti 2005</LINK>). For subjective outcomes, all four trials were considered to be at high risk of bias.</P>
<P>For two of the trials data were available from the authors for those participants with cancer of the oral cavity or oropharynx only (<LINK REF="STD-Ang-2001" TYPE="STUDY">Ang 2001</LINK>; <LINK REF="STD-Sanguineti-2005" TYPE="STUDY">Sanguineti 2005</LINK>). In the trials by <LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK> and <LINK REF="STD-Ghoshal-2008" TYPE="STUDY">Ghoshal 2008</LINK> 71% and 65% of recruited participants had cancer of the oral cavity or oropharynx.</P>
<P>The radiotherapy regimens for the four trials are presented in the table below and are similar across trials. However, it should be noted that in the trials by <LINK REF="STD-Ang-2001" TYPE="STUDY">Ang 2001</LINK> and <LINK REF="STD-Sanguineti-2005" TYPE="STUDY">Sanguineti 2005</LINK>, radiotherapy was given post-operatively.</P>
<SUBSECTION>
<HEADING LEVEL="6">Summary of radiotherapy regimens: accelerated/boost versus conventional radiotherapy</HEADING>
<TABLE COLS="10" ROWS="6">
<TR>
<TD>
<P/>
</TD>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Accelerated/boost</P>
</TH>
<TH ALIGN="CENTER">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Conventional</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ang-2001" TYPE="STUDY">Ang 2001</LINK>*</P>
</TD>
<TD ALIGN="CENTER">
<P>1.8</P>
<P>1.8 (boost)</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
<P>10 (boost)</P>
</TD>
<TD ALIGN="CENTER">
<P>63</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
<P>(boost last 21 days of radiotherapy)</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>1.8</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>63</P>
</TD>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.8</P>
<P>1.5 (boost)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
<P>7 (boost)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>70.5</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>6</P>
<P>(boost last 11 days of radiotherapy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>70</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ghoshal-2008" TYPE="STUDY">Ghoshal 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.8</P>
<P>1.5 (boost)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
<P>5 (boost)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>67.5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
<P>(boost last 21 days of radiotherapy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>66</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>6.5</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sanguineti-2005" TYPE="STUDY">Sanguineti 2005</LINK>*</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
<P>1.4 (first week boost)</P>
<P>1.6 (fifth week boost)</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
<P>5 (boost)</P>
</TD>
<TD ALIGN="CENTER">
<P>64</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
<P>(boost during first and fifth week of radiotherapy)</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>50-60</P>
</TD>
<TD ALIGN="CENTER">
<P>5-6</P>
</TD>
</TR>
</TABLE>
<P>* post-operative radiotherapy</P>
<P>Three of the trials provided data for the calculation of HR for total mortality; IPD were available for one trial (<LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>, data presented in <LINK REF="REF-Bourhis-2006" TYPE="REFERENCE">Bourhis 2006</LINK>) and data were provided by the authors for two trials (<LINK REF="STD-Ang-2001" TYPE="STUDY">Ang 2001</LINK>; <LINK REF="STD-Sanguineti-2005" TYPE="STUDY">Sanguineti 2005</LINK>). No statistically significant difference in total mortality between treatment schedules was shown (HR 0.95, 95% CI 0.80 to 1.13) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>IPD on locoregional control was available for one trial (<LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>, data from <LINK REF="REF-Bourhis-2006" TYPE="REFERENCE">Bourhis 2006</LINK> ). A statistically significant difference in favour of the accelerated schedule with boost was shown in this single study (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>All four trials provided data on disease free survival, and the pooled estimate showed a statistically significant difference on favour of the accelerated/boost schedule. However, it should be noted that there is statistical heterogeneity (P = 0.05, I<SUP>2 </SUP>= 63%) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Accelerated/split versus conventional</HEADING>
<P>One trial, recruiting 147 participants, compared split course, accelerated radiotherapy with conventional radiotherapy (<LINK REF="STD-Marcial-1993" TYPE="STUDY">Marcial 1993</LINK>). The trial was assessed as being at unclear risk of bias for the outcome of total mortality and high risk of bias for more subjective outcomes. The trial recruited participants with cancer of the oropharynx only.</P>
<SUBSECTION>
<HEADING LEVEL="6">Summary of radiotherapy regimens: accelerated/split versus conventional radiotherapy</HEADING>
<TABLE COLS="10" ROWS="3">
<TR>
<TD>
<P/>
</TD>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Accelerated/split</P>
</TH>
<TH>
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Conventional</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Marcial-1993" TYPE="STUDY">Marcial 1993</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>60</P>
</TD>
<TD ALIGN="CENTER">
<P>2 weeks, 3 weeks rest then 2 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>2-2.2</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>60-66</P>
</TD>
<TD ALIGN="CENTER">
<P>6</P>
</TD>
</TR>
</TABLE>
<P>Dichotomous data were available for the calculation of 5 year risk ratios for total mortality (Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). No statistically significant difference was shown between schedules for any of these outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Summary: any altered fractionation radiotherapy versus conventional radiotherapy</HEADING>
<P>When the 13 trials providing data on any altered fractionation radiotherapy regimen compared to a conventional schedule were pooled using a random-effects model, a statistically significant reduction in total mortality was shown (HR 0.86, 95% CI 0.76 to 0.98) (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). It should be noted that there was statistically significant heterogeneity between the trials for total mortality (P = 0.002, I<SUP>2 </SUP>= 59%).</P>
<P>Pooling of 11 trials providing data on locoregional control and comparing any altered schedule with conventional also showed a statistically significant difference in favour of the altered fractionation (HR 0.79, 95% CI 0.70 to 0.89) (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). No statistically significant difference was shown between altered fractionation and conventional radiotherapy when the eight trials providing data on disease free survival were combined (HR 0.85, 95% CI 0.70 to 1.03) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<P>A sensitivity analysis was undertaken to determine the effect of excluding trials assessed as being at high or unclear risk of bias (Additional <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). When the five trials assessed as being at low risk of bias were pooled using a random-effects model, no statistically significant difference in total mortality was shown between altered fractionation radiotherapy regimens compared to conventional schedules (HR 0.93, 95% CI 0.80 to 1.07). The findings of the sensitivity analyses for locoregional control and disease free survival were HR 0.79, 95% CI 0.68 to 0.91 (random-effects model) and HR 0.95, 95% CI 0.0.74 to 1.22 (fixed-effect model) respectively.</P>
<SUBSECTION>
<HEADING LEVEL="6">Summary of altered fractionation regimens versus conventional radiotherapy with data from more than one trial</HEADING>
<TABLE COLS="2" ROWS="7">
<TR>
<TH>
<P/>
</TH>
<TH ALIGN="CENTER">
<P>Total mortality</P>
</TH>
</TR>
<TR>
<TD>
<P>Hyperfractionated versus conventional radiotherapy</P>
</TD>
<TD ALIGN="CENTER">
<P>HR 0.78 (95% CI 0.68 to 0.90)</P>
<P>(3 trials)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Hyperfractionated/accelerated versus conventional radiotherapy</P>
</TD>
<TD ALIGN="CENTER">
<P>HR 0.87 (95% CI 0.75 to 1.00)</P>
<P>(4 trials)</P>
</TD>
</TR>
<TR>
<TD>
<P>Hyperfractionated/accelerated/split versus conventional radiotherapy</P>
</TD>
<TD ALIGN="CENTER">
<P>HR 1.02, (95% CI 0.90 to 1.17)</P>
<P>(4 trials)</P>
</TD>
</TR>
<TR>
<TD>
<P>Accelerated/boost versus conventional radiotherapy</P>
</TD>
<TD ALIGN="CENTER">
<P>HR 0.95 (95% CI 0.80 to 1.13)</P>
<P>(3 trials)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Any altered fractionation versus conventional radiotherapy (all trials)</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>HR 0.86 (95% CI 0.76 to 0.98)</P>
<P>(13 trials)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Any altered fractionation versus conventional radiotherapy (low risk of bias trials)</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>HR 0.93 (95% CI 0.80 to 1.07)</P>
<P>(5 trials)</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hyperfractionated/accelerated split course radiotherapy versus accelerated radiotherapy with concomitant boost</HEADING>
<P>One small trial (including 75 randomised participants), designed as a feasibility study, compared an accelerated split course with an accelerated schedule with boost (<LINK REF="STD-Fu-1995" TYPE="STUDY">Fu 1995</LINK>). The trial was assessed as being at high risk of bias for all outcomes. The trial participants had head and neck cancer; 61% had cancer of the oral cavity or oropharynx. The authors report no significant difference between the schedules in terms of total mortality, locoregional control or disease free survival, however, data are not presented in a way that allow for the calculation of HR.</P>
<SUBSECTION>
<HEADING LEVEL="6">Summary of radiotherapy regimens: <I>hyperfractionated/</I>accelerated split course versus accelerated boost</HEADING>
<TABLE COLS="10" ROWS="3">
<TR>
<TD>
<P/>
</TD>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Hyperfractionated/accelerated split course</P>
</TH>
<TH ALIGN="CENTER">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Accelerated boost</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fu-1995" TYPE="STUDY">Fu 1995</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.6</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>67.2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2.5 weeks, 2 weeks rest then 1.5 weeks</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.8</P>
<P>1.5 (boost)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
<P>7 (boost)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>70.5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>6</P>
<P>(boost last 11 days of radiotherapy)</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Split course versus accelerated</HEADING>
<P>A single trial of head and neck cancer patients (110 randomised participants; 72% oral cavity or oropharynx) compared a split course with an accelerated course of radiotherapy (<LINK REF="STD-Hukku-1991" TYPE="STUDY">Hukku 1991</LINK>). The trial was assessed to be at unclear risk of bias for total mortality and high risk of bias for locoregional control and disease free survival. Dichotomous data were available for the calculation of 2-year risk ratios for total mortality, locoregional control and disease free survival (Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). No statistically significant difference was shown between schedules for any of these outcomes.</P>
<SUBSECTION>
<HEADING LEVEL="6">Summary of radiotherapy regimens: split course versus accelerated</HEADING>
<TABLE COLS="10" ROWS="3">
<TR>
<TD>
<P/>
</TD>
<TH ALIGN="CENTER" COLSPAN="4" VALIGN="MIDDLE">
<P>Split course</P>
</TH>
<TH VALIGN="MIDDLE">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="4" VALIGN="MIDDLE">
<P>Accelerated</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hukku-1991" TYPE="STUDY">Hukku 1991</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2.3 (2.5 after split)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>59.5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>3 weeks, 2 weeks rest then 2 weeks</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>44</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2.1</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Variable total dose/duration</HEADING>
<P>One trial compared three different total doses, delivered over varying times (<LINK REF="STD-Cox-1990" TYPE="STUDY">Cox 1990</LINK>). A total dose of 72 Gy was considered to be the conventional dose. Total doses of 76.8 Gy (over 6.4 weeks) and 67.2 Gy (over 5.6 weeks) were compared with the conventional dose. The trial was considered to be at unclear risk of bias for total mortality and high risk of bias for subjective outcomes. Data were available for the calculation of HR for total mortality and locoregional control (Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). No statistically significant difference was shown between either of the altered doses and the conventional dose with regard to total mortality or locoregional control.</P>
<SUBSECTION>
<HEADING LEVEL="6">Summary of radiotherapy regimens: altered dose versus conventional dose</HEADING>
<TABLE COLS="10" ROWS="4">
<TR>
<TD>
<P/>
</TD>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Altered dose</P>
</TH>
<TH ALIGN="CENTER">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Conventional dose</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Dose/fraction</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Fractions/week</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total dose (Gy)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Total duration (weeks)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Cox-1990" TYPE="STUDY">Cox 1990</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>76.8</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>6.4</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="TOP">
<P>1.2</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="TOP">
<P>72</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="TOP">
<P>6</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Cox-1990" TYPE="STUDY">Cox 1990</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>67.2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5.6</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Neutron therapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Mixed beam versus photon</HEADING>
<P>One trial (327 randomised participants) compared mixed beam radiotherapy with conventional photon radiotherapy (<LINK REF="STD-Griffin-1989" TYPE="STUDY">Griffin 1989</LINK>). The trial was assessed as being at unclear risk of bias with regard to total mortality and high risk of bias for the assessment of locoregional control. A total of 79% of those recruited had cancer of the oral cavity or oropharynx. No statistically significant difference was shown between the two schedules for either total mortality (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>) or locoregional control (Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Neutron versus photon</HEADING>
<P>Four trials compared neutron radiotherapy with conventional photon radiotherapy, including a total of 531 participants (<LINK REF="STD-Griffin-1984" TYPE="STUDY">Griffin 1984</LINK>; <LINK REF="STD-MacDougall-1990" TYPE="STUDY">MacDougall 1990</LINK>; <LINK REF="STD-Maor-1986" TYPE="STUDY">Maor 1986</LINK>; <LINK REF="STD-Maor-1995" TYPE="STUDY">Maor 1995</LINK>). All trials were considered to be at unclear or high risk of bias for the outcome of total mortality, and high risk of bias for subjective outcomes.</P>
<P>All four trials included participants with head and neck cancer, the percentage of those with cancer of the oral cavity or oropharynx varied from 58% (<LINK REF="STD-Griffin-1984" TYPE="STUDY">Griffin 1984</LINK>) to 77% (<LINK REF="STD-Maor-1986" TYPE="STUDY">Maor 1986</LINK>).</P>
<P>Three of the four trials provided data that allowed for the calculation of a HR for total mortality (<LINK REF="STD-Griffin-1984" TYPE="STUDY">Griffin 1984</LINK>; <LINK REF="STD-Maor-1986" TYPE="STUDY">Maor 1986</LINK>; <LINK REF="STD-Maor-1995" TYPE="STUDY">Maor 1995</LINK>). No statistically significant difference was shown between neutron or photon radiotherapy (HR 1.10, 95% CI 0.90 to 1.34) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). <LINK REF="STD-MacDougall-1990" TYPE="STUDY">MacDougall 1990</LINK> provided dichotomous data allowing calculation of 5-year risk ratios for total mortality. Again, no statistically significant difference was shown between the two groups (Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
<P>Only one trial provided useable data for the outcome of locoregional control and disease free survival (<LINK REF="STD-MacDougall-1990" TYPE="STUDY">MacDougall 1990</LINK>). 5-year risk ratios were calculated; no statistically significant differences were shown for either outcome (Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pre-operative radiotherapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Pre-operative radiotherapy versus surgery alone</HEADING>
<P>Three trials were included in this comparison, including over 470 randomised participants (<LINK REF="STD-Ketcham-1969" TYPE="STUDY">Ketcham 1969</LINK>; <LINK REF="STD-Lawrence-1974" TYPE="STUDY">Lawrence 1974</LINK>; <LINK REF="STD-Terz-1981" TYPE="STUDY">Terz 1981</LINK>). All three trials were considered to be at unclear or high risk of bias for all outcomes. All included participants with head and neck cancer, the percentage of those with cancer of the oral cavity or oropharynx varied from 56% (<LINK REF="STD-Ketcham-1969" TYPE="STUDY">Ketcham 1969</LINK>) to 77% (<LINK REF="STD-Lawrence-1974" TYPE="STUDY">Lawrence 1974</LINK>).</P>
<P>Only one trial provided data on total mortality in a useable format (<LINK REF="STD-Terz-1981" TYPE="STUDY">Terz 1981</LINK>). No statistically significant difference was shown between the two groups (Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). <LINK REF="STD-Ketcham-1969" TYPE="STUDY">Ketcham 1969</LINK> provides dichotomous data on locoregional control which showed no statistically significant difference between groups, however, the timing of the assessment of this outcome is unclear (Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Pre-operative and post-operative radiotherapy versus post-operative radiotherapy alone</HEADING>
<P>One trial was included in this comparison (<LINK REF="STD-Bergermann-1992" TYPE="STUDY">Bergermann 1992</LINK>). The trial, including patients with cancer of the oral cavity alone, was judged to be at high risk of bias across all outcomes. Data were available for the calculation of HRs for total mortality, locoregional control and disease free survival. No statistically significant difference was seen for any outcome (Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Timing of radiotherapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Morning radiotherapy versus afternoon radiotherapy</HEADING>
<P>One trial recruited 216 participants to either morning or afternoon radiotherapy (<LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>). Four different schedules were used, either 50 Gy in 25 fractions, or 60 Gy in 25-30 fractions or 66 Gy in 33 fractions, or 70 Gy in 25 fractions and randomisation was stratified on planned total dose. The trial was assessed as being at unclear risk of bias for objective outcomes and high risk of bias for all other outcomes. The primary aim of the trial was to assess associated toxicity with the different radiotherapy regimens. No statistically significant differences were shown in terms of overall survival or locoregional control (Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Morning radiotherapy was associated with significantly less weight loss after 5 months but no statistically significant difference in quality of life scores (data not reported).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Low dose rate interstitial radiotherapy versus high dose rate interstitial radiotherapy</HEADING>
<P>One trial randomised 59 patients with early mobile tongue cancer (<LINK REF="STD-Inoue-2001" TYPE="STUDY">Inoue 2001</LINK>) to receive either low or high dose rate interstitial radiotherapy. The trial was assessed as being at unclear risk of bias for total mortality and high risk of bias for all subjective outcomes. No statistically significant difference was shown for locoregional control between treatment groups (Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-11-05 12:52:54 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2010-11-05 12:46:45 +0000" MODIFIED_BY="[Empty name]">
<P>The main comparison within this review was altered fractionation radiotherapy and conventional radiotherapy.  Pooling of all studies of altered fractionation versus conventional radiotherapy showed a statistically significant difference in favour of the altered fractionation for the outcomes of total mortality (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76 to 0.98 (random-effects model)) and locoregional control (HR 0.79, 95% CI 0.70 to 0.89 (random-effects model)). This statistically significant difference was not shown for disease free survival (the outcome with least available data), although the direction of effect was towards altered fractionation. </P>
<P>Comparing the current review's findings with the earlier individual patient data (IPD) meta-analysis of hyperfractionated or accelerated radiotherapy in head and neck cancer (<LINK REF="REF-Bourhis-2006" TYPE="REFERENCE">Bourhis 2006</LINK>) shows similar results, despite slight discrepancies in trials included and methods used. <LINK REF="REF-Bourhis-2006" TYPE="REFERENCE">Bourhis 2006</LINK> showed a statistically significant benefit in terms of total mortality (HR 0.92, 95% CI 0.86 to 0.97 (fixed-effect model)) in favour of altered fractionation radiotherapy compared to conventional radiotherapy. Again, for locoregional control a statistically significant difference in favour of altered fractionation radiotherapy was shown (HR 0.82, 95% CI 0.77 to 0.88 (fixed-effect model)).</P>
<P>The meta-analysis by <LINK REF="REF-Bourhis-2006" TYPE="REFERENCE">Bourhis 2006</LINK> reports a significantly higher survival benefit with hyperfractionated radiotherapy than with accelerated radiotherapy. Trials were classified differently in the current review and the meta-analysis by <LINK REF="REF-Bourhis-2006" TYPE="REFERENCE">Bourhis 2006</LINK>, not allowing for a direct comparison. However, of trials included within the current review, those classed as purely 'hyperfractionated' were the only pooled group to show a statistically significant difference in favour of the altered fractionation for the outcome of total mortality (HR 0.78, 95% CI 0.68 to 0.90). </P>
<P>Comparisons between mixed beam versus conventional photon radiotherapy, and neutron versus photon radiotherapy showed no statistically significant difference between treatment groups for total mortality, locoregional control or disease free survival. This supports the findings reported by <LINK REF="REF-Duncan-1994" TYPE="REFERENCE">Duncan 1994</LINK> and <LINK REF="REF-Koh-1994" TYPE="REFERENCE">Koh 1994</LINK> in evaluations of neutron therapy trials in a variety of cancers, including head and neck cancers. Neither show mixed beam or neutron therapy to be advantageous to photon radiotherapy and both raise concern over late morbidity associated with neutron therapy. Current evidence does not justify the use of mixed beam or neutron therapy for the treatment of head and neck cancers.</P>
<P>The addition of pre-operative radiotherapy was evaluated in four trials; three looked at pre-operative versus surgery alone (<LINK REF="STD-Ketcham-1969" TYPE="STUDY">Ketcham 1969;</LINK> <LINK REF="STD-Lawrence-1974" TYPE="STUDY">Lawrence 1974;</LINK> <LINK REF="STD-Terz-1981" TYPE="STUDY">Terz 1981</LINK>), one evaluated pre-operative plus post-operative versus post-operative alone (<LINK REF="STD-Bergermann-1992" TYPE="STUDY">Bergermann 1992</LINK>). All trials were considered to be at unclear or high risk of bias and showed no statistically significant difference for any reported outcome. There is insufficient evidence to support or refute the addition of pre-operative radiotherapy for the treatment of cancer of the oral cavity or oropharynx.</P>
<P>Similarly, there is insufficient evidence to support or refute the use of high dose rate interstitial radiotherapy over low dose rate interstitial radiotherapy (<LINK REF="STD-Inoue-2001" TYPE="STUDY">Inoue 2001</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-11-05 12:49:47 +0000" MODIFIED_BY="[Empty name]">
<P>A limitation of the review is that it aims to evaluate the role of radiotherapy for the treatment of cancers of the oral cavity and oropharynx. The prevalence of trials of treatments of combined head and neck malignancies suggests that those undertaking the primary studies seldom confine trials to patients with a primary lesion in either oral cavity or oropharynx, probably for pragmatic reasons. Of the 30 included trials only two included recruited participants with oral cavity cancer only and a further four included only those with oropharyngeal cancer. The authors of two trials provided us with separate data (<I>see</I> Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for details) and one trial recruited only those with cancer of either the oral cavity or oropharynx. In the remaining included trials at least 50% of participants had either oral cavity or oropharyngeal cancer. As for previous reviews assessing the effectiveness of surgery and chemotherapy for the treatment of patients with cancers of the oral cavity/oropharynx, we have included these trials because we believe that they still contribute important information in the absence of separate data in the research literature. We acknowledge that data on oral cavity cancers or oropharynx cancers alone may provide better evidence upon which to inform clinical practice, and we encourage that in future researchers publish the data for the different primary tumour sites separately. A subgroup analysis was undertaken in the IPD meta-analysis by <LINK REF="REF-Bourhis-2006" TYPE="REFERENCE">Bourhis 2006</LINK>. They report that the effect of altered fractionation on tumour control, when compared to conventional radiotherapy, did not differ significantly according to tumour site (oral cavity, oropharynx, larynx, hypopharynx).</P>
<P>This review does not present a comprehensive systematic review of adverse event data, but does report toxicity data presented in the included trials. The reporting of adverse events within the included trials varied greatly. It has previously been acknowledged that reliable collection and reporting on adverse events remains challenging for clinical trials in oncology, with no uniform method being used for summarising the key elements of such data (<LINK REF="REF-Trotti-2007" TYPE="REFERENCE">Trotti 2007</LINK>). Adverse effects from radiotherapy are usually considered in two groups: acute effects, which occur within 90 days of the start of treatment and late effects which occur more than 90 days after the start of treatment. In general acute adverse effects of radiotherapy include mucositis and skin reactions. Late effects include fibrosis, necrosis, myelitis, xerostomia or dysphagia. However, this classification of acute and late adverse effects was developed to reflect observations from conventional fractionation. The development of altered fractionation and combined modality treatment has lead to the reporting of extended acute effects, lasting beyond 90 days (<LINK REF="REF-Trotti-2000" TYPE="REFERENCE">Trotti 2000</LINK>).</P>
<P>The severity of acute adverse effects is increased with increased daily dose, both with schedules that use increased dose per fraction and those that include more than one radiotherapy fraction per day. Lengthening the interfraction interval to at least 6 hours appears to mitigate some of this increased acute toxicity. A treatment 'rest', as in split course regimens, does not appear to reduce acute toxicity.</P>
<P>Late adverse effects are also more severe in the accelerated regimens which use dose/fraction greater than 1.1 Gy and short (&lt; 5 hours) interfraction interval. This is supported by <LINK REF="STD-Ang-2001" TYPE="STUDY">Ang 2001</LINK> who reports on a large body of radiobiologic data "showing that fraction size rather than radiotherapy duration is the major determinant of radiotherapy-induced injury to normal tissues manifesting as late complications." </P>
<P>It has been reported that the major limitation of altered fractionation radiotherapy (and combined radio-chemotherapy) for head and neck cancer is increased acute reaction primarily acute mucositis (<LINK REF="STD-Fu-2000" TYPE="STUDY">Fu 2000</LINK>). The role of molecular targeted therapies and improved radiotherapy techniques including intensity modulated radiotherapy (IMRT) for maintaining acceptable toxicities need further evaluation. There are currently no trials of IMRT in this systematic review, however, the PARSPORT trial is underway and likely to complete follow-up in 2013 (<LINK REF="STD-Nutting-2009a" TYPE="STUDY">Nutting 2009a</LINK>).</P>
<P>The management of head and neck cancer often requires a combination of chemotherapy, radiotherapy or surgery, although current standard treatment is predominantly chemoradiotherapy with standard fractionation. This review focuses purely on trials to which the treatment under evaluation is some form of radiotherapy. While altered fractionation radiotherapy has been shown to improve overall survival when compared to conventional radiotherapy, it has not been directly compared to chemoradiotherapy. Also, there are no completed trials of altered fractionation plus chemotherapy versus chemoradiotherapy with standard fractionation. It is perhaps due to the cost and resource considerations of altered fractionation (especially hyperfractionation) that chemoradiotherapy remains the standard. For patients who have relative contraindications to chemotherapy (or specifically platinums), there is evidence to recommend the use of altered fractionation radiotherapy alone (especially hyperfractionation). To get a more complete overview of the role of each treatment modality, this review needs to be considered alongside the findings of previous reviews of surgery and chemotherapy for the treatment of cancers of the oral cavity and oropharynx (<LINK REF="REF-Furness-2010" TYPE="REFERENCE">Furness 2010</LINK>; <LINK REF="REF-Oliver-2007" TYPE="REFERENCE">Oliver 2007</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<POTENTIAL_BIASES MODIFIED="2010-11-05 12:52:54 +0000" MODIFIED_BY="[Empty name]">
<P>A comparison between meta-analyses of individual patient data and data obtained from published literature has previously been explored (<LINK REF="REF-Duchateau-2001" TYPE="REFERENCE">Duchateau 2001</LINK>). The study focused on meta-analyses of randomised controlled trials of chemotherapy in head and neck cancer. The outcome of interest was survival. For the meta-analysis of individual patient data, the estimate of effect was the hazard ratio and for the literature-based meta-analysis the odds ratio for death at particular time point was used. The two meta-analyses differed substantially in terms of number of comparisons, patients and events examined. However, even though the data sets vary, the treatment effect estimates and their 95% confidence intervals show little variation. The authors report that the main source of difference between the results of the meta-analyses is due to the fact that one is based on the hazard ratio and the other on the odds ratio. </P>
<P>In the current review, the hazard ratio was used as preferred estimate of effect. For 21 of the trials included in the review data for the calculation of a hazard ratio were available for the outcome of total mortality, 15 for locoregional control and 8 for disease free survival. It is acknowledged that where data are determined from Kaplan-Meier graphs there is scope for bias. Few trials present hazard ratios themselves, or data that allow for the calculation of hazard ratios without having to determine the number of events from a graph. When available, individual patient data were used over data presented in the published trials.</P>
</POTENTIAL_BIASES>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-11-05 12:53:58 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-11-05 12:53:01 +0000" MODIFIED_BY="[Empty name]">
<P>Altered fractionation radiotherapy is associated with an improvement in overall survival and locoregional control in patients with oral cavity and oropharyngeal cancers. The benefit may be greater with hyperfractionated regimens rather than accelerated regimens. More accurate methods of reporting adverse events are needed in order to truly assess the clinical performance of different radiotherapy regimens.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-11-05 12:53:58 +0000" MODIFIED_BY="[Empty name]">
<P>The role of molecular targeted therapies and improved radiotherapy techniques including intensity modulated radiotherapy for maintaining acceptable toxicities needs further evaluation. In addition, further research on the relative efficacy and toxicity of altered fractionation radiotherapy (+/- chemotherapy or biologics) versus conventional chemoradiotherapy is needed, as conventional chemoradiotherapy is still considered the current standard.</P>
<P>Trialists are encouraged to follow the Consolidated Standards of Reporting Trials (CONSORT) guidelines when reporting on their trials. Ideally trials should report hazard ratios with 95% confidence intervals for survival data, or present data that allow for the calculation of this estimate of effect. In addition, reporting of outcomes by tumour site and stage would allow for greater understanding of patient selection for different treatment modalities.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-11-05 12:54:32 +0000" MODIFIED_BY="[Empty name]">
<P>Thanks to:</P>
<UL>
<LI>May Wong for her statistical input during data extraction</LI>
<LI>Emma Tavender for her contribution to the drafting of the original protocol for this review, and helping to secure funding for the review</LI>
<LI>Sylvia Bickley and Anne Littlewood - Cochrane Oral Health Group, Trials Search Co-ordinators</LI>
<LI>Phil Riley - retrieval of papers</LI>
<LI>Chris O'Brien for his contribution to the CSROC Expert Panel</LI>
<LI>Dr KK Ang and Dr G Sanguineti for providing additional data.</LI>
</UL>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-11-05 17:29:55 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Conceiving the review and writing of protocol: Helen Worthington (HW), Jan Clarkson (JC), Anne-Marie Glenny (AMG), Richard Oliver (RO)</LI>
<LI>Designing the review: HW, JC, AMG, RO, Sue Pavitt (SP), Michaelina Macluskey (MM), David Conway (DC) and CSROC Expert Panel</LI>
<LI>Co-ordinating the review: AMG, Susan Furness (SF)</LI>
<LI>Data collection for the review: AMG, HW, JC, SF, MM, DC</LI>
<LI>Designing search strategies: Anne Littlewood (AL) (Trials Seach Co-ordinator, Cochrane Oral Health Group) in collaboration with SF and AMG</LI>
<LI>Undertaking searches: AL</LI>
<LI>Screening search results: SF, HW, AMG</LI>
<LI>Organizing retrieval of papers: AMG, SF, SP</LI>
<LI>Screening retrieved papers against eligibility criteria: AMG, SF, HW, JC, RO, SP, MM, DC</LI>
<LI>Appraising risk of bias: AMG, SF, Paul Brocklehurst (PB)</LI>
<LI>Extracting data from papers: AMG, HW, SF, PB</LI>
<LI>Writing to authors of papers for additional information: SP, SF</LI>
<LI>Data management for the review: AMG, SF, HW, SP</LI>
<LI>Entering data into RevMan: AMG, SF</LI>
<LI>Analysis of data: AMG, SF, HW</LI>
<LI>Interpretation of data: AMG, SF, HW, Kelvin KW Chan (KC)</LI>
<LI>Writing the review: AMG, SF, HW, KC.</LI>
</UL>
<P>The CSROC Expert Panel comprises:<BR/>Bertrand Baujat, Gerry Humphris, Iain Hutchison, Jean-Pierre Pignon, Gerry Robertson, Simon Rogers, Jatin Shah, Nick Slevin, Phil Sloan, David Soutar, Erich Sturgis, Jan Vermorken, Steve Wardell, Saman Warnakulasuriya, Keith Webster.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-11-05 13:00:43 +0000" MODIFIED_BY="[Empty name]">
<P>Types of studies: As the primary outcome for this review is total mortality we have added a requirement that included studies have a minimum of 6 months of follow-up of participants after the end of treatment. </P>
<P>Types of participants: We have only included studies where at least 50% of the participants have either oral cavity or oropharyngeal cancer, or where data for the oral cavity and oropharyngeal patients only are available.</P>
<P>Types of interventions: The intervention under evaluation must be radiotherapy. Trials where all participants receive the same radiotherapy regimen and are randomised to other treatments were excluded. </P>
<P>Types of outcomes: The protocol for this review stated that quality of life would be a primary outcome for this review. Quality of life is an important outcome, for both patients with oral cavity and oropharyngeal cancers and their doctors. However, quality of life is infrequently and inconsistently reported in trials which address a primary outcome of overall survival. Therefore we have opted to transfer this outcome to the list of secondary outcomes to be considered in future updates of this review as appropriate.</P>
<P>Search methods: The search strategy has been updated.</P>
<P>Quality assessment has been replaced by the new risk of bias tool.</P>
<P>Data synthesis has been updated. The primary outcome is total mortality expressed as a hazard ratio. A meta-analysis of individual patient data (IPD) for altered fractionation versus conventional fractionation has previously been published (<LINK REF="STD-Bourhis-2006" TYPE="STUDY">Bourhis 2006</LINK>). For trials included in the Bourhis meta-analysis, the IPD were used instead of data presented in the published reports. For dichotomous outcomes, the estimates of effect of an intervention were expressed as risk ratios together with 95% confidence intervals. Dichotomous data were only used for primary outcomes where hazard ratios were unavailable or could not be calculated.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-11-05 17:30:40 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-11-05 11:08:07 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-11-05 09:29:49 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ang-2001" MODIFIED="2010-08-31 15:21:01 +0100" MODIFIED_BY="[Empty name]" NAME="Ang 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-08-31 15:21:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, et al</AU>
<TI>Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2001</YR>
<VL>51</VL>
<NO>3</NO>
<PG>571-8</PG>
<MD>? incl oral cancer radio review</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bartelink-2002" MODIFIED="2010-11-05 08:54:33 +0000" MODIFIED_BY="[Empty name]" NAME="Bartelink 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-05 08:54:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bartelink H, van den Bogaert W, Horiot JC, Jager J, van Glabbeke M</AU>
<TI>Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial</TI>
<SO>European Journal of Cancer</SO>
<YR>2002</YR>
<VL>38</VL>
<NO>5</NO>
<PG>667-73</PG>
<MD>incl chemo/radio reviews - printed and pdf in file-in RM5 x2</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergermann-1992" MODIFIED="2010-11-05 08:54:49 +0000" MODIFIED_BY="[Empty name]" NAME="Bergermann 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-11-05 08:54:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergermann M, Dieckmann J, Machtens E</AU>
<TI>Preoperative short-term preliminary irradiation with 3 x 6 Gy, immediate radical tumor resection and postoperative booster irradiation to 60 Gy as an effective therapy concept for the treatment of T2 squamous cell carcinomas of the mouth. Results of a prospective randomized bi-center study</TI>
<SO>Fortschritte der Kiefer und Gesichts Chirurgie</SO>
<YR>1992</YR>
<VL>37</VL>
<PG>17-20</PG>
<MD>incl Radio - check if paper copy is found</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bjarnason-2009" MODIFIED="2010-11-05 08:55:13 +0000" MODIFIED_BY="[Empty name]" NAME="Bjarnason 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-05 08:55:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjarnason GA, Mackenzie RG, Nabid A, Hodson ID, El-Sayed S, Grimard L, et al</AU>
<TI>Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3)</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2009</YR>
<VL>73</VL>
<NO>1</NO>
<PG>166-72</PG>
<MD>incl radio review - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bourhis-2006" MODIFIED="2010-11-05 08:55:30 +0000" MODIFIED_BY="[Empty name]" NAME="Bourhis 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-05 08:55:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S, et al</AU>
<TI>Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>18</NO>
<PG>2873-8</PG>
<MD>incl radio review -in RM5 (this is the published version of ref #25 from Bourhis 2004) linked also to clin Trials ID NCT 00162708</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cox-1990" MODIFIED="2010-11-05 08:57:09 +0000" MODIFIED_BY="[Empty name]" NAME="Cox 1990" YEAR="">
<REFERENCE MODIFIED="2010-11-05 08:55:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cox JD, Pajak TF, Marcial VA, Coia L, Mohiuddin M, Fu KK, et al</AU>
<TI>ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1991</YR>
<VL>20</VL>
<NO>6</NO>
<PG>1191-5</PG>
<MD>incl radio review - in RM5 - RTOG 8313 trial</MD>
<IDENTIFIERS MODIFIED="2010-02-09 14:02:49 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 08:55:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cox JD, Pajak TF, Marcial VA, Coia L, Mohiuddin M, Fu KK, et al</AU>
<TI>Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts. New evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol 8313</TI>
<SO>Cancer</SO>
<YR>1992</YR>
<VL>69</VL>
<NO>11</NO>
<PG>2744-8</PG>
<MD>incl radio review - in RM5 - RTOG 8313 trial</MD>
<IDENTIFIERS MODIFIED="2010-02-09 14:02:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 08:56:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cox JD, Pajak TF, Marcial VA, Hanks GE, Mohiuddin M, Fu KK, et al</AU>
<TI>Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of radiation therapy oncology group protocol 83-13</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1990</YR>
<VL>18</VL>
<NO>3</NO>
<PG>515-21</PG>
<MD>incl radio review - in RM5 - RTOG 8313 trial</MD>
<IDENTIFIERS MODIFIED="2010-02-09 14:03:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 08:56:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fu KK, Cox JD, Pajak TF, Marcial VA, Coia LR, Mohiuddin M, et al</AU>
<TI>Carcinomas of the oropharynx treated with hyperfractionated radiation therapy on Radiation Therapy Oncology Group Protocol 8313</TI>
<SO>Recent Results in Cancer Research</SO>
<YR>1994</YR>
<VL>134</VL>
<PG>145-54</PG>
<MD>incl radio review - in RM5 - RTOG 8313 trial</MD>
<IDENTIFIERS MODIFIED="2010-02-09 14:03:05 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 08:56:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fu KK, Pajak TF, Marcial VA, Ortiz HG, Rotman M, Asbell SO, et al</AU>
<TI>Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1995</YR>
<VL>32</VL>
<NO>3</NO>
<PG>577-88</PG>
<MD>incl radio review - in RM5 - RTOG 8313 trial</MD>
<IDENTIFIERS MODIFIED="2010-02-09 14:03:10 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 08:57:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herrmann T</AU>
<TI>Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. Radiation Therapy Oncology Group</TI>
<SO>Strahlentherapie und Onkologie</SO>
<YR>1995</YR>
<VL>171</VL>
<NO>4</NO>
<PG>244-5</PG>
<MD>incl radio review RTOG 83-13 see also Cox 1990 and Fu 1994 - in RM5</MD>
<IDENTIFIERS MODIFIED="2010-02-09 14:03:15 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dobrowsky-2000" MODIFIED="2010-11-05 08:57:59 +0000" MODIFIED_BY="[Empty name]" NAME="Dobrowsky 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-11-05 08:57:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dobrowsky W, Dobrowsky E, Naude J, Millesi W, Pavelka R, Kautzky M, et al</AU>
<TI>Conventional vs accelerated fractionation in head and neck cancer</TI>
<SO>British Journal of Cancer - Supplement</SO>
<YR>1996</YR>
<VL>27</VL>
<PG>S279-81</PG>
<MD>incl radio review - in RM5- link to Dobrowsky 2000</MD>
<IDENTIFIERS MODIFIED="2010-02-09 14:01:53 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 08:57:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dobrowsky W, Naude J</AU>
<TI>Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>2000</YR>
<VL>57</VL>
<NO>2</NO>
<PG>119-24</PG>
<MD>incl radio review - in RM5 - link to Dobrowsky 1996</MD>
<IDENTIFIERS MODIFIED="2010-02-09 14:02:24 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fu-1995" MODIFIED="2010-11-05 08:58:18 +0000" MODIFIED_BY="[Empty name]" NAME="Fu 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-11-05 08:58:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fu KK, Clery M, Ang KK, Byhardt RW, Maor MH, Beitler JJ</AU>
<TI>Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1995</YR>
<VL>32</VL>
<NO>3</NO>
<PG>589-97</PG>
<MD>incl radio review RTOG 88-09 - In RM5</MD>
<IDENTIFIERS MODIFIED="2010-02-09 14:02:42 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fu-2000" MODIFIED="2010-11-05 09:07:25 +0000" MODIFIED_BY="[Empty name]" NAME="Fu 2000" YEAR="">
<REFERENCE MODIFIED="2010-11-05 08:58:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubben HH, Beck-Bornholdt HP</AU>
<TI>A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard-fractionation radiotherapy for head-and-neck squamous cell carcinomas: first report of RTOG 9003: in regard to Fu et al. IJROBP 2000;48:7-16. Actuarial estimates of late normal-tissue effects...now!</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2001</YR>
<VL>51</VL>
<NO>2</NO>
<PG>563</PG>
<MD>incl radio review - link to Fu 2000 RTOG 9003</MD>
<IDENTIFIERS MODIFIED="2010-02-09 14:02:12 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 08:59:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, et al</AU>
<TI>A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2000</YR>
<VL>48</VL>
<NO>1</NO>
<PG>7-16</PG>
<MD>incl Radio review - link to Dubben 2001 and Logie 2002</MD>
<IDENTIFIERS MODIFIED="2010-02-09 14:01:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-11 13:33:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konski AA, Winter K, Cole BF, Ang KK, Fu KK</AU>
<TI>Quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) 90-03: phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma</TI>
<SO>Head and Neck</SO>
<YR>2009</YR>
<VL>31</VL>
<PG>207-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:07:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Logie MB</AU>
<TI>Radiation therapy oncology: in regard to Fu et al., IJROBP 2000;48:7-16</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2002</YR>
<VL>52</VL>
<NO>4</NO>
<PG>1148</PG>
<MD>Incl radio review - Link to Fu 2000 and Dubben 2001</MD>
<IDENTIFIERS MODIFIED="2010-02-09 14:01:17 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghoshal-2008" MODIFIED="2010-11-05 09:07:39 +0000" MODIFIED_BY="[Empty name]" NAME="Ghoshal 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-05 09:07:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghoshal S, Goda JS, Mallick I, Kehwar TS, Sharma SC</AU>
<TI>Concomitant boost radiotherapy compared with conventional radiotherapy in squamous cell carcinoma of the head and neck--a phase III trial from a single institution in India</TI>
<SO>Clinical Oncology (Royal College of Radiologists)</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>3</NO>
<PG>212-20</PG>
<MD>incl radio review - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Griffin-1984" MODIFIED="2010-11-05 09:07:54 +0000" MODIFIED_BY="[Empty name]" NAME="Griffin 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-11-05 09:07:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Griffin TW, Davis R, Hendrickson FR, Maor MH, Laramore GE</AU>
<TI>Fast neutron radiation therapy for unresectable squamous cell carcinomas of the head and neck: the results of a randomized RTOG study</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1984</YR>
<VL>10</VL>
<NO>12</NO>
<PG>2217-21</PG>
<MD>incl radio review - in RM5- RTOG study</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Griffin-1989" MODIFIED="2010-11-05 09:08:21 +0000" MODIFIED_BY="[Empty name]" NAME="Griffin 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-11-05 09:08:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Griffin TW, Davis R, Laramore GE, Maor MH, Hendrickson FR, Rodriguez-Antunez A, et al</AU>
<TI>Mixed beam radiation therapy for unresectable squamous cell carcinomas of the head and neck: the results of a randomized RTOG study</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1984</YR>
<VL>10</VL>
<NO>12</NO>
<PG>2211-5</PG>
<MD>fast neutron studies/ incl radio review</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:08:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Griffin TW, Pajak TF, Maor MH, Laramore GE, Hendrickson FR, Parker RG, et al</AU>
<TI>Mixed neutron/photon irradiation of unresectable squamous cell carcinomas of the head and neck: the final report of a randomized cooperative trial</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1989</YR>
<VL>17</VL>
<NO>5</NO>
<PG>959-65</PG>
<MD>incl radio review - in RM5</MD>
<IDENTIFIERS MODIFIED="2010-02-09 16:43:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horiot-1992" MODIFIED="2010-11-05 09:13:24 +0000" MODIFIED_BY="[Empty name]" NAME="Horiot 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-11-05 09:08:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernier J, Thames HD, Smith CD, Horiot JC</AU>
<TI>Tumor response, mucosal reactions and late effects after conventional and hyperfractionated radiotherapy</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>1998</YR>
<VL>47</VL>
<NO>2</NO>
<PG>137-43</PG>
<MD>incl oral cancer radio review - link to Horiot 1992 - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:09:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horiot JC, Begg AC, Le Fur R, Schraub S, van den Bogaert W, van Glabbeke M, et al</AU>
<TI>Present status of EORTC trials of hyperfractionated and accelerated radiotherapy on head and neck carcinoma</TI>
<SO>Recent Results in Cancer Research</SO>
<YR>1994</YR>
<VL>134</VL>
<PG>111-9</PG>
<MD>included radio review / review which references EORTC 22851 &amp; 22791</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:11:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horiot JC, Bontemps P, Begg AC, Le Fur R, van den Bogaert W, Bolla M, et al</AU>
<TI>Hyperfractionated and accelerated radiotherapy in head and neck cancers: results of the EORTC trials and impact on clinical practice</TI>
<SO>Bulletin du Cancer. Radiotherapie</SO>
<YR>1996</YR>
<VL>83</VL>
<NO>4</NO>
<PG>314-20</PG>
<MD>incl radio review - long term results of EORTC protocols 22791( Horiot 1992) and 22851 (Horiot 1997)</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:11:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horiot JC, Le Fur R, N'Guyen T, Chenal C, Schraub S, Alfonsi S, et al</AU>
<TI>Hyperfractionated compared with conventional radiotherapy in oropharyngeal carcinoma: an EORTC randomized trial</TI>
<SO>European Journal of Cancer</SO>
<YR>1990</YR>
<VL>26</VL>
<NO>7</NO>
<PG>779-80</PG>
<MD>included radio review / review which references EORTC 22791</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:12:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Horiot JC, Le Fur R, N'Guyen T, Chenal C, Schraub S, Alfonsi S, et al</AU>
<TI>Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>1992</YR>
<VL>25</VL>
<NO>4</NO>
<PG>231-41</PG>
<MD>incl Radio review - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:12:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horiot JC, Le Fur R, NGuyen T, Schraub S, Chenal C, de Pauw M, et al</AU>
<TI>Two fractions per day versus a single fraction per day in the radiotherapy of oropharynx carcinoma: results of an EORTC randomized trial</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1988</YR>
<VL>15</VL>
<PG>179</PG>
<MD>included radio review / review which references EORTC 22791</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:13:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horiot JC</AU>
<TI>Controlled clinical trials of hyperfractionated and accelerated radiotherapy in otorhinolaryngologic cancers</TI>
<SO>Bulletin de l'Academie Nationale de Medecine</SO>
<YR>1998</YR>
<VL>182</VL>
<NO>6</NO>
<PG>1247-60</PG>
<MD>included radio review / review which references EORTC 22851 &amp; 22791</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horiot-1997" MODIFIED="2010-11-05 09:15:31 +0000" MODIFIED_BY="[Empty name]" NAME="Horiot 1997" YEAR="">
<REFERENCE MODIFIED="2010-11-05 09:14:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horiot JC, Bontemps P, Begg AC, Le Fur R, van den Bogaert W, Bolla M, et al</AU>
<TI>Hyperfractionated and accelerated radiotherapy in head and neck cancers: results of the EORTC trials and impact on clinical practice</TI>
<SO>Bulletin du Cancer. Radiotherapie</SO>
<YR>1996</YR>
<VL>83</VL>
<NO>4</NO>
<PG>314-20</PG>
<MD>incl radio review - long term results of EORTC protocols 22791( Horiot 1992) and 22851 (Horiot 1997)</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:15:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Horiot JC, Bontemps P, van den Bogaert W, Le Fur R, van den Weijngaert D, Bolla M, et al</AU>
<TI>Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>1997</YR>
<VL>44</VL>
<NO>2</NO>
<PG>111-21</PG>
<MD>incl Radio review in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:15:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horiot JC</AU>
<TI>Controlled clinical trials of hyperfractionated and accelerated radiotherapy in otorhinolaryngologic cancers</TI>
<SO>Bulletin de l'Academie Nationale de Medecine</SO>
<YR>1998</YR>
<VL>182</VL>
<NO>6</NO>
<PG>1247-60</PG>
<MD>included radio review / review which references EORTC 22851 &amp; 22751</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hukku-1991" MODIFIED="2010-11-05 09:15:52 +0000" MODIFIED_BY="[Empty name]" NAME="Hukku 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-11-05 09:15:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hukku S</AU>
<TI>Comparison of high fractional dose continuous versus conventional split course radiation therapy in advanced head and neck cancer</TI>
<SO>Indian Journal of Radiology and Imaging</SO>
<YR>1991</YR>
<VL>I</VL>
<NO>Suppl 1 (Pt 1)</NO>
<PG>434-9</PG>
<MD>? incl oral cancer radio review - paper copy requested from Phil 30 Sept 09 - paper copy received 23/11/09 - in radio review - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inoue-2001" MODIFIED="2010-11-05 09:16:23 +0000" MODIFIED_BY="[Empty name]" NAME="Inoue 2001" YEAR="">
<REFERENCE MODIFIED="2010-11-05 09:16:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inoue T, Inoue T, Teshima T, Murayama S, Shimizutani K, Fuchihata H, et al</AU>
<TI>Phase III trial of high and low dose rate interstitial radiotherapy for early oral tongue cancer</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1996</YR>
<VL>36</VL>
<NO>5</NO>
<PG>1201-4</PG>
<MD>incl radio review - randomised trial - pdf on file - In RM5 link to Inoue 2001</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:16:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Inoue T, Inoue T, Yoshida K, Yoshioka Y, Shimamoto S, Tanaka E, et al</AU>
<TI>Phase III trial of high- vs. low-dose-rate interstitial radiotherapy for early mobile tongue cancer</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2001</YR>
<VL>51</VL>
<NO>1</NO>
<PG>171-5</PG>
<MD>incl Radio review -pdf on file- link to Inoue 1996 - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ketcham-1969" MODIFIED="2010-11-05 09:16:36 +0000" MODIFIED_BY="[Empty name]" NAME="Ketcham 1969" YEAR="1969">
<REFERENCE MODIFIED="2010-11-05 09:16:36 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;5347088&lt;br&gt;RefMgr field[1]: Journal&lt;br&gt;RefMgr field[8]: Not in File&lt;/p&gt;" NOTES_MODIFIED="2010-11-05 09:16:36 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ketcham AS, Hoye RC, Chretien PB, Brace KC</AU>
<TI>Irradiation twenty-four hours preoperatively</TI>
<SO>American Journal of Surgery</SO>
<YR>1969</YR>
<VL>118</VL>
<NO>5</NO>
<PG>691-7</PG>
<MD>not rand</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lawrence-1974" MODIFIED="2010-11-05 09:16:51 +0000" MODIFIED_BY="[Empty name]" NAME="Lawrence 1974" YEAR="1974">
<REFERENCE MODIFIED="2010-11-05 09:16:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lawrence W Jr, Terz JJ, Rogers C, King RE, Wolf JS, King ER</AU>
<TI>Proceedings: Preoperative irradiation for head and neck cancer: a prospective study</TI>
<SO>Cancer</SO>
<YR>1974</YR>
<VL>33</VL>
<PG>318-23</PG>
<MD>Incl radio review - randomised comparison of preop RT + surg vs surg alone - pdf on file - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacDougall-1990" MODIFIED="2010-11-05 09:18:34 +0000" MODIFIED_BY="[Empty name]" NAME="MacDougall 1990" YEAR="1984">
<REFERENCE MODIFIED="2010-11-05 09:17:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnott SJ, Duncan W</AU>
<TI>An interim assessment of the experience of fast neutron therapy in patients with head and neck cancer in Edinburgh</TI>
<SO>Journal Europeen de Radiotherapie</SO>
<YR>1984</YR>
<VL>5</VL>
<PG>138-41</PG>
<MD>incl oral cancer radio review - in RM5 - Edinburgh study</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:17:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duncan W, Arnott SJ, Battermann JJ, Orr JA, Schmitt G, Kerr GR</AU>
<TI>Fast neutrons in the treatment of head and neck cancers: the results of a multi-centre randomly controlled trial</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>1984</YR>
<VL>2</VL>
<NO>4</NO>
<PG>293-300</PG>
<MD>incl radio review - in RM5</MD>
<IDENTIFIERS MODIFIED="2010-02-09 14:00:23 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:18:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duncan W, Arnott SJ, Orr JA, Kerr GR</AU>
<TI>The Edinburgh experience of fast neutron therapy</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1982</YR>
<VL>8</VL>
<NO>12</NO>
<PG>2155-7</PG>
<MD>incl oral cancer radio review - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:18:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duncan W, Orr JA, Arnott SJ, Jack WJ, Kerr GR, Williams JR</AU>
<TI>Fast neutron therapy for squamous cell carcinoma in the head and neck region: results of a randomized trial</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1987</YR>
<VL>13</VL>
<NO>2</NO>
<PG>171-8</PG>
<MD>incl oral cancer radio review - in RM5 - Edinburgh study</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:18:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>MacDougall RH, Orr JA, Kerr GR, Duncan W</AU>
<TI>Fast neutron treatment for squamous cell carcinoma of the head and neck: final report of Edinburgh randomised trial</TI>
<SO>BMJ</SO>
<YR>1990</YR>
<VL>301</VL>
<NO>6763</NO>
<PG>1241-2</PG>
<MD>incl oral cancer radio review - in RM5 - Edinburgh study</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maor-1986" MODIFIED="2010-11-05 09:18:45 +0000" MODIFIED_BY="[Empty name]" NAME="Maor 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-11-05 09:18:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maor MH, Schoenfeld DA, Hendrickson FR, Davis LW, Laramore GE, Thomas FJ, et al</AU>
<TI>Evaluation of a neutron boost in head and neck cancer. Results of the randomized RTOG trial 78-08</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>1986</YR>
<VL>9</VL>
<NO>1</NO>
<PG>61-6</PG>
<MD>incl oral cancer radio review - in RM5 RTOG 78-08</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maor-1995" MODIFIED="2010-11-05 09:19:48 +0000" MODIFIED_BY="[Empty name]" NAME="Maor 1995" YEAR="1996">
<REFERENCE MODIFIED="2010-11-05 09:19:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cranberg L</AU>
<TI>Regarding Maor et al. IJROBP 1995;32(3):599-604</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1996</YR>
<VL>34</VL>
<NO>4</NO>
<PG>972</PG>
<MD>incl oral cancer radio review - link to Maor 1995 - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:19:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laramore GE, Griffin TW</AU>
<TI>Fast neutron radiotherapy: where have we been and where are we going? The jury is still out--regarding Maor et al., IJROBP 32:599-604; 1995</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1995</YR>
<VL>32</VL>
<NO>3</NO>
<PG>879-82</PG>
<MD>Editorial - link to Maor 1995 incl in oral cancer radio review - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:19:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maor MH, Errington RD, Caplan RJ, Griffin TW, Laramore GE, Parker RG, et al</AU>
<TI>Fast-neutron therapy in advanced head and neck cancer: a collaborative international randomized trial</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1995</YR>
<VL>32</VL>
<NO>3</NO>
<PG>599-604</PG>
<MD>incl oral cancer radio review - obtain paper copy fast neutron studies/ incl Radio - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcial-1987" MODIFIED="2010-11-05 09:20:28 +0000" MODIFIED_BY="[Empty name]" NAME="Marcial 1987" YEAR="">
<REFERENCE MODIFIED="2010-11-05 09:20:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marcial VA, Pajak TF, Chang C, Tupchong L, Stetz J</AU>
<TI>Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG)</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1987</YR>
<VL>13</VL>
<NO>1</NO>
<PG>41-7</PG>
<MD>incl oral cancer radio review - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:20:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marcial VA, Pajak TF, Chang C</AU>
<TI>Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx and sinuses, using radiotherapy as the only planned modality: a Radiation Therapy Oncology Group report</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1985</YR>
<VL>11</VL>
<PG>142</PG>
<MD>notrel oral cancer chemo /radio reviews</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcial-1993" MODIFIED="2010-11-05 09:23:14 +0000" MODIFIED_BY="[Empty name]" NAME="Marcial 1993" YEAR="">
<REFERENCE MODIFIED="2010-11-05 09:21:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marcial VA, Hanley JA, Hendrickson F, Ortiz H</AU>
<TI>Split-course radiation therapy of carcinoma of the base of the tongue: results of a prospective national collaborative clinical trial conducted by the Radiation Therapy Oncology Group</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1983</YR>
<VL>9</VL>
<NO>4</NO>
<PG>437-43</PG>
<MD>incl oral cancer radio review - link to Ortiz 1985 - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:22:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marcial VA, Pajak TF, Rotman M, Brady LW, Amato D</AU>
<TI>'Compensated' split-course versus continuous radiation therapy of carcinoma of the tonsillar fossa. Final results of a prospective randomized clinical trial of the Radiation Therapy Oncology Group</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>16</VL>
<NO>5</NO>
<PG>389-96</PG>
<MD>incl oral cancer radio review - link to Marcial 1983 - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:23:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ortiz H, Marcial VA, Hanley JA, Ramirez C, Pacheco JC</AU>
<TI>Protocol variations and their influence on the final outcome: critical review of the split-course base of tongue study of the RTOG</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1985</YR>
<VL>11</VL>
<PG>885-92</PG>
<MD>incl oral cancer radio review - link to Marcial 1983 - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olmi-2003" MODIFIED="2010-11-05 09:25:59 +0000" MODIFIED_BY="[Empty name]" NAME="Olmi 2003" YEAR="">
<REFERENCE MODIFIED="2010-11-05 09:25:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Crispino S, Olmi P, Fallai C, Rossi F, Marsoni S, Tinazzi A, et al</AU>
<TI>Conventional radiotherapy (RT) versus accelerated hyperfractionated RT versus conventional RT and concomitant chemotherapy in locally advanced oropharyngeal carcinoma (ORO-93/01)</TI>
<SO>Proceedings of the Annual Meeting of the American Society of Clinical Oncology</SO>
<YR>1997</YR>
<PG>Abs No 1423</PG>
<MD>incl oral cancer chemo/radio - link to Olmi 2003 - RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:25:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fallai C, Bolner A, Signor M, Gava A, Franchin G, Ponticelli P, et al</AU>
<TI>Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx</TI>
<SO>Tumori</SO>
<YR>2006</YR>
<VL>92</VL>
<NO>1</NO>
<PG>41-54</PG>
<MD>Incl oral cancer chemo and radio- paper copy in file - in RM5 x2 - link to Olmi 2003</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:25:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Olmi P, Crispino S, Fallai C, Torri V, Rossi F, Bolner A, et al</AU>
<TI>Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2003</YR>
<VL>55</VL>
<NO>1</NO>
<PG>78-92</PG>
<MD>incl oral cancer Radio/incl chemo - in RM5 x2 - link to Fallai 2006</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pinto-1991" MODIFIED="2010-11-05 09:26:57 +0000" MODIFIED_BY="[Empty name]" NAME="Pinto 1991" YEAR="">
<REFERENCE MODIFIED="2010-11-05 09:26:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pinto LH, Canary PC, Araujo CM, Bacelar SC, Souhami L</AU>
<TI>Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1991</YR>
<VL>21</VL>
<NO>3</NO>
<PG>557-62</PG>
<MD>incl oral cancer radio review - in RM5 - link to Pinto 1990</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:26:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinto LH, Canary PC, Araujo CM, Bacelar SC, Souhami L</AU>
<TI>Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharynx carcinoma</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1990</YR>
<VL>19</VL>
<PG>140-1</PG>
<MD>incl oral cancer radio review - in RM5 - link to Pinto 1991</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poulsen-2001" MODIFIED="2010-11-05 09:27:42 +0000" MODIFIED_BY="[Empty name]" NAME="Poulsen 2001" YEAR="">
<REFERENCE MODIFIED="2010-11-05 09:27:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daly T, Poulsen MG, Denham JW, Peters LJ, Lamb DS, Krawitz H, et al</AU>
<TI>The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>2003</YR>
<VL>68</VL>
<NO>2</NO>
<PG>113-22</PG>
<MD>notrel oral cancer chemo/radio reviews - subgroup analysis of Poulsen 2001</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:27:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poulsen M, Denham J, Spry N, Lamb D, Peters L, Krawitz H, et al</AU>
<TI>Acute toxicity and cost analysis of a phase III randomized trial of accelerated and conventional radiotherapy for squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group study</TI>
<SO>Australasian Radiology</SO>
<YR>1999</YR>
<VL>43</VL>
<NO>4</NO>
<PG>487-94</PG>
<MD>incl oral cancer radio review - link to Poulsen 2001- in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:27:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Poulsen MG, Denham JW, Peters LJ, Lamb DS, Spry NA, Hindley A, et al</AU>
<TI>A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>2001</YR>
<VL>60</VL>
<NO>2</NO>
<PG>113-22</PG>
<MD>incl oral cancer radio review - link to Poulsen 2001- see also Daly 2003 anaemia as prog indicator - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanguineti-2005" MODIFIED="2010-11-05 09:28:23 +0000" MODIFIED_BY="[Empty name]" NAME="Sanguineti 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-05 09:28:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antogoni P, Bignardi M, Richetti A, Corvo R, Sormani M, Gabriele P, et al</AU>
<TI>Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2003</YR>
<VL>57</VL>
<NO>2</NO>
<PG>S154</PG>
<MD>Excl oral cancer radio review - link to Sanguineti 2005 - 37% OC/OP</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:28:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sanguineti G, Richetti A, Bignardi M, Corvo R, Gabriele P, Sormani MP, et al</AU>
<TI>Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2005</YR>
<VL>61</VL>
<NO>3</NO>
<PG>762-71</PG>
<MD>incl oral cancer radio review</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skladowski-2006" MODIFIED="2010-11-05 09:28:52 +0000" MODIFIED_BY="[Empty name]" NAME="Skladowski 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-05 09:28:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maciejewski B, Skladowski K, Pilecki B, Taylor JM, Withers RH, Miszczyk L, et al</AU>
<TI>Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicity</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>1996</YR>
<VL>40</VL>
<NO>2</NO>
<PG>137-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:28:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skladowski K, Maciejewski B, Golen M, Pilecki B, Przeorek W, Tarnawski R</AU>
<TI>Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>2</NO>
<PG>101-10</PG>
<MD>Excluded radio - 50% oral cavity or oropharyngeal cancer only - in Bourhis metanalysis</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:28:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Skladowski K, Maciejewski B, Golen M, Tarnawski R, Slosarek K, Suwinski R, et al</AU>
<TI>Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>3</NO>
<PG>706-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terz-1981" MODIFIED="2010-11-05 09:29:06 +0000" MODIFIED_BY="[Empty name]" NAME="Terz 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-11-05 09:29:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terz JJ, King ER, Lawrence W Jr</AU>
<TI>Preoperative irradiation for head and neck cancer: results of a prospective study</TI>
<SO>Surgery</SO>
<YR>1981</YR>
<VL>89</VL>
<NO>4</NO>
<PG>449-53</PG>
<MD>incl oral cancer radio/surgery reviews - in RM5 x2</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weissberg-1983" MODIFIED="2010-11-05 09:29:49 +0000" MODIFIED_BY="[Empty name]" NAME="Weissberg 1983" YEAR="">
<REFERENCE MODIFIED="2010-11-05 09:29:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Percarpio B, Fischer JJ</AU>
<TI>Irradiation of advanced head and neck cancer with large daily fractions. Preliminary results of a prospectively randomized clinical trial</TI>
<SO>Radiology</SO>
<YR>1976</YR>
<VL>121</VL>
<NO>2</NO>
<PG>489-90</PG>
<MD>incl radio review - link to Weissberg 1982 &amp; Weissberg 1983</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:29:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Weissberg JB, Pillsbury H, Sasaki CT, Son YH, Fischer JJ</AU>
<TI>High fractional dose irradiation of advanced head and neck cancer. Implications for combined radiotherapy and surgery</TI>
<SO>Archives of Otolaryngology</SO>
<YR>1983</YR>
<VL>109</VL>
<NO>2</NO>
<PG>98-102</PG>
<MD>incl radio review - link with prelim report by Percarpio 1976, and paper Weissberg 1982 - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:29:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weissberg JB, Son YH, Percarpio B, Fischer JJ</AU>
<TI>Randomized trial of conventional versus high fractional dose radiation therapy in the treatment of advanced head and neck cancer</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1982</YR>
<VL>8</VL>
<NO>2</NO>
<PG>179-85</PG>
<MD>incl radio review - link with prelim report by Percarpio 1976, and paper Weissberg 1983 - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-11-05 10:21:02 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Arimoto-2003" MODIFIED="2010-11-05 09:30:31 +0000" MODIFIED_BY="[Empty name]" NAME="Arimoto 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-05 09:30:31 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;RefMgr field[1]: Journal&lt;br&gt;RefMgr field[8]: Not in File&lt;/p&gt;" NOTES_MODIFIED="2010-11-05 09:30:31 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arimoto T, Yamazaki A, Yonesaka A, Matsuzawa T, Kanai N</AU>
<TI>Clinical application of AcMAR (accelerated multiple-arc radiotherapy) for head and neck tumors - Results of a randomized, two-dose study in Kitami Red-Cross General Hospital</TI>
<SO>Journal of JASTRO</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>3</NO>
<PG>203-11</PG>
<MD>? incl radio review - request copy from phil</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Awwad-1992" MODIFIED="2010-11-05 09:30:55 +0000" MODIFIED_BY="[Empty name]" NAME="Awwad 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-11-05 09:30:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Awwad HK, Khafagy Y, Barsoum M, Ezzat S, el-Attar I, Farag H, et al</AU>
<TI>Accelerated versus conventional fractionation in the postoperative irradiation of locally advanced head and neck cancer: influence of tumour proliferation</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>1992</YR>
<VL>25</VL>
<NO>4</NO>
<PG>261-6</PG>
<MD>Excl radio review - request copy from phil/ see also Awwad 2002 - paper copy sighted less than 50% OC/OP/</MD>
<IDENTIFIERS MODIFIED="2010-02-09 14:03:53 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Awwad-2002" MODIFIED="2010-11-05 09:31:08 +0000" MODIFIED_BY="[Empty name]" NAME="Awwad 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-05 09:31:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Awwad HK, Lotayef M, Shouman T, Begg AC, Wilson G, Bentzen SM, et al</AU>
<TI>Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation</TI>
<SO>British Journal of Cancer</SO>
<YR>2002</YR>
<VL>86</VL>
<NO>4</NO>
<PG>517-23</PG>
<MD>Excl radio review - request copy from phil - paper copy sighted - 40% OC/OP</MD>
<IDENTIFIERS MODIFIED="2010-02-09 14:04:05 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baumann-2001" MODIFIED="2010-11-05 09:31:22 +0000" MODIFIED_BY="[Empty name]" NAME="Baumann 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-05 09:31:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baumann M, Klages HT</AU>
<TI>Comparison of various fractionation schedule in curative radiotherapy alone of locally advanced head and neck tumors</TI>
<SO>Strahlentherapie und Onkologie</SO>
<YR>2001</YR>
<VL>177</VL>
<NO>3</NO>
<PG>162-5</PG>
<MD>notrel oral cancer chemo reviews</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Catterall-1977" MODIFIED="2010-11-05 09:31:54 +0000" MODIFIED_BY="[Empty name]" NAME="Catterall 1977" YEAR="1977">
<REFERENCE MODIFIED="2010-11-05 09:31:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Catterall M, Bewley DK, Sutherland I</AU>
<TI>Second report on results of a randomised clinical trial of fast neutrons compared with chi or gamma rays in treatment of advanced tumours of head and neck</TI>
<SO>British Medical Journal</SO>
<YR>1977</YR>
<VL>1</VL>
<NO>6077</NO>
<PG>1642</PG>
<MD>incl radio review -in RM5 link to Catterall 1975 and Catterall 1977 'first randomized clinical....'</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:31:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Catterall M, Sutherland I, Bewley DK</AU>
<TI>First results of a randomized clinical trial of fast neutrons compared with X or gamma rays in treatment of advanced tumours of the head and neck. Report to the Medical Research Council</TI>
<SO>British Medical Journal</SO>
<YR>1975</YR>
<VL>2</VL>
<NO>5972</NO>
<PG>653-6</PG>
<MD>incl radio review -in RM5 link to Catterall 1977 'first randomized clinical...' and Catterall 1977 'second report ....'</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:31:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Catterall M</AU>
<TI>First randomized clinical trial of fast neutrons compared with photons in advanced carcinoma of the head and neck</TI>
<SO>Clinical Otolaryngology &amp; Allied Sciences</SO>
<YR>1977</YR>
<VL>2</VL>
<NO>4</NO>
<PG>359-72</PG>
<MD>incl radio review -in RM5 link to Catterall 1975 and Catterall 1977 'second report ....'</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CHART-1997" MODIFIED="2010-11-05 09:33:27 +0000" MODIFIED_BY="[Empty name]" NAME="CHART 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-05 09:32:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baumann M, Herrmann T</AU>
<TI>Outcome of CHART radiotherapy in squamous cell carcinoma of the head and neck and in non-small cell bronchial carcinoma</TI>
<SO>Strahlentherapie und Onkologie</SO>
<YR>1997</YR>
<VL>173</VL>
<NO>6</NO>
<PG>341-3</PG>
<MD>excl chemo/radio review - paper includes both non-smallcell lung cancer and head and neck so is unlikely that &gt; 50% are OC/OP. CHART study is excl low OC/OP</MD>
<IDENTIFIERS MODIFIED="2010-02-09 14:04:14 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:32:25 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;HW&lt;/p&gt;" NOTES_MODIFIED="2010-11-05 09:32:25 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M</AU>
<TI>A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>1997</YR>
<VL>44</VL>
<NO>2</NO>
<PG>123-36</PG>
<MD>Excluded radio less than 50% oral cavity or oropharyngeal cancer</MD>
<IDENTIFIERS MODIFIED="2010-08-05 16:57:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:32:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Griffiths GO, Parmar MK, Bailey AJ</AU>
<TI>Physical and psychological symptoms of quality of life in the CHART randomized trial in head and neck cancer: short-term and long-term patient reported symptoms. CHART Steering Committee. Continuous hyperfractionated accelerated radiotherapy</TI>
<SO>British Journal of Cancer</SO>
<YR>1999</YR>
<VL>81</VL>
<NO>7</NO>
<PG>1196-205</PG>
<MD>? incl radio review - QoL outcomes</MD>
<IDENTIFIERS MODIFIED="2010-08-05 16:58:39 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:32:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saunders MI, Dische S, Barrett A, Parmar MK, Harvey A, Gibson D</AU>
<TI>Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee</TI>
<SO>British Journal of Cancer</SO>
<YR>1996</YR>
<VL>73</VL>
<NO>12</NO>
<PG>1455-62</PG>
<MD>excl radio review - less than 50% OC/OP cancer /CHART study</MD>
<IDENTIFIERS MODIFIED="2010-08-05 16:59:06 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:33:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saunders MI, Rojas AM, Parmar MKB, Dische S, CHART Trial Collaborators</AU>
<TI>Mature results of a randomized trial of accelerated hyperfractionated versus conventional radiotherapy in head-and-neck cancer</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2010</YR>
<VL>77</VL>
<PG>3-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cummings-2007" MODIFIED="2010-11-05 09:33:39 +0000" MODIFIED_BY="[Empty name]" NAME="Cummings 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-05 09:33:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cummings B, Keane T, Pintilie M, Warde P, Waldron J, Payne D, et al</AU>
<TI>Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>2007</YR>
<VL>85</VL>
<NO>1</NO>
<PG>7-16</PG>
<MD>AA Excl oral cancer radio review - less than 50% OC/OP cancer</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DAHANCA-2003" MODIFIED="2010-11-05 09:43:18 +0000" MODIFIED_BY="[Empty name]" NAME="DAHANCA 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-05 09:39:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Overgaard J, Hansen H, Specht L, Grau C, Overgaard M, Andersen E, et al</AU>
<TI>The Danish Head and Neck Cancer Study Group DAHANCA 6&amp;7 randomized trial of 5 versus 6 fractions per week of conventional radiotherapy of squamous cell carcinoma of the head and neck</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2003</YR>
<PG>Abs No 1994</PG>
<MD>Excl oral cancer radio review/ DAHANCA 6&amp;7 less than 50% OC/OP</MD>
<IDENTIFIERS MODIFIED="2010-08-05 17:00:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:35:12 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;14511925&lt;br&gt;RefMgr field[1]: Journal&lt;br&gt;RefMgr field[8]: Not in File&lt;/p&gt;" NOTES_MODIFIED="2010-11-05 09:35:12 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al</AU>
<TI>Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>362</VL>
<NO>9388</NO>
<PG>933-40</PG>
<MD>Excluded radio less than 50% oral cavity or oropharyngeal cancer</MD>
<IDENTIFIERS MODIFIED="2010-11-05 09:35:12 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:36:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Overgaard J, Hansen HS, Specht L</AU>
<TI>Erratum: Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial (Lancet 2003;362:933-40)</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>362</VL>
<NO>9395</NO>
<PG>1588</PG>
<MD>excl oral cancer radio review/ DAHANCA 6&amp;7 less than 50% OC/OP</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:36:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Overgaard J, Sand HH, Overgaard M, Grau C, Specht L, Andersen E, et al</AU>
<TI>A randomized trial with 1485 patients evaluating the importance of accelerated versus conventional fractionated radiotherapy in squamous cell carcinoma of the head and neck. Final results of the DAHANCA 6&amp;7 study</TI>
<SO>European Journal of Cancer</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>5</NO>
<PG>S318</PG>
<MD>Excl oral cancer radio review/ DAHANCA 6&amp;7 less than 50% OC/OP</MD>
<IDENTIFIERS MODIFIED="2010-08-05 17:00:16 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:43:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Overgaard J, Sand Hansen H, Sapru W, Overgaard M, Grau C, Jorgensen K, et al</AU>
<TI>Conventional radiotherapy as the primary treatment of squamous cell carcinoma (SCC) of the head and neck. A randomised multicentre study of 5 versus 6 fractions per week. Preliminary report from the Dahanca 6 and 7 trial</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>1996</YR>
<VL>40 Suppl 1</VL>
<PG>S31</PG>
<MD>Excl oral cancer radio review/ DAHANCA 6&amp;7 less than 50% OC/OP</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 09:37:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toubiana T, Racadot S, Mazeron JJ</AU>
<TI>Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&amp;7 randomised controlled trial</TI>
<SO>Bulletin du Cancer/Radiotherapie</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>3</NO>
<PG>209-10</PG>
<MD>incl oral cancer radio review</MD>
<IDENTIFIERS MODIFIED="2010-11-05 09:37:12 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Datta-1989" MODIFIED="2010-11-05 09:44:52 +0000" MODIFIED_BY="[Empty name]" NAME="Datta 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-11-05 09:44:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Datta NR, Dutta Choudhry A, Gupta S, Bose AK</AU>
<TI>Twice a day versus once a day radiation therapy in head and neck cancer</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1989</YR>
<VL>17</VL>
<NO>Suppl 1</NO>
<PG>132-3</PG>
<MD>excl oral cancer radio review - need a paper copy - paper copy/pdf on file- Abstract only, no subsequent publication identified. no % OC/OP known therefore exclude oral cancer radio/</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dieckmann-1990" MODIFIED="2010-11-05 09:45:03 +0000" MODIFIED_BY="[Empty name]" NAME="Dieckmann 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-11-05 09:45:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dieckmann J</AU>
<TI>Combined pre-and postoperative radiotherapy (RT) in the treatment of carcinomas of the floor of the mouth</TI>
<SO>Journal of Cancer Research &amp; Clinical Oncology</SO>
<YR>1990</YR>
<VL>116</VL>
<PG>797</PG>
<MD>? incl oral cancer radio review</MD>
<IDENTIFIERS MODIFIED="2010-08-05 17:00:51 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dvivedi-1978" MODIFIED="2010-11-05 09:45:32 +0000" MODIFIED_BY="[Empty name]" NAME="Dvivedi 1978" YEAR="1978">
<REFERENCE MODIFIED="2010-11-05 09:45:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dvivedi M, Pradhan DG</AU>
<TI>Immediate results of weekly fractionation in external radiotherapy</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1978</YR>
<VL>4</VL>
<NO>7-8</NO>
<PG>573-8</PG>
<MD>exclude oral cancer radio review - published 1978, 59% of incl pts have SCCHN - ?% OC/OP - too old to get more data</MD>
<IDENTIFIERS MODIFIED="2010-08-05 17:00:58 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flores-1996" MODIFIED="2010-11-05 09:45:46 +0000" MODIFIED_BY="[Empty name]" NAME="Flores 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-11-05 09:45:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flores AD, Kandil A, Jamshed A, Khafaga Y, Schultz H, Rostom A, et al</AU>
<TI>The Saudi experience with neutron therapy in locally advanced head and neck cancers</TI>
<SO>Bulletin du Cancer/Radiotherapie</SO>
<YR>1996</YR>
<VL>83 Suppl</VL>
<PG>106s-9s</PG>
<MD>incl radio review - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garden-2004" MODIFIED="2010-11-05 09:46:02 +0000" MODIFIED_BY="[Empty name]" NAME="Garden 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-05 09:46:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, et al</AU>
<TI>Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>14</NO>
<PG>2856-64</PG>
<MD>Incl oral cancer chemo review</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giglio-1997" MODIFIED="2010-11-05 09:46:46 +0000" MODIFIED_BY="[Empty name]" NAME="Giglio 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-05 09:46:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Giglio R, Mickiewicz E, Pradier R, Roth B, Gatica G, Califano L, et al</AU>
<TI>Chemotherapy + alternating hyperfractionated radiotherapy vs hyperfractionated radiotherapy alone in patients with inoperable stage III and IV epidermoid carcinoma</TI>
<SO>Prensa Medica Argentina</SO>
<YR>1997</YR>
<VL>84</VL>
<NO>5</NO>
<MD>Incl oral cancer chemo - needs translation. Link to abstract Giglio 1996</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-1997" MODIFIED="2010-11-05 09:47:00 +0000" MODIFIED_BY="[Empty name]" NAME="Hansen 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-05 09:47:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansen O, Overgaard J, Hansen HS, Overgaard M, Hoyer M, Jorgensen KE, et al</AU>
<TI>Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>1997</YR>
<VL>43</VL>
<NO>1</NO>
<PG>47-51</PG>
<MD>Exclude oral cancer radio review - AMG/SF agree - renalysis of DAHANCA studies - in RM5 excl st</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hering-1981" MODIFIED="2010-11-05 09:57:11 +0000" MODIFIED_BY="[Empty name]" NAME="Hering 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-11-05 09:57:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dieckmann J, Morgenroth K, Hering KG, Will CH</AU>
<TI>Histo-morphologic findings and first clinical results after preoperative short term preliminary irradiation with telecobalt in patients with epidermoid cancers of the mouth floor</TI>
<SO>Strahlentherapie. Sonderbande</SO>
<YR>1981</YR>
<VL>76</VL>
<PG>206-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hintz-1979" MODIFIED="2010-11-05 09:57:22 +0000" MODIFIED_BY="[Empty name]" NAME="Hintz 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-11-01 21:58:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hintz B, Charyulu K, Chandler JR, Sudarsanam A, Garciga C</AU>
<TI>Randomized study of local control and survival following radical surgery or radiation therapy in oral and laryngeal carcinomas</TI>
<SO>Journal of Surgical Oncology</SO>
<YR>1979</YR>
<VL>12</VL>
<PG>61-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holsti-1988" MODIFIED="2010-11-05 10:05:03 +0000" MODIFIED_BY="[Empty name]" NAME="Holsti 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-11-05 10:05:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holsti LR, Mantyla M</AU>
<TI>Split-course versus continuous radiotherapy. Analysis of a randomized trial from 1964 to 1967</TI>
<SO>Acta Oncologica</SO>
<YR>1988</YR>
<VL>27</VL>
<NO>2</NO>
<PG>153-61</PG>
<MD>incl radio review - in RM5</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jackson-1997" MODIFIED="2010-11-05 10:05:11 +0000" MODIFIED_BY="[Empty name]" NAME="Jackson 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-05 10:05:11 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;9165135&lt;br&gt;RefMgr field[1]: Journal&lt;br&gt;RefMgr field[8]: Not in File&lt;/p&gt;" NOTES_MODIFIED="2010-11-05 10:05:11 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jackson SM, Weir LM, Hay JH, Tsang VH, Durham JS</AU>
<TI>A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>1997</YR>
<VL>43</VL>
<NO>1</NO>
<PG>39-46</PG>
<MD>Excluded radio - some participants randomly allocated to treatment sna some not. Minority of participants have oral cancer</MD>
<IDENTIFIERS MODIFIED="2010-02-17 12:01:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janot-2008" MODIFIED="2010-11-05 10:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="Janot 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-05 10:05:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janot F, de Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensadoun RJ, et al</AU>
<TI>Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>34</NO>
<PG>5518-23</PG>
<MD>Excl recurrent disease</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1995" MODIFIED="2010-11-05 10:06:38 +0000" MODIFIED_BY="[Empty name]" NAME="Johnson 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-11-05 10:06:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson CR, Schmidt-Ullrich RK, Arthur DW, Huang DT, Duffy EW</AU>
<TI>Standard once-daily versus thrice-daily concomitant boost accelerated superfractionated irradiation for advanced squamous cell carcinoma of the head and neck: preliminary results of a prospective randomized trial</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1995</YR>
<VL>32</VL>
<NO>971</NO>
<PG>162</PG>
<MD>excl oral cancer radio review/ AMG/SF Abstract only, no subsequent publication found, no information on % OC/OP/ in RM5 excl</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katori-2007" MODIFIED="2010-11-05 10:07:04 +0000" MODIFIED_BY="[Empty name]" NAME="Katori 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-05 10:07:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katori H, Tsukuda M, Watai K</AU>
<TI>Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)</TI>
<SO>Cancer Chemotherapy &amp; Pharmacology</SO>
<YR>2007</YR>
<VL>60</VL>
<NO>3</NO>
<PG>399-406</PG>
<MD>AA Excl oral cancer radio - less than 50% OC/OP cancer</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klima-1988" MODIFIED="2010-11-05 10:09:23 +0000" MODIFIED_BY="[Empty name]" NAME="Klima 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-08-11 09:51:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klima A, Bergmann I, Szepesi S</AU>
<TI>Multimodality treatment in stage IV squamous cell carcinoma of the head and neck. A long-term follow-up</TI>
<SO>Journal of Laryngology &amp; Otology</SO>
<YR>1992</YR>
<VL>106</VL>
<NO>3</NO>
<PG>234-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 10:08:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Klima A, Klippstein TH, Bergmann L, Szepesi S, Ilberg CV</AU>
<TI>Adjuvant chemotherapy in stage III and IV squamous cell carcinoma of the head and neck</TI>
<SO>Journal of Laryngology &amp; Otology</SO>
<YR>1988</YR>
<VL>102</VL>
<PG>337-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 10:08:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klima A, von Ilberg C, Bergmann L, Klippstein T, Zoubek A, Mitrou PS, et al</AU>
<TI>The effect of radio- and chemotherapy on survival in advanced head and neck tumors</TI>
<SO>Strahlentherapie und Onkologie</SO>
<YR>1987</YR>
<VL>163</VL>
<NO>5</NO>
<PG>297-300</PG>
<MD>Incl Oral cancer - chemo - link to Klima 88</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 10:08:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klima A, von Ilberg C, Bergmann L, Zoubek A, Klippstein T, Mitrou PS, et al</AU>
<TI>Chemotherapy or chemotherapy and radiotherapy in advanced head and neck tumors. A prospective, randomized study comparing the 2 therapeutic modalities</TI>
<SO>Head &amp; Neck Oncology (HNO)</SO>
<YR>1987</YR>
<VL>35</VL>
<NO>2</NO>
<PG>78-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 10:09:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klima A, von Ilberg C, Klippstein T, Szepesi S</AU>
<TI>Chemotherapy of advanced head and neck tumors. A prospective randomized study comparing the effectiveness of chemotherapy alone to a chemo-radiotherapy procedure</TI>
<SO>Laryngologie, Rhinologie, Otologie</SO>
<YR>1987</YR>
<VL>66</VL>
<NO>4</NO>
<PG>205-10</PG>
<MD>Incl Oral cancer - chemo - link to Klima 88</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kokal-1988" MODIFIED="2010-11-05 10:10:13 +0000" MODIFIED_BY="[Empty name]" NAME="Kokal 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-11-05 10:10:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kokal WA, Neifeld JP, Eisert D, Lipsett JA, Lawrence W, Beatty JD, et al</AU>
<TI>Postoperative radiation as adjuvant treatment for carcinoma of the oral cavity, larynx, and pharynx: preliminary report of a prospective randomized trial</TI>
<SO>Journal of Surgical Oncology</SO>
<YR>1988</YR>
<VL>38</VL>
<PG>71-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kramer-1987" MODIFIED="2010-11-05 10:10:22 +0000" MODIFIED_BY="[Empty name]" NAME="Kramer 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-11-05 10:10:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kramer S, Gelber RD, Snow JB, Marcial VA, Lowry LD, Davis LW, et al</AU>
<TI>Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group</TI>
<SO>Head &amp; Neck Surgery</SO>
<YR>1987</YR>
<VL>10</VL>
<NO>1</NO>
<PG>19-30</PG>
<MD>excl from radio review - paper copy sighted- pts have laryngeal or hyopharyngeal cancer/</MD>
<IDENTIFIERS MODIFIED="2010-08-05 17:01:42 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maor-1983" MODIFIED="2010-11-05 10:12:05 +0000" MODIFIED_BY="[Empty name]" NAME="Maor 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-11-05 10:10:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maor MH, Hussey DH, Barkley HT Jr, Peters LJ</AU>
<TI>Neutron therapy for head and neck cancer: II. Further follow-up on the M.D. Anderson TAMVEC randomized clinical trial</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1983</YR>
<VL>9</VL>
<PG>1261-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 10:12:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maor MH, Hussey DH, Barkley HT, Jesse RH, Fletcher GH</AU>
<TI>Further follow-up on the M. D. Anderson trial on fast neutron therapy for head and neck cancer</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1981</YR>
<VL>7</VL>
<NO>9</NO>
<PG>1212-3</PG>
<MD>incl oral cancer radio review Maor 1981 - link with 2 other papers by Maor 1981</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 10:10:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maor MH, Hussey DH, Fletcher GH, Jesse RH</AU>
<TI>Fast neutron therapy for locally advanced head and neck tumors</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1981</YR>
<VL>7</VL>
<NO>2</NO>
<PG>155-63</PG>
<MD>incl oral cancer radio review Maor 1981 - link with 2 other papers by Maor 1981</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 10:11:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maor MH, Hussey DH</AU>
<TI>Experience with fast neutron radiotherapy at the M.D. Anderson Hospital with emphasis on the randomized head and neck trial</TI>
<SO>Strahlentherapie. Sonderbande</SO>
<YR>1981</YR>
<VL>77</VL>
<PG>11-6</PG>
<MD>incl oral cancer radio review Maor 1981 - link with 2 other papers by Maor 1981</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mishra-1996" MODIFIED="2010-11-05 10:12:22 +0000" MODIFIED_BY="[Empty name]" NAME="Mishra 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-11-05 10:12:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mishra RC, Singh DN, Mishra TK</AU>
<TI>Post-operative radiotherapy in carcinoma of buccal mucosa, a prospective randomized trial</TI>
<SO>European Journal of Surgical Oncology</SO>
<YR>1996</YR>
<VL>22</VL>
<NO>5</NO>
<PG>502-4</PG>
<MD>excl oral cancer radio review - post - op RT vs no further RX - but only some of the pts are randomised - "however some surgeons preferred to put more clinically node-positive cases into the post operative radiotherapy group"</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nissenbaum-1984" MODIFIED="2010-11-05 10:12:32 +0000" MODIFIED_BY="[Empty name]" NAME="Nissenbaum 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-11-05 10:12:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nissenbaum M, Browde S, Bezwoda WR, de Moor NG, Derman DP</AU>
<TI>Treatment of advanced head and neck cancer: multiple daily dose fractionated radiation therapy and sequential multimodal treatment approach</TI>
<SO>Medical &amp; Pediatric Oncology</SO>
<YR>1984</YR>
<VL>12</VL>
<NO>3</NO>
<PG>204-8</PG>
<MD>Excl oral cancer chemo /excl oral cancer radio reviews - less than 6 months follow up</MD>
<IDENTIFIERS MODIFIED="2010-08-05 17:01:53 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noel-1997" MODIFIED="2010-11-05 10:13:21 +0000" MODIFIED_BY="[Empty name]" NAME="Noel 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-05 10:13:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noel G, Feuvret L, Coeffic D, Germain I, Mazeron JJ</AU>
<TI>Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial</TI>
<SO>Cancer/Radiotherapie</SO>
<YR>1997</YR>
<VL>1</VL>
<NO>3</NO>
<PG>265-6</PG>
<MD>excl radio and chemo reviews - unclear % OC/OP cancer</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noel-1997a" MODIFIED="2010-11-05 10:13:44 +0000" MODIFIED_BY="[Empty name]" NAME="Noel 1997a" YEAR="1997">
<REFERENCE MODIFIED="2010-11-05 10:13:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noel G, Feuvret L, Coeffic D, Germain I, Mazeron JJ</AU>
<TI>Five-year update of a randomized trial alternating radiotherapy and chemotherapy compared with radiotherapy in treatment of unresectable squamous cell carcinoma of the head and neck</TI>
<SO>Cancer/Radiotherapie</SO>
<YR>1997</YR>
<VL>1</VL>
<NO>3</NO>
<PG>262-3</PG>
<MD>excl radio and chemo reviews - unclear % OC/OP cancer</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noel-1997b" MODIFIED="2010-11-05 10:14:27 +0000" MODIFIED_BY="[Empty name]" NAME="Noel 1997b" YEAR="1997">
<REFERENCE MODIFIED="2010-11-05 10:14:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noel G, Feuvret L, Coeffic D, Germain I, Mazeron JJ</AU>
<TI>Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small cell lung cancer: An interim report</TI>
<SO>Cancer/Radiotherapie</SO>
<YR>1997</YR>
<VL>1</VL>
<NO>3</NO>
<PG>263-4</PG>
<MD>excl radio and chemo reviews - unclear % OC/OP cancer</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noel-2001" MODIFIED="2010-11-05 10:14:48 +0000" MODIFIED_BY="[Empty name]" NAME="Noel 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-05 10:14:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noel G, Mazeron JJ</AU>
<TI>Randomized clinical trial on 7-day continuous accelerated irradiation (CAIR) of head and neck cancer. Report on 3-year tumour control and normal tissue toxicity</TI>
<SO>Cancer/Radiotherapie</SO>
<YR>2001</YR>
<VL>5</VL>
<NO>2</NO>
<PG>207-8</PG>
<MD>excl radio review - commentary in French on 4 trials - no data</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rink-1989" MODIFIED="2010-11-05 10:15:08 +0000" MODIFIED_BY="[Empty name]" NAME="Rink 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-11-05 10:15:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rink B, Neumann HJ, Kuchler I</AU>
<TI>Clinical experience with different modes of preoperative radiotherapy in advanced carcinomas of the tongue and the floor of the mouth</TI>
<SO>Deutsche Zeitschrift fur Mund-, Kiefer-, und Gesichts-Chirurgie</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>4</NO>
<PG>286-90</PG>
<MD>excl oral cancer chemo&amp; radio reviews- not randomised</MD>
<IDENTIFIERS MODIFIED="2010-11-05 10:15:08 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robertson-1998" MODIFIED="2010-11-05 10:15:34 +0000" MODIFIED_BY="[Empty name]" NAME="Robertson 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-11-05 10:15:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robertson AG, Soutar DS, Paul J, Webster M, Leonard AG, Moore KP, et al</AU>
<TI>Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours</TI>
<SO>Clinical Oncology</SO>
<YR>1998</YR>
<VL>10</VL>
<PG>155-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchiz-1990" MODIFIED="2010-11-05 10:16:49 +0000" MODIFIED_BY="[Empty name]" NAME="Sanchiz 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-11-05 10:16:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchiz F, Milla A, Torner J, Bonet F, Artola N, Carreno L, et al</AU>
<TI>Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1990</YR>
<VL>19</VL>
<NO>6</NO>
<PG>1347-50</PG>
<MD>excl oral cancer chemo &amp; radio -less than 50% OC/OP/</MD>
<IDENTIFIERS MODIFIED="2010-08-05 17:02:22 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-1984" MODIFIED="2010-11-05 10:17:06 +0000" MODIFIED_BY="[Empty name]" NAME="Singh 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-11-05 10:17:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh R, Rai G, Singh SK, Tandon VK, Bhadury S, Shrivastava M, et al</AU>
<TI>Fractionation study on 3f/wk or 5f/wk treatment of oral carcinoma</TI>
<SO>Indian Journal of Radiology and Imaging</SO>
<YR>1984</YR>
<VL>38</VL>
<NO>2</NO>
<PG>153-9</PG>
<MD>incl oral cancer radio/ RCT - get copy - ask phil to order 16/4/2010 - online from 1999 only/ pdf on file paper copy printed</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Snow-1981" MODIFIED="2010-11-05 10:18:35 +0000" MODIFIED_BY="[Empty name]" NAME="Snow 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-11-05 10:18:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marcial VA, Gelber R, Kramer S, Snow JB, Davis LW, Vallecillo LA</AU>
<TI>Does preoperative irradiation increase the rate of surgical complications in carcinoma of the head and neck? A Radiation Therapy Oncology Group Report</TI>
<SO>Cancer</SO>
<YR>1982</YR>
<VL>49</VL>
<PG>1297-1301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 10:18:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Snow JB, Gelber RD, Kramer S, Davis LW, Marcial VA, Lowry LD</AU>
<TI>Comparison of preoperative and postoperative radiation therapy for patients with carcinoma of the head and neck. Interim report</TI>
<SO>Acta Otolaryngologica</SO>
<YR>1981</YR>
<VL>91</VL>
<NO>5-6</NO>
<PG>611-26</PG>
<MD>excl oral cancer chemo - less than 50% oral cavity cancer 3</MD>
<IDENTIFIERS MODIFIED="2010-08-05 17:02:52 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Srivastava-2001" MODIFIED="2010-11-05 10:18:46 +0000" MODIFIED_BY="[Empty name]" NAME="Srivastava 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-05 10:18:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Srivastava K, Srivastava M</AU>
<TI>Concomitant boost radiotherapy vs conventional radiotherapy in advanced oral cavity and oropharynx cancers</TI>
<SO>Indian Journal of Radiology and Imaging</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>3</NO>
<PG>127-30</PG>
<MD>AA Excl oral cancer radio - less than 50% oc/op cancer - random not mentioned</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strong-1978" MODIFIED="2010-11-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" NAME="Strong 1978" YEAR="1978">
<REFERENCE MODIFIED="2010-11-05 10:18:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strong MS, Vaughan CW, Kayne HL, Aral IM, Ucmakli A, Feldman M, et al</AU>
<TI>A randomized trial of preoperative radiotherapy in cancer of the oropharynx and hypopharynx</TI>
<SO>American Journal of Surgery</SO>
<YR>1978</YR>
<VL>136</VL>
<NO>4</NO>
<PG>494-500</PG>
<MD>incl oral cancer radio review - in RM5 - no % OC/OP given but all patients have either hypopharynx or oropharynx cancer and the latter has 6x the incidence</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suwinski-2008" MODIFIED="2010-11-05 10:21:02 +0000" MODIFIED_BY="[Empty name]" NAME="Suwinski 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-05 10:20:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Suwinski R, Bankowska-Wozniak M, Majewski W, Idasiak A, Maciejewski A, Ziolkowska E, et al</AU>
<TI>Randomized clinical trial on 7-days-a-week postoperative radiotherapy for high-risk squamous cell head and neck cancer</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>2008</YR>
<VL>87</VL>
<NO>2</NO>
<PG>155-63</PG>
<MD>Excl oral cancer radio review - less than 50% OC/OP</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 10:20:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suwinski R, Bankowska-Wozniak M, Majewski W, Sowa A, Galwas K, Ziolkowska E, et al</AU>
<TI>A randomized clinical trial on continuous 7-day-a-week postoperative radiotherapy in high-risk squamous cell head and neck cancer: a preliminary report on acute normal tissue reactions</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2003</YR>
<VL>57</VL>
<NO>2 Suppl</NO>
<PG>S403</PG>
<MD>excl oral cancer reviews - prelim report of first 100 pts in suwinski 2005 which is excl b/c less than 50% OC/OP</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 10:20:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suwinski R, Bankowska-Wozniak M, Majewski W, Sowa A, Idasiak A, Ziolkowska E, et al</AU>
<TI>Randomized clinical trial on continuous 7-days-a-week postoperative radiotherapy for high-risk squamous cell head-and-neck cancer: a report on acute normal tissue reactions</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>2005</YR>
<VL>77</VL>
<NO>1</NO>
<PG>58-64</PG>
<MD>incl oral cancer radio review</MD>
<IDENTIFIERS MODIFIED="2010-08-05 17:03:06 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 10:21:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suwinski R, Jaworska M, Nikiel B, Bankowska-Wozniak M</AU>
<TI>E22 - Randomized clinical trial on 7-days-a-week postoperative radiotherapy for high risk head and neck cancer: factors influencing loco-regional control</TI>
<SO>Strahlentherapie und Onkologie</SO>
<YR>2007</YR>
<VL>183</VL>
<NO>Suppl 2</NO>
<PG>81-3</PG>
<MD>excl radio review - less than 50% OC/OP</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tupchong-1991" MODIFIED="2010-11-05 10:19:03 +0000" MODIFIED_BY="[Empty name]" NAME="Tupchong 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-11-05 10:19:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tupchong L, Scott CB, Blitzer PH, Marcial VA, Lowry LD, Jacobs JR, et al</AU>
<TI>Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1991</YR>
<VL>20</VL>
<NO>1</NO>
<PG>21-8</PG>
<MD>Excl oral cancer radio review 31% OC/OP cancer</MD>
<IDENTIFIERS MODIFIED="2010-02-08 12:43:23 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-11-05 11:08:07 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ang-2007" MODIFIED="2010-11-05 10:21:53 +0000" MODIFIED_BY="[Empty name]" NAME="Ang 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-05 10:21:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ang K, Pajak T, Rosenthal DI, Nguyen F, Lu C, Kim H, et al</AU>
<TI>A phase III trial to compare standard versus accelerated fractionation in combination with concurrent cisplatin for head and neck carcinomas (RTOG 0129): report of compliance and toxicity</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2007</YR>
<VL>69</VL>
<NO>3 Suppl 1</NO>
<PG>S12-3, Abs No 21</PG>
<MD>paper copy on file - incl in radio review</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghosh-2006" MODIFIED="2010-11-05 10:22:23 +0000" MODIFIED_BY="[Empty name]" NAME="Ghosh 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-05 10:22:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghosh S, Agarwal JP, Bhutani R, Vora A, Prabhas K, D'Cruz A, et al</AU>
<TI>Randomized trial of conventional fractionated RT (CFRT) vs. concomitant chemo radiotherapy (CTRT) and accelerated radiotherapy (ACRT) in patients with advanced, non nasopharyngeal, squamous cell cancers of the head and neck region</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>3</NO>
<PG>S191</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nutting-2009a" MODIFIED="2010-11-05 10:23:51 +0000" MODIFIED_BY="[Empty name]" NAME="Nutting 2009a" YEAR="2009">
<REFERENCE MODIFIED="2010-11-05 10:23:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nutting C, A'Hern R, Rogers MS, Sydenham MA, Adab F, Harrington K, et al</AU>
<TI>First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). Proceedings from the 45th American Society of Clinical Oncology (ASCO) Annual Meeting, Orlando, FL, USA, May 29-June 2 2009</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>15S</NO>
<PG>Abs No LBA6006</PG>
<MD>studies awaiting classification - radio review interim report only outcome is xerostomia, but full report due 2010 or 2011</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodrigo-2004" MODIFIED="2010-11-05 10:24:48 +0000" MODIFIED_BY="[Empty name]" NAME="Rodrigo 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-05 10:24:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodrigo JP, Maseda E, Maldonado M, Aldama P, Puente M, Llorente JL et al</AU>
<TI>Efficacy of postoperative radiation therapy for squamous cell carcinoma of the head and neck: results of a prospective randomised clinical trial</TI>
<SO>Acta Otorrinolaringologica Espanola</SO>
<YR>2004</YR>
<VL>55</VL>
<NO>9</NO>
<PG>415-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenthal-2006" MODIFIED="2010-11-05 10:27:28 +0000" MODIFIED_BY="[Empty name]" NAME="Rosenthal 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-05 10:26:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters LJ, Goepfert H, Ang KK, Byers RM, Maor MH, Guillamondegui O, et al</AU>
<TI>Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1993</YR>
<VL>26</VL>
<NO>1</NO>
<PG>3-11</PG>
<MD>Incl oral cancer radio review - AMG/SF - 50% OC/OP - ? full publication</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 10:27:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rosenthal DI, Peters LJ, Morrison WH, Garden AS, Oswald MJ, El-Naggar A, et al</AU>
<TI>The final report of a prospective randomized trial to evaluate the dose-response relationship for postoperative radiation therapy (PORT) and pathologic risk groups in patients with head and neck cancer (HNC)</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>3</NO>
<PG>S411</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skladowski-2001" MODIFIED="2010-11-05 11:08:07 +0000" MODIFIED_BY="[Empty name]" NAME="Skladowski 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-05 11:02:51 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;7th International Meeting on Progress in Radio-Oncology (ICRO/OGRO 7)&lt;br&gt;MAY 15-19, 2002&lt;br&gt;SALZBURG, AUSTRIA&lt;/p&gt;" NOTES_MODIFIED="2010-11-05 11:02:51 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Skladowski K, Golen M, Wygoda A, Przeorek W, Sygula M, Pilecki B, et al</AU>
<TI>What is new with ,,CAIR" fractionation? - A next Gliwice trial on 7 fractions in 7 days versus 7 fractions in 5 days is undergoing</TI>
<SO>Progress in Radio-Oncology VII, Proceedings of the 7th International Meeting on Progress in Radio Oncology - ICRO/OGRO 7</SO>
<YR>2002</YR>
<PG>459-64</PG>
<ED>Kogelnik HD, Lukas P, Sedlmayer F</ED>
<PB>Monduzzi Editore</PB>
<CY>Italy</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 11:03:38 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;8th International Meeting on Progress in Radio-Oncology (ICRO/OGRO 8)&lt;br&gt;MAY 16-19, 2007&lt;br&gt;Salzburg, AUSTRIA&lt;/p&gt;" NOTES_MODIFIED="2010-11-05 11:03:38 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skladowski K, Hutnik M, Wygoda A, Golen M, Pilecki B, Rutkowski T, et al</AU>
<TI>Randomised clinical trial on two accelerated radiation treatments for patients with head and neck cancer. First report on early results of Cair-2 study</TI>
<SO>Strahlentherapie und Onkologie</SO>
<YR>2007</YR>
<VL>183</VL>
<PG>A07</PG>
<MD>CAIR-2 study (ongoing) in RM5 as ongoing study for Oral Cancer Radio review/</MD>
<IDENTIFIERS MODIFIED="2010-11-05 11:03:29 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 11:04:24 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;International Meeting on Innovative Approaches in Head and Neck Oncology&lt;br&gt;FEB 22-27, 2007&lt;br&gt;Barcelona, SPAIN&lt;/p&gt;" NOTES_MODIFIED="2010-11-05 11:04:24 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skladowski K, Hutnik M, Wygoda A, Sasiadek W, Rutkowski T, Golen M, et al</AU>
<TI>Two accelerated radiation treatments have produced identical acute mucosal toxicity profile. An interim report on CAIR-2 phase III trial for head and neck cancer patients</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>2007</YR>
<VL>82</VL>
<PG>235</PG>
<MD>CAIR-2 study (ongoing) in RM5 as ongoing study for Oral Cancer Radio review/</MD>
<IDENTIFIERS MODIFIED="2010-11-05 11:04:10 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 11:04:39 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;23rd Annual Meeting of the European-Society-for-Therapeutic-Radiology-and-Oncology (ESTRO 23)&lt;br&gt;OCT 24-28, 2004&lt;br&gt;Amsterdam, NETHERLANDS&lt;/p&gt;" NOTES_MODIFIED="2010-11-05 11:04:39 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skladowski K, Hutnik M, Wygoda A, Sygula M, Golen M, Pilecki B, et al</AU>
<TI>7 fractions in 7 days versus 7 fractions in 5 days - an interim report on early treatment tolerance in CAIR-2 randomized clinical trial for head and neck cancer patients</TI>
<SO>Radiotherapy &amp; Oncology</SO>
<YR>2004</YR>
<VL>73</VL>
<PG>S16-7</PG>
<MD>CAIR-2 study (ongoing) in RM5 as ongoing study for Oral Cancer Radio review/</MD>
<IDENTIFIERS MODIFIED="2010-11-05 11:04:36 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 11:05:17 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;2nd World Congress of the International-Academy-of-Oral-Oncology&lt;br&gt;JUL 08-11, 2009&lt;br&gt;Toronto, CANADA&lt;/p&gt;" NOTES_MODIFIED="2010-11-05 11:05:17 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Skladowski K, Wygoda A, Maciejewski A, Rutkowski T, Poltorak S, Maciejewski B</AU>
<TI>Definitive accelerated radiotherapy for head and neck cancer patients - The results of organ preservation and prognostic-factor analysis of CAIR-2 phase III trial</TI>
<SO>Oral Oncology</SO>
<YR>2009</YR>
<PG>198</PG>
<MD>CAIR-2 study (ongoing) in RM5 as ongoing study for Oral Cancer Radio review/</MD>
<IDENTIFIERS MODIFIED="2010-11-05 11:04:58 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 11:06:03 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology&lt;br&gt;SEP 21-25, 2008&lt;br&gt;Boston, MA&lt;/p&gt;" NOTES_MODIFIED="2010-11-05 11:06:03 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skladowski KA, Hutnik M, Rutkowski T, Golen M, Wygoda A, Heyda A, et al</AU>
<TI>Weekend breaks have no impact on the outcome of head and neck cancer when definitive radiotherapy is accelerated-results of phase III clinical trial (CAIR-2)</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2008</YR>
<VL>72</VL>
<NO>1</NO>
<PG>S97</PG>
<MD>CAIR-2 study (ongoing) in RM5 as ongoing study for Oral Cancer Radio review/</MD>
<IDENTIFIERS MODIFIED="2010-11-05 11:05:54 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 11:06:41 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Notes: Web address: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/150/CN-00597150/frame.html&lt;/p&gt;" NOTES_MODIFIED="2010-11-05 11:06:41 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skladowski KA, Hutnik M, Wygoda A, Sasiadek W, Golen M, Rutkowski T, et al</AU>
<TI>Identity of acute effects in two accelerated radiation treatments: 7 fractions in 7 days versus 7 fractions in 5 days. An interim report on early tolerance of CAIR-2 randomized clinical trial for head and neck cancer patients</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>3 Suppl 1</NO>
<PG>S187</PG>
<MD>CAIR-2 study (ongoing) in RM5 as ongoing study for Oral Cancer Radio review/</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-05 11:08:07 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;51st Annual Meeting of the American-Society-for-Radiation-Oncology&lt;br&gt;NOV 01-05, 2009&lt;br&gt;Chicago, IL&lt;/p&gt;" NOTES_MODIFIED="2010-11-05 11:08:07 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skladowski KA, Hutnik M</AU>
<TI>Sublethal-damage-repair and clonogen repopulation during accelerated radiation therapy of head and neck cancer - The biological interpretation of CAIR-2 trial</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2009</YR>
<VL>75</VL>
<NO>3</NO>
<PG>S180</PG>
<MD>CAIR-2 study (ongoing) in RM5 as ongoing study for Oral Cancer Radio review/</MD>
<IDENTIFIERS MODIFIED="2010-11-05 11:06:53 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2010-11-05 10:28:44 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Moergel-2009" MODIFIED="2010-11-05 10:28:44 +0000" MODIFIED_BY="[Empty name]" NAME="Moergel 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-05 10:28:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moergel M, Jahn-Eimermacher A, Krummernauer F, Reichert TE, Wagner W, Wendt TG, et al</AU>
<TI>Effectiveness of adjuvant radiotherapy in patients with oropharyngeal and floor of mouth squamous cell carcinoma and concomitant histological verification of singular ipsilateral cervical lymph node metastasis (pN1-state)--a prospective multicenter randomized controlled clinical trial using a comprehensive cohort design</TI>
<SO>Trials</SO>
<YR>2009</YR>
<VL>10</VL>
<PG>118</PG>
<IDENTIFIERS MODIFIED="2010-11-05 10:28:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-11-05 17:30:40 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-11-05 17:30:40 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Attner-2010" MODIFIED="2010-11-05 11:08:52 +0000" MODIFIED_BY="[Empty name]" NAME="Attner 2010" TYPE="JOURNAL_ARTICLE">
<AU>Attner P, Du J, Nasman A, Hammarstedt L, Ramqvist T, Lindholm J, et al</AU>
<TI>The role of human papillomavirus in the increased incidence of base of tongue cancer</TI>
<SO>International Journal of Cancer</SO>
<YR>2010</YR>
<VL>126</VL>
<PG>2879-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bernier-2005" MODIFIED="2008-09-03 15:05:26 +0100" MODIFIED_BY="Philip Riley" NAME="Bernier 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bernier J</AU>
<TI>Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology?</TI>
<SO>Nature Clinical Practice. Oncology</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>6</NO>
<PG>305-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bernier-2006" NAME="Bernier 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bernier J, Bentzen SM</AU>
<TI>Radiotherapy for head and neck cancer: latest developments and future perspectives</TI>
<SO>Current Opinion in Oncology</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>3</NO>
<PG>240-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bjordal-1992" NAME="Bjordal 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bjordal K, Kaasa S</AU>
<TI>Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients</TI>
<SO>Acta Oncologica</SO>
<YR>1992</YR>
<VL>31</VL>
<NO>3</NO>
<PG>311-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bourhis-2006" MODIFIED="2010-08-31 16:57:28 +0100" MODIFIED_BY="[Empty name]" NAME="Bourhis 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bourhis J, Overgaard J, Audry H, Ang K, Saunders M, Bernier J et al</AU>
<TI>Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>368</VL>
<PG>843-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conway-2008" MODIFIED="2010-11-05 11:09:54 +0000" MODIFIED_BY="[Empty name]" NAME="Conway 2008" TYPE="JOURNAL_ARTICLE">
<AU>Conway DI, Petticrew M, Marlborough H, Berthiller J, Hashibe M, Macpherson LM</AU>
<TI>Socioeconomic inequalities and oral cancer risk: a systematic review and meta-analysis of case-control studies</TI>
<SO>International Journal of Cancer</SO>
<YR>2008</YR>
<VL>122</VL>
<NO>12</NO>
<PG>2811-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CRUK-2009" MODIFIED="2010-11-05 11:10:31 +0000" MODIFIED_BY="[Empty name]" NAME="CRUK 2009" TYPE="OTHER">
<AU>Cancer Research UK</AU>
<TI>About chemotherapy for mouth cancer</TI>
<SO>http://www.cancerhelp.org.uk/help/default.asp?page=13205</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Souza-2007" MODIFIED="2010-09-10 09:29:48 +0100" MODIFIED_BY="[Empty name]" NAME="D'Souza 2007" TYPE="JOURNAL_ARTICLE">
<AU>D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al</AU>
<TI>Case-control study of human papillomavirus and oropharyngeal cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>356</VL>
<NO>19</NO>
<PG>1944-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Day-1992" MODIFIED="2008-09-03 15:05:46 +0100" MODIFIED_BY="Philip Riley" NAME="Day 1992" TYPE="JOURNAL_ARTICLE">
<AU>Day GL, Blot WJ</AU>
<TI>Second primary tumors in patients with oral cancer</TI>
<SO>Cancer</SO>
<YR>1992</YR>
<VL>70</VL>
<NO>1</NO>
<PG>14-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Day-2003" MODIFIED="2010-11-05 11:11:07 +0000" MODIFIED_BY="[Empty name]" NAME="Day 2003" TYPE="JOURNAL_ARTICLE">
<AU>Day TA, Davis BK, Gillespie MB, Joe JK, Kibbey M, Martin-Harris B, et al</AU>
<TI>Oral cancer treatment</TI>
<SO>Current Treatment Options in Oncology</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>1</NO>
<PG>27-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deleyiannis-1997" NAME="Deleyiannis 1997" TYPE="JOURNAL_ARTICLE">
<AU>Deleyiannis FW, Weymuller EA Jr, Coltrera MD</AU>
<TI>Quality of life of disease-free survivors of advanced (stage III or IV) oropharyngeal cancer</TI>
<SO>Head &amp; Neck</SO>
<YR>1997</YR>
<VL>19</VL>
<NO>6</NO>
<PG>466-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duchateau-2001" MODIFIED="2010-11-05 11:11:38 +0000" MODIFIED_BY="[Empty name]" NAME="Duchateau 2001" TYPE="JOURNAL_ARTICLE">
<AU>Duchateau L, Pignon JP, Bijnens L, Bertin S, Bourhis J, Sylvester R</AU>
<TI>Individual patient-versus literature-based meta-analysis of survival data: time to event and event rate at a particular time can make a difference, an example based on head and neck cancer</TI>
<SO>Controlled Clinical Trials</SO>
<YR>2001</YR>
<VL>22</VL>
<NO>5</NO>
<PG>538-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duncan-1994" MODIFIED="2010-09-09 12:09:19 +0100" MODIFIED_BY="[Empty name]" NAME="Duncan 1994" TYPE="JOURNAL_ARTICLE">
<AU>Duncan W</AU>
<TI>An evaluation of the results of neutron therapy trials</TI>
<SO>Acta Oncologica</SO>
<YR>1994</YR>
<VL>33</VL>
<NO>3</NO>
<PG>299-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Faggiano-1997" MODIFIED="2010-11-05 11:12:37 +0000" MODIFIED_BY="[Empty name]" NAME="Faggiano 1997" TYPE="BOOK_SECTION">
<AU>Faggiano F, Partanen T, Kogevinas M, Boffetta P</AU>
<TI>Socioeconomic differences in cancer incidence and mortality</TI>
<SO>Social Inequalities and Cancer</SO>
<YR>1997</YR>
<ED>Kogevinas M, Pearce N, Susser M, Boffetta P</ED>
<PB>IARC Scientific Publications No 138. International Agency for Research in Cancer</PB>
<CY>Lyon</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fakhry-2006" MODIFIED="2010-11-05 11:13:07 +0000" MODIFIED_BY="[Empty name]" NAME="Fakhry 2006" TYPE="JOURNAL_ARTICLE">
<AU>Fakhry C, Gillison ML</AU>
<TI>Clinical implications of human papillomavirus in head and neck cancers</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>17</NO>
<PG>2606-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fakhry-2008" MODIFIED="2010-09-10 09:41:18 +0100" MODIFIED_BY="[Empty name]" NAME="Fakhry 2008" TYPE="JOURNAL_ARTICLE">
<AU>Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al</AU>
<TI>Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2008</YR>
<VL>100</VL>
<NO>4</NO>
<PG>261-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fanucchi-2006" MODIFIED="2008-09-03 15:05:56 +0100" MODIFIED_BY="Philip Riley" NAME="Fanucchi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Fanucchi M, Khuri FD, Shin D, Johnstone PAS, Chen A</AU>
<TI>Update in the management of head and neck cancer</TI>
<SO>Update on Cancer Therapeutics</SO>
<YR>2006</YR>
<VL>1</VL>
<NO>2</NO>
<PG>211-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freedman-2007" MODIFIED="2010-09-10 09:31:19 +0100" MODIFIED_BY="[Empty name]" NAME="Freedman 2007" TYPE="JOURNAL_ARTICLE">
<AU>Freedman ND, Abnet CC, Leitzmann MF, Hollenbeck AR, Schatzkin A</AU>
<TI>Prospective investigation of the cigarette smoking-head and neck cancer association by sex</TI>
<SO>Cancer</SO>
<YR>2007</YR>
<VL>110</VL>
<NO>7</NO>
<PG>1593-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furness-2010" MODIFIED="2010-11-05 11:15:41 +0000" MODIFIED_BY="[Empty name]" NAME="Furness 2010" TYPE="COCHRANE_REVIEW">
<AU>Furness S, Glenny AM, Worthington HV, Pavitt S, Oliver R, Clarkson JE, et al</AU>
<TI>Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2010-11-05 11:15:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-11-05 11:15:41 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006386.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Garg-2004" NAME="Garg 2004" TYPE="JOURNAL_ARTICLE">
<AU>Garg M, Beitler JJ</AU>
<TI>Controversies in management of the neck in head and neck cancer</TI>
<SO>Current Treatment Options in Oncology</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>1</NO>
<PG>35-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hammarstedt-2006" MODIFIED="2010-09-10 09:36:00 +0100" MODIFIED_BY="[Empty name]" NAME="Hammarstedt 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, et al</AU>
<TI>Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer</TI>
<SO>International Journal of Cancer</SO>
<YR>2006</YR>
<VL>119</VL>
<NO>11</NO>
<PG>2620-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hammerlid-1997" MODIFIED="2010-11-05 11:16:01 +0000" MODIFIED_BY="[Empty name]" NAME="Hammerlid 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hammerlid E, Bjordal K, Ahlner-Elmqvist M, Jannert M, Kaasa S, Sullivan M, et al</AU>
<TI>Prospective, longitudinal quality-of-life study of patients with head and neck cancer: a feasibility study including the EORTC QLQ-C30</TI>
<SO>Otolaryngology Head and Neck Surgery</SO>
<YR>1997</YR>
<VL>116</VL>
<NO>6 Pt 1</NO>
<PG>666-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harari-2005" MODIFIED="2008-09-03 15:06:20 +0100" MODIFIED_BY="Philip Riley" NAME="Harari 2005" TYPE="JOURNAL_ARTICLE">
<AU>Harari PM</AU>
<TI>Promising new advances in head and neck radiotherapy</TI>
<SO>Annals of Oncology</SO>
<YR>2005</YR>
<VL>16 Suppl 6</VL>
<PG>vi13-vi19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hassan-1993" MODIFIED="2010-11-05 11:16:17 +0000" MODIFIED_BY="[Empty name]" NAME="Hassan 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hassan SJ, Weymuller EA Jr</AU>
<TI>Assessment of quality of life in head and neck cancer patients</TI>
<SO>Head &amp; Neck</SO>
<YR>1993</YR>
<VL>15</VL>
<NO>6</NO>
<PG>485-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-11-05 11:17:35 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions version 5.0.2 (updated September 2009). The Cochrane Collaboration 2009</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hindle-1996" NAME="Hindle 1996" TYPE="JOURNAL_ARTICLE">
<AU>Hindle I, Downer MC, Speight PM</AU>
<TI>The epidemiology of oral cancer</TI>
<SO>British Journal of Oral and Maxillofacial Surgery</SO>
<YR>1996</YR>
<VL>34</VL>
<NO>5</NO>
<PG>471-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koh-1994" MODIFIED="2010-11-05 11:18:24 +0000" MODIFIED_BY="[Empty name]" NAME="Koh 1994" TYPE="JOURNAL_ARTICLE">
<AU>Koh WJ, Griffin TW, Laramore GE, Stelzer KJ, Russell KJ</AU>
<TI>Fast neutron radiation therapy. Results of phase III randomized trials in head and neck, lung, and prostate cancers</TI>
<SO>Acta Oncologica</SO>
<YR>1994</YR>
<VL>33</VL>
<NO>3</NO>
<PG>293-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-La-Vecchia-1997" NAME="La Vecchia 1997" TYPE="JOURNAL_ARTICLE">
<AU>La Vecchia C, Tavani A, Franceschi S, Levi F, Corrao G, Negri E</AU>
<TI>Epidemiology and prevention of oral cancer</TI>
<SO>Oral Oncology</SO>
<YR>1997</YR>
<VL>33</VL>
<NO>5</NO>
<PG>302-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Licitra-2006" MODIFIED="2010-09-10 09:42:17 +0100" MODIFIED_BY="[Empty name]" NAME="Licitra 2006" TYPE="JOURNAL_ARTICLE">
<AU>Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, et al</AU>
<TI>High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>36</NO>
<PG>5630-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Macfarlane-1995" MODIFIED="2010-11-05 11:18:55 +0000" MODIFIED_BY="[Empty name]" NAME="Macfarlane 1995" TYPE="JOURNAL_ARTICLE">
<AU>Macfarlane GJ, Zheng T, Marshall JR, Boffetta P, Niu S, Brasure J, et al</AU>
<TI>Alcohol, tobacco, diet and the risk of oral cancer: a pooled analysis of three case-control studies</TI>
<SO>European Journal of Cancer. Part B, Oral Oncology</SO>
<YR>1995</YR>
<VL>31B</VL>
<NO>3</NO>
<PG>181-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGurk-2005" MODIFIED="2010-09-10 09:47:31 +0100" MODIFIED_BY="[Empty name]" NAME="McGurk 2005" TYPE="JOURNAL_ARTICLE">
<AU>McGurk M, Chan C, Jones J, O'Regan E, Sherriff M</AU>
<TI>Delay in diagnosis and its effect on outcome in head and neck cancer</TI>
<SO>British Journal of Oral and Maxillofacial Surgery</SO>
<YR>2005</YR>
<VL>43</VL>
<NO>4</NO>
<PG>281-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oliver-2007" MODIFIED="2010-11-05 11:21:49 +0000" MODIFIED_BY="[Empty name]" NAME="Oliver 2007" TYPE="COCHRANE_REVIEW">
<AU>Oliver R, Clarkson JE, Conway D, Glenny AM, Macluskey M, Pavitt S et al</AU>
<TI>Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-11-05 11:20:14 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-11-05 11:20:14 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006205.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parkin-1999" NAME="Parkin 1999" TYPE="JOURNAL_ARTICLE">
<AU>Parkin DM, Pisani P, Ferlay J</AU>
<TI>Estimates of the worldwide incidence of 25 major cancers in 1990</TI>
<SO>International Journal of Cancer</SO>
<YR>1999</YR>
<VL>80</VL>
<NO>6</NO>
<PG>827-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parkin-2001" NAME="Parkin 2001" TYPE="JOURNAL_ARTICLE">
<AU>Parkin DM</AU>
<TI>Global cancer statistics in the year 2000</TI>
<SO>Lancet Oncology</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>9</NO>
<PG>533-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parkin-2005" MODIFIED="2008-09-03 15:06:27 +0100" MODIFIED_BY="Philip Riley" NAME="Parkin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Parkin DM, Bray F, Ferlay J, Pisani P</AU>
<TI>Global cancer statistics, 2002</TI>
<SO>CA: a Cancer Journal for Clinicians</SO>
<YR>2005</YR>
<VL>55</VL>
<NO>2</NO>
<PG>74-108</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MK, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>24</NO>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Partridge-2000" NAME="Partridge 2000" TYPE="JOURNAL_ARTICLE">
<AU>Partridge M, Li SR, Pateromichelakis S, Francis R, Phillips E, Huang XH et al</AU>
<TI>Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment</TI>
<SO>Clinical Cancer Research</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>7</NO>
<PG>2718-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pavitt-2007" MODIFIED="2010-11-05 17:30:40 +0000" MODIFIED_BY="[Empty name]" NAME="Pavitt 2007" TYPE="COCHRANE_PROTOCOL">
<AU>Pavitt S, Clarkson JE, Conway D, Glenny AM, Macluskey M, Oliver R, et al</AU>
<TI>Interventions for the treatment of oral and oropharyngeal cancer: immunotherapy/biotherapy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-11-04 10:30:55 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-11-04 10:30:55 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006845"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pignon-2000" MODIFIED="2010-11-05 11:22:27 +0000" MODIFIED_BY="[Empty name]" NAME="Pignon 2000" TYPE="COCHRANE_PROTOCOL">
<AU>Pignon JP, Sylvester R, Bourhis J</AU>
<TI>Hyperfractionated and/or accelerated radiotherapy versus conventional radiotherapy for head and neck cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-11-05 11:22:27 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-11-05 11:22:27 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002026"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pignon-2007" MODIFIED="2010-11-05 11:24:12 +0000" MODIFIED_BY="[Empty name]" NAME="Pignon 2007" TYPE="COCHRANE_REVIEW">
<AU>Delbaldo C, Michiels S, Rolland E, Syz N, Soria JC, Le Chevalier T, Pignon J</AU>
<TI>Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-11-05 11:23:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-11-05 11:23:13 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004569.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Robinson-2003" NAME="Robinson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Robinson KL, Macfarlane GJ</AU>
<TI>Oropharyngeal cancer incidence and mortality in Scotland: are rates still increasing?</TI>
<SO>Oral Oncology</SO>
<YR>2003</YR>
<VL>39</VL>
<NO>1</NO>
<PG>31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ryerson-2008" MODIFIED="2010-09-10 09:39:11 +0100" MODIFIED_BY="[Empty name]" NAME="Ryerson 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ryerson AB, Peters ES, Coughlin SS, Chen VW, Gillison ML, Reichman ME, et al</AU>
<TI>Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003</TI>
<SO>Cancer</SO>
<YR>2008</YR>
<VL>113</VL>
<NO>10 Suppl</NO>
<PG>2901-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shah-1990" MODIFIED="2008-09-03 15:06:46 +0100" MODIFIED_BY="Philip Riley" NAME="Shah 1990" TYPE="JOURNAL_ARTICLE">
<AU>Shah JP</AU>
<TI>Cervical lymph node metastases--diagnostic, therapeutic, and prognostic implications</TI>
<SO>Oncology (Williston Park, NY)</SO>
<YR>1990</YR>
<VL>4</VL>
<NO>10</NO>
<PG>61-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sturgis-2007" MODIFIED="2010-09-10 09:34:26 +0100" MODIFIED_BY="[Empty name]" NAME="Sturgis 2007" TYPE="JOURNAL_ARTICLE">
<AU>Sturgis EM, Cinciripini PM</AU>
<TI>Trends in head and neck cancer incidence in relation to smoking prevalence</TI>
<SO>Cancer</SO>
<YR>2007</YR>
<VL>110</VL>
<NO>7</NO>
<PG>1429-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trotti-2000" MODIFIED="2010-11-05 11:25:18 +0000" MODIFIED_BY="[Empty name]" NAME="Trotti 2000" TYPE="JOURNAL_ARTICLE">
<AU>Trotti A</AU>
<TI>Toxicity in head and neck cancer: a review of trends and issues</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2000</YR>
<VL>47</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trotti-2007" MODIFIED="2010-11-05 11:25:28 +0000" MODIFIED_BY="[Empty name]" NAME="Trotti 2007" TYPE="JOURNAL_ARTICLE">
<AU>Trotti A, Pajak TF, Gwede CK, Paulus R, Cooper J, Forastiere A, et al</AU>
<TI>TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>8</VL>
<PG>613-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Warnakulasuriya-2009" MODIFIED="2010-09-10 09:33:01 +0100" MODIFIED_BY="[Empty name]" NAME="Warnakulasuriya 2009" TYPE="JOURNAL_ARTICLE">
<AU>Warnakulasuriya S</AU>
<TI>Global epidemiology of oral and oropharyngeal cancer</TI>
<SO>Oral Oncology</SO>
<YR>2009</YR>
<VL>45</VL>
<NO>4-5</NO>
<PG>309-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1992" MODIFIED="2010-11-05 11:26:11 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 1992" TYPE="BOOK">
<AU>WHO</AU>
<SO>ICD-O. International Statistical Classification of Diseases and Related Health Problems, 1989 Revision</SO>
<YR>1992</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woolgar--2003" NAME="Woolgar  2003" TYPE="JOURNAL_ARTICLE">
<AU>Woolgar JA, Rogers SN, Lowe D, Brown JS, Vaughan ED</AU>
<TI>Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread</TI>
<SO>Oral Oncology</SO>
<YR>2003</YR>
<VL>39</VL>
<NO>2</NO>
<PG>130-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2010-08-11 14:49:48 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-11-10 13:44:02 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-11-10 13:44:02 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-11-05 15:24:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ang-2001">
<CHAR_METHODS MODIFIED="2010-11-05 15:22:36 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: US.</P>
<P>Number of centres: 3.</P>
<P>Funding: National Cancer Institute (grants CA-06294 and CA-16672), Gilbert H. Fletcher Chair, and Texas Tobacco Settlement Funds.</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 15:23:25 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: histologically proven squamous cell carcinomas with advanced cancer (Stage II-IV) of the oral cavity, oropharynx, larynx or hypopharynx, deemed likely to require treatment with a combination of surgery and post-operative radiotherapy, and having a Zubrod performance status of 0-2 were eligible for this trial. Median age 57 years.</P>
<P>Exclusion criteria: not explicit.</P>
<P>Recruitment period: August 1991 and August 1997.</P>
<P>OC: 80/213 (38%).</P>
<P>OP: 66/213 (31%).</P>
<P>OC+OP: 146/213 (69%) (<I>see</I> notes).</P>
<P>Number randomised: 151.</P>
<P>Number analysed: 151.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 15:24:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Accelerated radiotherapy with boost versus conventional radiotherapy </B>
</P>
<P>Accelerated/boost (n = 76): 1.8 Gy/fraction, 5 fractions per week for 3 weeks, followed by 10 fractions per week for 2 weeks (total 63 Gy).</P>
<P>Conventional (n = 75): 1.8 Gy/fraction, 5 fractions per week for 7 weeks (total 63 Gy).</P>
<P>Median interval between surgery and post-operative radiotherapy was 31 days for those receiving accelerated radiotherapy and 29 days for those receiving conventional radiotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 15:24:28 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: locoregional control.</P>
<P>Secondary: overall survival, toxicity.</P>
<P>Duration of follow-up: unclear for randomised participants alone.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 15:24:36 +0000" MODIFIED_BY="[Empty name]">
<P>258 participants underwent surgery and were classified as being low, intermediate or high risk according to pathologic risk features. Those classed as high risk were randomised to the 2 intervention groups (n = 151).</P>
<P>HR calculated for OC/OP participants only, using data provided by authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 15:30:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bartelink-2002">
<CHAR_METHODS MODIFIED="2010-11-05 15:25:14 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Europe.</P>
<P>Number of centres: 11.</P>
<P>Funding: not stated.</P>
<P>Trial ID: not stated (EORTC trial).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 15:25:24 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: locally advanced, inoperable head &amp; neck cancer with primaries in oral cavity, oropharynx, larynx and hypopharynx. T2-T4 included.</P>
<P>Exclusion criteria: not explicit.</P>
<P>Recruitment period: not stated.</P>
<P>OC: 16/49 (33%).</P>
<P>OP: 23/49 (47%).</P>
<P>OC+OP: 39/49 (80%).</P>
<P>Number randomised: 53.</P>
<P>Number analysed: 49.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 15:29:45 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Hyperfractionated/accelerated/split course radiotherapy plus chemotherapy versus conventional radiotherapy plus chemotherapy</B>
</P>
<P>Hyperfractionated/accelerated/split (n = 25): 1.6 Gy per fraction, 3 fractions per day on weeks 1, 4 &amp; 7 (total dose 72 Gy) with 10 mg/m<SUP>2</SUP> cisplatin IV administered daily between fractions 1 &amp; 2. Interfraction interval varied between 3 &amp; 4 hours.</P>
<P>Conventional (n = 24): 2 Gy per fraction, 5 fractions per week for a total dose of 70 Gy over 7 weeks together with 6 mg/m<SUP>2 </SUP>cisplatin IV 30-60 minutes prior to RT daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 15:29:59 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: toxicity.</P>
<P>Secondary: overall survival, locoregional control.</P>
<P>Duration of follow-up: minimum 24 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 15:30:12 +0000" MODIFIED_BY="[Empty name]">
<P>HR data taken from Kaplan-Meier graphs (numbers at risk presented).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 15:32:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bergermann-1992">
<CHAR_METHODS MODIFIED="2010-11-05 15:30:48 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Germany.</P>
<P>Number of centres: 2.</P>
<P>Funding: not stated.</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 15:31:06 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: histologically confirmed squamous cell carcinoma, primary tumour, T2, N0-N2, M0, with no prior treatment. Tumour of the floor of the mouth, tongue edge and pars alveolaris (lower jaw) were included.</P>
<P>Exclusion criteria: not explicitly stated in translation.</P>
<P>Recruitment period: March 1982 to February 1987.</P>
<P>OC: 100%.</P>
<P>Number randomised: 100.</P>
<P>Number analysed: 85.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 15:32:12 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Pre-operative radiotherapy plus post-operative radiotherapy versus post-operative radiotherapy alone </B>
</P>
<P>Pre-operative (n = 44): 6 Gy on days 1-3 followed by surgery on day 4. From day 21 saturation radiotherapy of 6 Gy/day (total 60 Gy).</P>
<P>No pre-operative (n = 41): surgery followed by saturation radiotherapy from day 21 of 6 Gy/day (total 60 Gy).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 15:32:20 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome unclear.</P>
<P>Overall survival, local recurrent disease, regional metastases, distant metastases, second tumour.</P>
<P>Duration of follow-up: 9 years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 15:32:31 +0000" MODIFIED_BY="[Empty name]">
<P>Data from translation.</P>
<P>Data taken from Kaplan-Meier graphs (no numbers at risk).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 15:34:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bjarnason-2009">
<CHAR_METHODS MODIFIED="2010-11-05 15:32:54 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Canada.</P>
<P>Number of centres: 12.</P>
<P>Funding: National Cancer Institute of Canada.</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 15:33:54 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: histologically proven squamous cell carcinomas of oral cavity, pharynx, larynx were eligible to receive radiotherapy without chemotherapy, 2 or more visible areas of oral mucosa in target area, ECOG performance status 0-1, adequate haematological function. T1-T4 included.</P>
<P>Exclusion criteria: shift workers, patients with abnormal sleep habits, previous radiotherapy or chemotherapy within 6 months, planned use of radioprotective agents, connective tissue disease or AIDS.</P>
<P>Recruitment period: August 1999 to November 2002.</P>
<P>OC: 40/216 (19%).</P>
<P>OP: 76/216 (35%).</P>
<P>OC+OP: 116/216 (54%).</P>
<P>Number randomised: 216.</P>
<P>Number analysed: 216 (for overall survival); 205 (for toxicity).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 15:34:11 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Morning radiotherapy versus afternoon radiotherapy </B>
</P>
<P>Morning (n = 108 ): radiotherapy between 8 &amp;10 am.</P>
<P>Afternoon (n = 108 ): radiotherapy between 4 &amp; 6 pm.</P>
<P>4 different schedules were used, either 50 Gy in 25 fractions, or 60 Gy in 25-30 fractions or 66 Gy in 33 fractions of 70 Gy in 25 fractions. Randomisation was stratified on planned total dose.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 15:34:21 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: oral mucositis incidence of grade 3 or higher.</P>
<P>Secondary: interval to development of grade 2 mucositis, duration of various grades of mucositis, treatment days lost due to toxicity, other acute/late toxicities, quality of life, weight loss during/after treatment, overall survival, locoregional control.</P>
<P>Duration of follow-up: maximum 5 years, 7 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 15:34:37 +0000" MODIFIED_BY="[Empty name]">
<P>Sample size calculation: hypothesised that incidence of grade 3 or greater mucositis with afternoon RT would be 35% and 17.5% for morning RT and it was estimated that 216 patients would be required to detect this difference with 80% power at a 2-sided 0.05 level, after taking into account a potential 5% withdrawal rate.</P>
<P>HR presented in text.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 15:36:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bourhis-2006">
<CHAR_METHODS MODIFIED="2010-11-05 15:34:49 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: France.</P>
<P>Number of centres: 11.</P>
<P>Funding: not stated.</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 15:35:05 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients with no previous history of cancer, or previous chemotherapy or radiotherapy, performance status 0-2, squamous cell cancer of oral cavity, oropharynx, hypopharynx and larynx, T3-T4, N0-N3 not eligible for surgery.</P>
<P>Exclusion criteria: not explicitly stated.</P>
<P>Recruitment period: November 1994 to September 1998.</P>
<P>OC: 36/266 (14%).</P>
<P>OP: 205/266 (77%).</P>
<P>OC+OP: 241/266 (91%).</P>
<P>Number randomised: 268.</P>
<P>Number analysed: 266.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 15:35:27 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Hyperfractionated/accelerated radiotherapy versus conventional radiotherapy</B>
</P>
<P>Hyperfractionated/accelerated (n = 137): 62-64 Gy in 31-32 fractions over 22-23 days, 2 Gy/fraction, 2 fraction/day, 20 Gy/week over 3 weeks. Interfraction interval 8 hours.</P>
<P>Conventional (n = 129): 70 Gy in 35 fractions, 2 Gy per fraction, over 7 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 15:35:35 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: locoregional control.</P>
<P>Secondary: overall survival, disease free survival, toxicity.</P>
<P>Duration of follow-up: median &gt; 6 years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 15:36:00 +0000" MODIFIED_BY="[Empty name]">
<P>Sample size calculation "estimated that a minimum of 100 patients per group would be necessary to demonstrate an increase in the locoregional tumour control rate, from 30% in the conventional group to 55% in the very accelerated group, with an &#945; = 5% and &#946; = 5% (two tailed test)."</P>
<P>Data from Kaplan-Meier figures.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 15:38:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cox-1990">
<CHAR_METHODS MODIFIED="2010-11-05 15:36:33 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: US.</P>
<P>Number of centres: multicentre (number unclear).</P>
<P>Funding: National Cancer Institute, National Institute for Health (grants 21661, 32115, 12258, 13457, 20235, 21439, 29565, 12262).</P>
<P>Trial ID: RTOG 83-13.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 15:36:55 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: squamous cell carcinoma of the upper aerodigestive tract, Stages III &amp; IV considered inoperable, with no prior resection or radiotherapy. Adequate bone marrow and renal function. T1-T4 included.</P>
<P>Exclusion criteria: history of previous malignant tumour. Prior chemotherapy within 6 weeks of randomisation.</P>
<P>Recruitment period: April 1983 to February 1986 (Scheme A).</P>
<P>OC: 47/237 (20%).</P>
<P>OP: 104/237 (44%).</P>
<P>OC+OP: 151/237 (64%).</P>
<P>Number randomised: 260.</P>
<P>Number analysed: 237.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 15:37:34 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Different doses of hyperfractionated radiotherapy </B>
</P>
<P>Gr A (n = 63): 67.2 Gy.</P>
<P>Gr B (n = 58): 72.0 Gy.</P>
<P>Gr C (n = 116): 76.8 Gy.</P>
<P>All fractions were 1.2 Gy given twice daily 5 days per week. Interval between fractions was permitted to be 4-8 hours. Radiotherapy was administered with photons of 1.25 MV or greater with minimum source axis distance of 80 cm.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 15:37:47 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: locoregional control.</P>
<P>Secondary: overall survival, toxicity, late effects.</P>
<P>Duration of follow-up: minimum 2 years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 15:38:00 +0000" MODIFIED_BY="[Empty name]">
<P>Trial also randomised patients to 81.6 Gy or 72.0 Gy between February 1986 to November 1987 (Scheme B). However, the trial focuses on data from Scheme A.</P>
<P>HR data taken from Kaplan-Meier graphs (no numbers at risk).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 15:40:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dobrowsky-2000">
<CHAR_METHODS MODIFIED="2010-11-05 15:38:28 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Europe.</P>
<P>Number of centres: 21.</P>
<P>Funding: Medizinischwissenschaftlicher Fonds des Burgermeisters der Bundeshauptstadt Wien.</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 15:38:39 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: squamous cell cancers originating in head and neck. Most were advanced tumours with lymph node involvement and were considered inoperable by the referring specialist. T1-T4 included.</P>
<P>Exclusion criteria: distant metastases.</P>
<P>Recruitment period: October 1990 to December 1997.</P>
<P>OC: 72/239 (30%).</P>
<P>OP: 98/239 (41%).</P>
<P>OC/OP: 170/239 (71%).</P>
<P>Number randomised: 243.</P>
<P>Number analysed: 239.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 15:39:19 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Hyperfractionated/accelerated radiotherapy versus conventional radiotherapy</B>
</P>
<P>Hyperfractionated/accelerated (vCHART) (n = 78): 2.5 Gy on day 1 as single fraction, then 16 consecutive days of 1.65 Gy twice daily with interfraction interval of &#8805;6 hours to a total dose of 55.3 Gy. On weekdays therapy was performed with photons/electrons from a linear accelerator, and on weekends and holidays a Cobalt-60 unit was used. Maximum dose to spinal cord was 38.8 Gy.</P>
<P>Conventional (n = 81): 70 Gy delivered in 35 fractions over 7 weeks, 5 fractions of 2 Gy/week on weekdays using a linear accelerator to deliver photons &amp; electrons. Maximum dose to spinal cord was 46 Gy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 15:39:36 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: overall survival.</P>
<P>Secondary: locoregional response, recurrence, distant metastases, secondaries, toxicity.</P>
<P>Duration of follow-up: median follow-up 48 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 15:40:09 +0000" MODIFIED_BY="[Empty name]">
<P>Sample size calculation reported. It was calculated that a sample size of 324 patients would be required to detect a "difference in survival of 15% (from 25% to 40%) after 3 years between 2 of the treatment groups with a probability of 85% at a significance level of 0.05."</P>
<P>The trial had a third treatment arm not used in this review as intervention under assessment was chemotherapy not radiotherapy (V-CHART+MMC).</P>
<P>HR data taken from Kaplan-Meier graphs.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:40:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fu-1995">
<CHAR_METHODS MODIFIED="2010-11-05 15:40:52 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: US.</P>
<P>Number of centres: 5.</P>
<P>Funding: National Cancer Institute, National Institute of Health.</P>
<P>Trial ID: RTOG 88-09.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 15:41:17 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: Stage III or IV of oral cavity, oropharynx, supraglottic larynx or nasopharynx, or Stage II, III, IV cancer of base of tongue or hypopharynx, age &#8805; 18 years with Karnofsky performance status &#8805; 60. No prior radiation therapy, chemotherapy or surgery.</P>
<P>Exclusion criteria: prior or simultaneous malignancy, unless patient has been cancer free for &gt; 5 years, metastases below clavicle.</P>
<P>Recruitment period: February 1989 to January 1990.</P>
<P>OC: 8/75 (11%).</P>
<P>OP: 38/75 (51%).</P>
<P>OC+OP: 46/75 (61%).</P>
<P>Number randomised: 75.</P>
<P>Number analysed: 70.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 12:40:16 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Hyperfractionated/accelerated split course radiotherapy versus accelerated radiotherapy with concomitant boost </B>
</P>
<P>Hyperfractionated/accelerated/split course (AHFX-S) (n = 38): radiotherapy to primary tumour and upper neck 1.6 Gy per fraction, twice daily with minimum 6-hour interfraction interval, 5 times per week to a total dose of 38.4 Gy in 2.5 weeks. Rest from radiotherapy for 14 days then 1.6 Gy per fraction, twice daily to a reduced boost volume including primary tumour and positive nodes to further 28.8 Gy. Total dose 67.2 Gy.</P>
<P>Accelerated/ boost accelerated (AFX-C) Gr B (n = 32): 1.8 Gy per fraction, once daily, 5 times per week to total dose of 54 Gy in 30 fractions over 6 weeks. During the last 11 days of basic treatment a second daily dose of 1.5 Gy was given to a reduced boost volume. Total dose 70.5 Gy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 15:41:57 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: locoregional control.</P>
<P>Secondary: overall survival, disease free survival, recurrence, toxicity.</P>
<P>Duration of follow-up: median follow-up 2 years (0.03 to 4.87 years).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 15:42:01 +0000" MODIFIED_BY="[Empty name]">
<P>Dichotomous data only; unable to calculate HR.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 15:48:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fu-2000">
<CHAR_METHODS MODIFIED="2010-11-05 15:45:40 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: US, Canada.</P>
<P>Number of centres: &gt; 40.</P>
<P>Funding: National Cancer Institute (grants CA21661, CA 37422, CA 32115, CA 06294).</P>
<P>Trial ID: RTOG 9003.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 15:46:07 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients aged at least 18 years, with Karnofsky performance status &#8805; 60%, no prior treatment, with Stage II-IV disease M0 squamous cell carcinoma of oral cavity, oropharynx or supraglottic larynx or Stage II-IV cancer of base of tongue or hypopharynx. T1-T4 included.</P>
<P>Exclusion criteria: prior or synchronous malignancy.</P>
<P>Recruitment period: September 1991 to August 1997.</P>
<P>OC: 110/1073 (10%).</P>
<P>OP: 649/1073 (60%).</P>
<P>OC+OP: 759/1073 (71%).</P>
<P>Number randomised: 1113.</P>
<P>Number analysed: 1073.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 15:47:26 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Hyperfractionated radiotherapy versus hyperfractionated/accelerated/split course radiotherapy versus accelerated/boost radiotherapy versus conventional radiotherapy</B>
</P>
<P>Hyperfractionated (n = 263): 1.2 Gy per fraction, 2 fractions per day, interfraction interval 6 hours, 5 times per week to total dose of 81.6 Gy in 35 fractions over 7 weeks.</P>
<P>Hyperfractionated/accelerated/split (n = 274): 1.6 Gy per fraction, 2 fractions per day, interfraction interval 6 hours, 5 times per week to 38.4 Gy then 2 weeks rest then resume as for Phase 1 with further 28.8 Gy for total of 67.2 Gy in 42 fractions over 6 weeks.</P>
<P>Accelerated/boost (n = 268): 1.8 Gy per fraction, daily, interfraction interval 6 hours, 5 times per week together with a 1.5 Gy boost field for last 12 treatment days to a total of 72 Gy in 42 fractions over 6 weeks.</P>
<P>Conventional (n = 268): 2 Gy per fraction, 5 fractions per week to a total of 70 Gy in 35 fractions over 7 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 15:47:47 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: locoregional control at 2 years.</P>
<P>Secondary: overall survival, disease free survival, acute and late toxicity.</P>
<P>Duration of follow-up: median follow-up was 23 months for all analysable patients and 41.2 for surviving patients.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 15:48:03 +0000" MODIFIED_BY="[Empty name]">
<P>Sample size calculation. Study was designed to detect an increase in locoregional control from 40% to 55% with a type 1 error of 0.05 and power of 80%. Sample size was increased by 20% to allow for patients being found to be ineligible, lost to follow-up or dying without locoregional failure within 2 years. Sample planned 1080 participants.</P>
<P>Data from Kaplan-Meier graphs (numbers at risk presented).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 15:50:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghoshal-2008">
<CHAR_METHODS MODIFIED="2010-11-05 15:48:35 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: India.</P>
<P>Number of centres: 1.</P>
<P>Funding: not stated.</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 15:49:22 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: previously untreated patients with locally advanced squamous cell carcinoma of oropharynx, hypopharynx &amp; larynx, Stage III &amp; IV, M0, aged &gt; 25 years, Karnofsky performance status &#8805; 70, adequate haematological function, and no comorbidities.</P>
<P>Exclusion criteria: large lymph nodes, extending beyond spinal cord where radiation therapy to spare cord area would be difficult.</P>
<P>Recruitment period: June 1998 to June 2004.</P>
<P>OC: 0/285 (0%).</P>
<P>OP: 186/285 (65%).</P>
<P>Number randomised: 290.</P>
<P>Number analysed: 285.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 15:49:55 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Accelerated fractionation with concomitant boost versus conventional fractionation radiotherapy</B>
</P>
<P>Accelerated/boost (n = 145): 1.8 Gy per fraction 5 times per week for 5 weeks to a total of 45 Gy with additional 1.5 Gy fraction given daily after 6-hour interfraction interval for last 3 weeks for additional 22.5 Gy. Total dose 67.5 Gy.</P>
<P>Conventional (n = 145): 2 Gy per fraction, 1 fraction per day, 5 times per week to a total dose of 66 Gy over 6.5 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 15:50:15 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: disease free survival.</P>
<P>Secondary: locoregional control, compliance with treatment protocol.</P>
<P>Duration of follow-up: median duration of follow-up 2 years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 15:50:23 +0000" MODIFIED_BY="[Empty name]">
<P>"Exploratory subgroup analyses were carried out on various prognostic variables."</P>
<P>HR presented in text.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 15:52:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Griffin-1984">
<CHAR_METHODS MODIFIED="2010-11-05 15:50:54 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: USA</P>
<P>Number of centres: 2</P>
<P>Funding: not stated.</P>
<P>Trial ID: RTOG 7610a.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 15:51:28 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: previously untreated histologically proven inoperable squamous cell carcinoma, T2-4, any N originating in oral cavity, oropharynx, supraglottic larynx or hypopharynx.</P>
<P>Exclusion criteria: distant metastases, prior treatment for head &amp; neck cancer.</P>
<P>Recruitment period: February 1977 to April 1982.</P>
<P>OC: 10/40 (25%).</P>
<P>OP: 13/40 (33%).</P>
<P>OC+OP: 23/40 (58%).</P>
<P>Number randomised: 40.</P>
<P>Number analysed: 35.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 15:51:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Neutron versus photon</B>
</P>
<P>Neutron (n = 26): neutron dose equivalent to 66-74 Gy megavoltage photon irradiation based on radiobiological effectiveness. Each fraction equivalent to 2.5 Gy photon irradiation 4 times per week. Uninvolved neck and supraclavicular region received equivalent of 46-50 Gy photon irradiation in neutrons. Duration of treatment was 7-8 weeks.</P>
<P>Photon (n = 14): 66-74 Gy megavoltage photon irradiation in fractions of 1.8 to 2 Gy per day, 5 fractions per week. Uninvolved neck and supraclavicular regions received 46-50 Gy and duration of treatment was 7-8 weeks.</P>
<P>Patients from both groups who had either residual or recurrent disease after RT were directed to surgery if this was considered feasible.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 15:52:09 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: unclear.</P>
<P>Locoregional control, overall survival, disease free survival.</P>
<P>Duration of follow-up: minimum of 4 years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 15:52:18 +0000" MODIFIED_BY="[Empty name]">
<P>HR data taken from Kaplan-Meier graphs (no numbers at risk).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 15:53:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Griffin-1989">
<CHAR_METHODS MODIFIED="2010-11-05 15:52:42 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: USA.</P>
<P>Number of centres: 5.</P>
<P>Funding: not stated.</P>
<P>Trial ID: RTOG 7610b.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 15:53:09 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: previously untreated histologically proven inoperable squamous cell carcinoma, T2-4, any N originating in oral cavity, oropharynx, supraglottic larynx or hypopharynx.</P>
<P>Exclusion criteria: distant metastases, Karnofsky performance status &lt; 60, prior treatment for head &amp; neck cancer.</P>
<P>Recruitment period: February 1977 to April 1982.</P>
<P>OC: 80/297 (27%).</P>
<P>OP: 154/297 (52%).</P>
<P>OC+OP: 234/297 (79%).</P>
<P>Number randomised: 327.</P>
<P>Number analysed: 297.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 15:53:36 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Neutron/photon mixed beam versus photon</B>
</P>
<P>Mixed beam (n = 163): combination of 40-44 Gy megavoltage photons and 7.5 to 10 Gy neutrons, delivered as 3 fractions photons &amp; 2 fractions neutrons per week. Each fraction 1.8 to 2 Gy or the equivalent based on the relative biological effectiveness of the neutron source. Uninvolved neck and supraclavicular region received 46-50 Gy over 7-8 weeks.</P>
<P>Photon (n = 134): 66-74 Gy megavoltage photon irradiation in fractions of 1.8 to 2 Gy per day, 5 fractions per week. Uninvolved neck and supraclavicular regions received 46-50 Gy and duration of treatment was 7-8 weeks.</P>
<P>Patients from both groups who had either residual or recurrent disease after RT were directed to surgery if this was considered feasible.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 15:53:44 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: tumour clearance rate.</P>
<P>Secondary: locoregional control, overall survival.</P>
<P>Duration of follow-up: minimum of 6 years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 15:53:53 +0000" MODIFIED_BY="[Empty name]">
<P>HR data taken from Kaplan-Meier graphs (no numbers at risk).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 15:55:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horiot-1992">
<CHAR_METHODS MODIFIED="2010-11-05 15:54:14 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Europe.</P>
<P>Number of centres: 28.</P>
<P>Funding: not stated.</P>
<P>Trial ID: EORTC 22791.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 15:54:53 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients aged &#8804; 75 years, with Karnofsky performance status &#8805; 60 who have oropharyngeal cancer, T2 or T3, either N0 or N1 (providing there is a single node involved and it is less than 3 cm).</P>
<P>Exclusion criteria: lesions in the base of the tongue, whether N0 or N1 (&lt; 3 cm).</P>
<P>Recruitment period: February 1980 to April 1987.</P>
<P>OP: 356/356 (100%).</P>
<P>Number randomised: 356.</P>
<P>Number analysed: 325.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 15:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Hyperfractionated radiotherapy versus conventional fractionation radiotherapy</B>
</P>
<P>Hyperfractionated (n = 166): 80.5 Gy in 70 fractions over 7 weeks. 2 fractions of 1.15 Gy daily with interfraction interval of 4-6 hours.</P>
<P>Conventional (n = 159): daily fraction of 1.75 to 2 Gy per fraction, to a total of 70 Gy in 35-40. Fractions over 7-8 weeks (the longer treatment time was used when large amounts of mucosa within target volume).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 15:55:37 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: locoregional control.</P>
<P>Secondary: overall survival, tolerance, late toxicity.</P>
<P>Duration of follow-up: mean follow-up is 200 weeks, maximum follow up is 11 years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 15:55:48 +0000" MODIFIED_BY="[Empty name]">
<P>HR data taken from Kaplan-Meier graphs (numbers at risk presented).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 15:58:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horiot-1997">
<CHAR_METHODS MODIFIED="2010-11-05 15:56:10 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: 11 countries in Europe.</P>
<P>Number of centres: 26.</P>
<P>Funding: 4th Medical and Health Research Programme, concerted action 1989-92, Quality Assurance in Cancer Clinical Research theme.</P>
<P>Trial ID: EORTC 22851.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 15:57:28 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: squamous cell carcinoma of head &amp; neck, T2-T4. Patients aged &#8804;75 years, with WHO performance status 0-2.</P>
<P>Exclusion criteria: cancer of the hypopharynx.</P>
<P>Recruitment period: December 1985 to April 1995.</P>
<P>OC: 16%.</P>
<P>OP: 64%.</P>
<P>OC+OP: 80%.</P>
<P>Number randomised: 512.</P>
<P>Number analysed: 512.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 15:58:11 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Hyperfractionated/accelerated/split course radiotherapy versus conventional radiotherapy</B>
</P>
<P>Hyperfractionated/accelerated/split (n = 257): Phase 1: 3 fractions of 1.6 Gy daily with minimum 4-hour interfraction interval, for total of 28.8 Gy in 18 fractions over 8 days. 12-14 day rest period.</P>
<P>Phase 2: 43.2 Gy in 27 fractions of 1.6 Gy per fraction over 17 days starting on day 21. Total dose of 72 Gy in 45 fractions over 5 weeks.</P>
<P>Conventional (n = 255): 2 Gy per fraction, 1 fraction per day, 5 days per week to total of 70 Gy in 35 fractions over 7 weeks.</P>
<P>In both groups the target volume was reduced once or twice after 50 Gy and spinal cord dose remained less than 50 Gy. The boost techniques used in each institution varied according to institution policy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 15:58:34 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: locoregional control.</P>
<P>Secondary: overall survival, disease specific survival, toxicity.</P>
<P>Duration of follow-up: median duration of follow-up 4 years and 9 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-04 15:17:21 +0100" MODIFIED_BY="[Empty name]">
<P>Sample size calculation reported: "Assuming a 2 year locoregional control rate of 35% in the CF arm, it was estimated that 340 patients followed for 2 years .... would be enough to detect a 15% difference in the 2 year LRC rates with an accuracy of 80% and a type 1 error probability of 0.05." However, "an excess of 172 patients was entered justified by the need to increase the statistical power of a 10 year trial that would obviously be difficult to reproduce."</P>
<P>HR presented in text.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 16:00:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hukku-1991">
<CHAR_METHODS MODIFIED="2010-11-05 15:59:03 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: India.</P>
<P>Number of centres: 1.</P>
<P>Funding: not stated.</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 15:59:13 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: histologically proven squamous cell carcinoma, T3-4, N0-3, with primary tumours in oral cavity, oropharynx, larynx and nasopharynx.</P>
<P>Exclusion criteria: chronic medical problems and distant metastases.</P>
<P>Recruitment period: January 1980 to August 1983.</P>
<P>OC: 7/110 (6%).</P>
<P>OP: 72/110 (65%).</P>
<P>OC+OP: 79/110 (70%).</P>
<P>Number randomised: 110.</P>
<P>Number analysed: 110.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 15:59:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Split course radiotherapy versus accelerated radiotherapy</B>
</P>
<P>Split course (n = 50): Phase 1: 15 fractions of 2.3 Gy over 3 weeks to primary tumour and bilateral neck. 2-week break. Phase 2: 2.5 Gy per fraction for 10 fractions over 2 weeks to primary tumour and residual lymphatic disease if present or upper neck if lymph nodes not palpable.</P>
<P>Conventional (n = 60): 4 Gy per fraction in 2 opposing fields, 5 fractions per week, total of 11 fractions and 44 Gy. Treatment delivered to primary tumour along with bilateral neck with reduction of neck field after 7 fractions.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 15:59:59 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: locoregional control.</P>
<P>Secondary: overall survival, disease free survival, toxicity.</P>
<P>Duration of follow-up: 2 years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 16:00:04 +0000" MODIFIED_BY="[Empty name]">
<P>Dichotomous data only; unable to calculate HR.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 16:01:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Inoue-2001">
<CHAR_METHODS MODIFIED="2010-11-05 16:00:21 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Japan.</P>
<P>Number of centres: 1.</P>
<P>Funding: not stated.</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:00:55 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients with early mobile tongue cancer, T1-2, N0 which could be treated with a single plane implantation, localisation of tumour at lateral border of the tongue, and tumour thickness less that 10 mm, performance status 0-3.</P>
<P>Exclusion criteria: any severe concurrent disease.</P>
<P>Recruitment period: April 1992 to October 1996.</P>
<P>OC: 59/59 (100%).</P>
<P>Number randomised: 59.</P>
<P>Number analysed: 51.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:01:14 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Low dose rate interstitial radiotherapy versus high dose rate interstitial radiotherapy</B>
</P>
<P>Low dose (n = 26): 0.30 to 0.93 Gy/h to total dose of 65-75 Gy (median 70 Gy) over 75 to 217 hours (median 117 hours).</P>
<P>High dose (n = 30): 0.99 to 4.1 Gy/min to total dose of 60 Gy in 10 fractions over 6-9 days (median 7 days) with 2 fractions per day and interfraction interval of &gt; 6 hours.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:01:25 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: locoregional control.</P>
<P>Secondary: cause specific survival.</P>
<P>Duration of follow-up: minimum of 46 months (median duration of follow-up is 85 and 78 months in the low dose and high dose groups respectively).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 16:01:37 +0000" MODIFIED_BY="[Empty name]">
<P>HR data taken from Kaplan-Meier graphs (no numbers at risk).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 16:05:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ketcham-1969">
<CHAR_METHODS MODIFIED="2010-11-05 16:03:34 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: US.</P>
<P>Number of centres: 1.</P>
<P>Funding: not stated.</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:03:57 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: squamous cell carcinoma of upper aerodigestive tract.</P>
<P>Exclusion criteria: previous RT, recurrent disease, more than 1 primary lesion, cancer of the lip. If the tumour was "inadvertently cut across during surgery" or if surgical margins were positive, patient was excluded.</P>
<P>Recruitment period: not stated.</P>
<P>OC: 44/79 (56%).</P>
<P>OP: unclear.</P>
<P>OC+OP: &gt; 56%.</P>
<P>Number randomised: unclear.</P>
<P>Number analysed: 79.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:04:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Pre-operative radiotherapy versus pre-operative sham radiotherapy</B>
</P>
<P>Pre-operative radiotherapy (n = 60): using a 2 MeV van der Graaf generator with output of 1 Gy per minute at 1 metre, a single dose of 10 Gy was administered over 15 minutes, 24 hours prior to surgery.</P>
<P>Pre-operative sham radiotherapy (n = 19).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:04:59 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: surgical complications.</P>
<P>Secondary: locoregional control, metastases.</P>
<P>Duration of follow-up: 36-86 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 16:05:08 +0000" MODIFIED_BY="[Empty name]">
<P>Dichotomous data only (unclear timing of outcome evaluation reported in paper); unable to calculate HR.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 16:12:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lawrence-1974">
<CHAR_METHODS MODIFIED="2010-11-05 16:10:59 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: US.</P>
<P>Number of centres: 1.</P>
<P>Funding: not stated.</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:11:25 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: previously untreated Stage II-IV squamous cell carcinoma of oral cavity, oropharynx, or pharynx with technically resectable disease.</P>
<P>Exclusion criteria: Stage I cancer (usually treated by radiation therapy alone), patients with other cancers, including lip, paranasal sinus, nasopharynx, or glottic carcinoma of larynx.</P>
<P>Recruitment period: January 1969 to December 1972.</P>
<P>OC: 64/143 (45%).</P>
<P>OP: 37/143 (26%).</P>
<P>OC+OP: 101/143 (71%).</P>
<P>Number randomised: 143.</P>
<P>Number analysed: 143.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:12:12 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Pre-operative radiotherapy plus surgery versus surgery alone</B>
</P>
<P>Pre-operative radiotherapy (n = 69): 2 fractions each of 1.4 Gy given 48 and 24 hours prior to surgery. RT delivered by Co-60 unit using 80 cm source skin distance followed by radical resection of primary carcinoma and simultaneous radical neck dissection.</P>
<P>Surgery alone (n = 74): radical resection of primary carcinoma &amp; simultaneous unilateral or bilateral radical neck dissection.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:12:23 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: surgical complications.</P>
<P>Secondary: overall survival, local recurrence.</P>
<P>Duration of follow-up: 4 years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 16:12:19 +0000" MODIFIED_BY="[Empty name]">
<P>Unable to use data.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 16:14:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MacDougall-1990">
<CHAR_METHODS MODIFIED="2010-11-05 16:12:47 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Edinburgh, Scotland.</P>
<P>Number of centres: 1.</P>
<P>Funding: Medical Research Council, Cancer Research Campaign, Scottish Home and Health Department, Lothian Health Board.</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:13:17 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: previously untreated patients with histologically confirmed squamous cell carcinoma of oral cavity, oropharynx, larynx or hypopharynx, less than 80 years old, deemed fit for radiotherapy.</P>
<P>Exclusion criteria: primary tumours with high probability of local control with photon treatment.</P>
<P>Recruitment period: 1977 to 1984.</P>
<P>OC: 66/165 (40%).</P>
<P>OP: 35/165 (21%).</P>
<P>OC+OP: 101/165 (61%).</P>
<P>Number randomised: 165.</P>
<P>Number analysed: 165.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:13:29 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Fast neutron radiotherapy versus photon radiotherapy</B>
</P>
<P>Fast neutron (n = 85): 20 daily fractions over 4 weeks. Total absorbed dose of 15.6 to 16.7 Gy.</P>
<P>Photon (n = 80): 20 daily fractions over 4 weeks. Total absorbed dose 54-56 Gy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:13:43 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: locoregional control.</P>
<P>Secondary: 5 and 10 year survival, disease free survival at 5 years, cause specific survival, late radiation necrosis.</P>
<P>Duration of follow-up: minimum of 5 years, up to 11 years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 16:14:01 +0000" MODIFIED_BY="[Empty name]">
<P>Sample size calculation: based on predicted increase of locoregional control from 40% to 70% it was estimated that 164 patients would be required to show this difference with power of 90% and &#945; = 0.05 on a tow tailed test of significance.</P>
<P>Part of multicentre trial but full data from 2 centres not available.</P>
<P>Dichotomous data only for outcomes of interest.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 16:15:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maor-1986">
<CHAR_METHODS MODIFIED="2010-11-05 16:14:37 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: US.</P>
<P>Number of centres: 4.</P>
<P>Funding: National Cancer Institute (core grant CA23113).</P>
<P>Trial ID: RTOG 7808.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:15:04 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: untreated squamous cell carcinoma, T2-T4, with any N but M0. Patients referred to trial following unsatisfactory response to initial radiotherapy.</P>
<P>Exclusion criteria: more than 1 primary tumour or Karnofsky status &lt; 50.</P>
<P>Recruitment period: October 1978 to August 1982.</P>
<P>OC: 30/115 (26%).</P>
<P>OP: 59/115 (51%).</P>
<P>OC+OP: 89/115 (77%).</P>
<P>Number randomised: 118.</P>
<P>Number analysed: 115.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:15:24 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Neutron boost versus photon boost</B>
</P>
<P>Neutron boost (n = 57): to include only areas involved by gross tumour, primary, or nodes plus a margin of 2 cm. Boost given in 4-6 fractions in 2-3 weeks. Neutron dose depended on radiobiological effectiveness, equivalent to 25-30 Gy photons.</P>
<P>Photon boost (n = 58): to include areas with gross tumour plus a 1 cm margin (2 cm with cobalt). 25-30 Gy over 2-3 weeks in 5 daily fractions per week.</P>
<P>All patients received 45-50 Gy photons in daily fractions of 1.8-2 Gy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:15:29 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome unclear.</P>
<P>Tumour clearance, locoregional control, overall survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 16:15:36 +0000" MODIFIED_BY="[Empty name]">
<P>Data taken from Kaplan-Meier graphs (no numbers at risk).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 16:17:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maor-1995">
<CHAR_METHODS MODIFIED="2010-11-05 16:16:17 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: US and UK.</P>
<P>Number of centres: 5 (4 US and 1 UK).</P>
<P>Funding: National Cancer Institute, Department of Health and Human Services (grants CA06294, CA16672, CM57775) and Medical Research Council in UK.</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:16:40 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients with Stage III-IV tumours in the oral cavity, oropharynx, hypopharynx and larynx, T3-4 with any N or T2 with N &gt; 1 or T1N3, Karnofsky performance status &gt; 60.</P>
<P>Exclusion criteria: no distant metastases, no history of another cancer.</P>
<P>Recruitment period: April 1986 to March 1991.</P>
<P>OC: 39/169 (23%).</P>
<P>OP: 87/169 (51%).</P>
<P>OC+OP: 126/169 (75%).</P>
<P>Number randomised: 178.</P>
<P>Number analysed: 169.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:16:48 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Neutrons versus photons</B>
</P>
<P>Neutrons (n = 83): 20.4 Gy neutrons delivered in 12 fractions of 1.7 Gy over 4 weeks (3 fractions per week).</P>
<P>Photons (n = 86): 70 Gy of photons delivered in 35 fractions, 2 Gy per fraction over 7 weeks (except in UK centre, 66 Gy in 30 fractions over 6 weeks).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:17:12 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: tumour clearance.</P>
<P>Secondary: locoregional control/relapse, overall survival, late toxicity.</P>
<P>Duration of follow-up: median duration of follow-up 3.5 years (range 3 months to 6.7 years).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 16:17:19 +0000" MODIFIED_BY="[Empty name]">
<P>HR data taken from Kaplan-Meier graphs (numbers at risk presented).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 16:19:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marcial-1987">
<CHAR_METHODS MODIFIED="2010-11-05 16:17:54 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: US.</P>
<P>Number of centres: unclear.</P>
<P>Funding: National Cancer Institute/National Institute for Health (grants CA12258, CA32115, CA20235, CA21661).</P>
<P>Trial ID: RTOG 79-13.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:18:32 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: advanced squamous cell carcinoma of oral cavity, pharynx, larynx and paranasal sinus whose only planned therapy was radiation (with possible surgical salvage). Patients had Stage III or IV tumours, or Stage II tumours of base of tongue, nasopharynx or maxillary sinus. T1-T4 included.</P>
<P>Exclusion criteria: metastatic disease, 2 primary tumours, previous chemotherapy or radiotherapy or surgery, Karnofsky performance status &lt; 60%.</P>
<P>Recruitment period: August 1979 to June 1983.</P>
<P>OC: 28/187 (15%).</P>
<P>OP: 86/187 (46%).</P>
<P>OC+OP: 114/187 (61%).</P>
<P>Number randomised: 210.</P>
<P>Number analysed: 187.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:18:50 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Hyperfractionated/accelerated radiotherapy versus conventional radiotherapy</B>
</P>
<P>Hyperfractionated/accelerated (n = 94): 1.2 Gy per fraction, 10 fractions per week with interfraction interval of 3-6 hours to total dose of 60 Gy over 5 weeks.</P>
<P>Conventional (n = 93): 1.8 to 2 Gy per fraction, 5 fractions per week, to total dose of 66-73.8 Gy over 7-8 weeks.</P>
<P>Co-60 or higher energy used, dose specified to mid plane from parallel opposed fields covering primary tumour and extensions with 1.5 cm margin. After 50 Gy lateral port was reduced to cover primary tumour only.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:19:03 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: tumour clearance.</P>
<P>Secondary: locoregional control, overall survival, early and late toxicity.</P>
<P>Duration of follow-up: estimated to be 30 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 16:19:10 +0000" MODIFIED_BY="[Empty name]">
<P>HR data taken from Kaplan-Meier graphs (no numbers at risk).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 16:21:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marcial-1993">
<CHAR_METHODS MODIFIED="2010-11-05 16:19:41 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: US.</P>
<P>Number of centres: approximately 7.</P>
<P>Funding: National Cancer Institute (grants CA12258 and CA32115).</P>
<P>Trial ID: RTOG trial (number unclear).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:20:01 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients with all stages of untreated cancer of the tonsillar fossa.</P>
<P>Exclusion criteria: patients aged &gt; 80 years, with adenocarcinoma, other cancers (previous or present except for skin cancers), presence of distant metastases, medical conditions which made treatment completion unlikely, or patient deemed unlikely to complete follow-up.</P>
<P>Recruitment period: 1971 to 1976.</P>
<P>OP: 147/147 (100%).</P>
<P>Number randomised: 147.</P>
<P>Number analysed: 137.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:20:55 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Accelerated split course radiotherapy versus continuous radiotherapy</B>
</P>
<P>Split course (n = 63): Phase 1: 3 Gy per fraction, 10 fractions over 2 weeks total of 30 Gy. 3 weeks rest. Phase 2: 3 Gy per fraction and further 10 fractions over 2 weeks.</P>
<P>Continuous (n = 74): 2.0-2.2 Gy per fraction, with 30-33 fractions over 6 weeks to a total dose of 66 Gy. Original protocol was modified to allow 2 Gy fractions to a total of 60-66 Gy.</P>
<P>Spinal cord protection was required after 50 Gy in Phase 2. Source was teletherapy energy at 1 MeV or higher with minimal source skin distance of 75 cm. Surgical salvage was permitted at least 2 months after completion of radiotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:21:16 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: tumour clearance.</P>
<P>Secondary: locoregional control, overall survival, acute and late toxicity.</P>
<P>Duration of follow-up: minimum of 7 years (4% of patients lost to follow-up prior to 7 years).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 16:21:34 +0000" MODIFIED_BY="[Empty name]">
<P>Dichotomous data only; unable to calculate HR. Locoregional control data presented as percentage but unclear of denominator.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 16:24:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Olmi-2003">
<CHAR_METHODS MODIFIED="2010-11-05 16:22:29 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Italy.</P>
<P>Number of centres: 18.</P>
<P>Funding: Consiglio Nazionale delle Richerche.</P>
<P>Trial ID: ORO-93 01.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:23:01 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: histologically proven squamous cell carcinoma of oropharynx, Stage III or IV, M0 no prior surgery, radiotherapy or chemotherapy, age &lt; 70 years, Karnofsky performance status &#8805;70 or ECOG 0-2, adequate bone marrow reserve, renal, hepatic cardiac and pulmonary function, available for follow-up, informed consent.</P>
<P>Exclusion criteria: T1N1 &amp; T2N1, previous tumours, active infectious disease, psychosis.</P>
<P>Recruitment period: January 1993 to June 1998.</P>
<P>OP: 192/192 (100%).</P>
<P>Number randomised: 192.</P>
<P>Number analysed: 182.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:24:14 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Conventional radiotherapy plus concomitant chemotherapy versus hyperfractionated/accelerated/split course radiotherapy versus conventional radiotherapy</B>
</P>
<P>Conventional radiotherapy plus concomitant chemotherapy (n = 64): 66-70 Gy in 33-35 fractions (2 Gy/fraction) 5 times per week over 6.5 to 7 weeks. 50 Gy to uninvolved neck nodes, tolerance dose for spinal cord 44 Gy. Carboplatin 75 mg/m<SUP>2</SUP> IV over 30 minutes on days 1-4 of RT, and 5FU 1000 mg/m<SUP>2</SUP>/day IV continuous over 96 hours on days 1-4, repeated on weeks 5 and 9 of RT.</P>
<P>Hyperfractionated/accelerated/split (n = 65): 64-67.2 Gy - 2 fractions each of 1.6 Gy daily with 4-6 hour interfraction interval, 5 times per week. After 38.4 Gy over 2 weeks 2-week split planned, followed by a repeat of phase 1.</P>
<P>Conventional (n = 63): 66-70 Gy in 33-35 fractions (2 Gy/fraction) 5 times per week over 6.5 to 7 weeks. 50 Gy to uninvolved neck nodes, tolerance dose for spinal cord 44 Gy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:24:28 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: survival at 5 years.</P>
<P>Secondary: overall survival, relapse free survival, locoregional control, acute and late toxicity.</P>
<P>Duration of follow-up: median follow-up 8.35 years (4.8 to 10.2 years).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 13:48:04 +0100" MODIFIED_BY="[Empty name]">
<P>Trial closed prior to planned accrual of 260 due to slowed accrual rate.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 16:27:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pinto-1991">
<CHAR_METHODS MODIFIED="2010-11-05 16:25:07 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Brazil.</P>
<P>Number of centres: 1.</P>
<P>Funding: not stated.</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:25:37 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients with previously untreated, histopathologically confirmed squamous cell carcinoma, Stage III &amp; IV oropharyngeal cancer, aged &lt; 70, no previous malignancy (except basal cell carcinoma of skin), no trismus, no metastases and Karnofsky performance status &#8805; 50%.</P>
<P>Exclusion criteria: not explicitly stated.</P>
<P>Recruitment period: April 1986 to May 1989.</P>
<P>OP: 112/112 (100%).</P>
<P>Number randomised: 112.</P>
<P>Number analysed: 98.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:27:18 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Hyperfractionated radiotherapy versus conventional radiotherapy</B>
</P>
<P>Hyperfractionated (n = 56): 64 fractions of 1.1 Gy given twice daily to a total dose of 70.4 Gy over 6.5 weeks with minimum interfraction interval of 6 hours.</P>
<P>Conventional (n = 54): 33 fractions of 2 Gy per fractions given 5 times per week over 6.5 weeks to total dose of 66 Gy.</P>
<P>The spinal cord was protected after 46.2 Gy and 46 Gy in the hyperfractionated and conventional groups respectively. Radiation delivered from Co-60 machine at distance of 80 cm.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:27:27 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: overall survival.</P>
<P>Secondary: locoregional control, early and late toxicity.</P>
<P>Duration of follow-up: median follow-up 22.5 months (7-41 months).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-09 15:17:57 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 16:30:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poulsen-2001">
<CHAR_METHODS MODIFIED="2010-11-05 16:29:08 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Australia and New Zealand.</P>
<P>Number of centres: 14.</P>
<P>Funding: Queensland Cancer Fund.</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:29:44 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: invasive squamous cell carcinoma in oral cavity, oropharynx, hypopharynx or larynx, disease at Stage III or IV, ECOG performance status 0-2, age &#8804; 80 years, weight &gt; 40 kg, loss of body weight &lt; 15%.</P>
<P>Exclusion criteria: prior radiotherapy, chemotherapy, or therapeutic surgery, other active malignancy, intercurrent illness likely to reduce life expectancy or exacerbate toxicity.</P>
<P>Recruitment period: 1991 to 1998.</P>
<P>OC: 37/343 (11%).</P>
<P>OP: 229/343 (67%).</P>
<P>OC+OP: 266/343 (78%).</P>
<P>Number randomised: 350.</P>
<P>Number analysed: 343.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:30:03 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Hyperfractionated/accelerated radiotherapy versus conventional radiotherapy</B>
</P>
<P>Hyperfractionated/accelerated (n = 172): 1.8 Gy per fraction twice daily to a dose of 39.6 Gy in 22 fractions over 16 days with macroscopic disease receiving a dose of 59.4 Gy in 33 fractions over 24 days. Spinal cord dose was initially limited to 42 Gy but this was decreased to 40 Gy after a case of myelitis.</P>
<P>Conventional (n = 171): large volume comprising primary site and all draining lymph nodes at risk were treated with 2 Gy per fraction 5 fractions per week to total of 50 Gy in 25 fractions over 35 days. Macroscopic disease with 1 cm margin was boosted to 70 Gy in 35 fractions over 49 days. Spinal cord dose was limited to 45 Gy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:30:13 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: disease free survival at 5 years.</P>
<P>Secondary: disease specific survival, locoregional control, toxicity.</P>
<P>Duration of follow-up: median 53 months (14-101 months).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 16:30:44 +0000" MODIFIED_BY="[Empty name]">
<P>Sample size: estimated that 342 patients were required to enable a difference of 15% in disease free survival from 40% to 55% to be detected with 80% power at 5% level of significance using a 2-sided test.</P>
<P>HR presented in text.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 16:32:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanguineti-2005">
<CHAR_METHODS MODIFIED="2010-11-05 16:31:17 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Italy.</P>
<P>Number of centres: 4.</P>
<P>Funding: not stated.</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:31:58 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: pathologically proven squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, and major surgical resection of primary disease and clinically involved neck lymph nodes without macroscopic residual; ECOG performance status &#8804; 2 before radiotherapy, no distant metastases.</P>
<P>Exclusion criteria: patients with other concurrent or previous (within 5 years) cancers other than basal cell carcinoma of the skin and in situ squamous cell carcinoma of the cervix.</P>
<P>Recruitment period: March 1994 to August 2000.</P>
<P>OC: 44/226 (19%).</P>
<P>OP: 40/226 (18%).</P>
<P>OC+OP: 84/226 (37%) (<I>see</I> notes).</P>
<P>Number randomised: 226.</P>
<P>Number analysed: 226.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:32:18 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Accelerated radiotherapy with boost versus conventional radiotherapy</B>
<BR/>
</P>
<P>Accelerated/boost (n = 113 (46 OC/OP patients)): 2 Gy/fraction, 5 fractions a week for 5 weeks. A concomitant boost of 1.4 Gy/fraction during first week and 1.6 Gy/fraction during fifth week of radiotherapy was given (total dose 64 Gy).</P>
<P>Conventional (n = 113 (38 OC/OP patients)): 2 Gy/fraction, 5 fractions a week for 5 weeks (total 50 Gy) to areas at low risk of macroscopic disease and 6 weeks (total 60 Gy) to areas at high risk.</P>
<P>All radiotherapy had to commence within 8 weeks following surgery. Surgery consisted of major surgical resection of both primary disease and clinically involved neck lymph nodes without macroscopic residual.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:32:24 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: locoregional control.</P>
<P>Secondary: overall survival, toxicity.</P>
<P>Duration of follow-up: 10 years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 16:32:36 +0000" MODIFIED_BY="[Empty name]">
<P>Sample size: estimated that 224 patients would provide power of 80% (with an &#945; error of 5%, 2-sided) to detect improvement of 81% in the probability of locoregional control at 2 years in the accelerated radiotherapy group compared with 70% in the conventional group.</P>
<P>HR calculated for OC/OP patients only using data supplied by authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 16:35:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Skladowski-2006">
<CHAR_METHODS MODIFIED="2010-11-05 16:33:07 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Poland.</P>
<P>Number of centres: 1.</P>
<P>Funding: Polish Scientific Research Committee (grant #4PO5 B15208).</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:33:34 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: histologically proven squamous cell carcinoma with primary tumour in oropharynx, hypopharynx oral cavity or supraglottic larynx, T2-4, N0-1, aged &#8804; 70 years, WHO performance status &#8804; 2 and no other neoplastic disorders.</P>
<P>Exclusion criteria: weight loss more than 10% in past 3 months, radiologically confirmed infiltration of mandible or thyroid cartridge or refusal.</P>
<P>Recruitment period: December 1993 to June 1996.</P>
<P>OC: 22/100 (22%).</P>
<P>OP: 28/100 (28%).</P>
<P>OC+OP: 50/100 (50%).</P>
<P>Number randomised: 100.</P>
<P>Number analysed: 100.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:34:42 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Accelerated radiotherapy versus conventional radiotherapy</B>
</P>
<P>Accelerated (n = 51): 2 Gy per fraction, 7 daily fractions per week to total of 66 Gy ± 2 Gy for T2, &amp; 70 Gy ± 2 Gy for T3-4 with overall treatment time of 33-36 days. Large fields covering the whole clinical target volume were used Monday to Friday and at weekends a smaller field, limited to primary tumour and involved nodes only, was irradiated. Patients were hospitalised for the duration of the treatment.</P>
<P>Conventional (n = 49): 2 Gy per day, 5 times per week, to a total of 66 Gy ± 2 Gy for T2 and 70 Gy ± 2 Gy for T3-4 with overall treatment time of 47-50 days. Small fields were used as a shrinking fields technique during last week of treatment.</P>
<P>From 1995 the fraction size was changed from 2 Gy to 1.8 Gy in both arms "due to the high rate of mucosal necrosis."</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:35:03 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: local tumour control.</P>
<P>Secondary: overall survival, morbidity free survival, disease free survival, acute and late toxicity.</P>
<P>Duration of follow-up: median follow-up 96 months (59-123 months).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 16:35:28 +0000" MODIFIED_BY="[Empty name]">
<P>Sample size calculation: to detect an expected increase in local tumour control in the CAIR arm of 24% it was estimated that about 200 patients were required with &#945; = 0.05 and 1-&#946; = 0.90 (2-sided test). Investigators planned an interim analysis and possible change to protocol, to detect unacceptable treatment toxicity, or unexpectedly high benefit.</P>
<P>HR data taken from graphs (no numbers at risk).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 16:37:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Terz-1981">
<CHAR_METHODS MODIFIED="2010-11-05 16:35:56 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: USA.</P>
<P>Number of centres: 2.</P>
<P>Funding: not stated.</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:36:16 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: previously untreated squamous cell carcinoma Stages II-IV of oral cavity, oropharynx or hypopharynx if disease appeared to be technically resectable.</P>
<P>Exclusion criteria: Stage 1 disease, patients with primary tumours of lip, nasopharynx, paranasal sinuses or larynx.</P>
<P>Recruitment period: January 1969 to September 1975.</P>
<P>OC: 94/248 (38%).</P>
<P>OP: 72/248 (29%).</P>
<P>OC+OP: 166/248 (67%).</P>
<P>Number randomised: 248.</P>
<P>Number analysed: unclear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:37:00 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Pre-operative radiotherapy versus surgery alone</B>
</P>
<P>Pre-operative radiotherapy (n = 126): 1.4 Gy in 2 equal fractions 48 and 24 hours prior to surgery. Radiotherapy administered through a pair of opposed fields to cover both primary lesion and entire cervical lymph drainage area. Co-60 source with source to skin = 80 cm. Followed by resection of primary tumour with uni or bilateral neck dissection.</P>
<P>Surgery alone (n = 122): resection of primary tumour with uni or bilateral neck dissection.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:37:15 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: complications, operative mortality.</P>
<P>Secondary: recurrence, 5-year disease free survival.</P>
<P>Duration of follow-up: 4-9 years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 16:37:26 +0000" MODIFIED_BY="[Empty name]">
<P>HR taken from Kaplan-Meier graph (no numbers at risk).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-05 16:39:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weissberg-1983">
<CHAR_METHODS MODIFIED="2010-11-05 16:37:53 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: US.</P>
<P>Number of centres: 1.</P>
<P>Funding: US Public Health Service (grant CA 06519).</P>
<P>Trial ID: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:38:15 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: inoperable advanced biopsy proven squamous cell carcinoma of head and neck.</P>
<P>Exclusion criteria: metastatic disease beyond neck nodes, Karnofsky performance status &lt; 60%, other malignant neoplasms in past 5 years.</P>
<P>Recruitment period: 1973 to 1979.</P>
<P>OC: 12/64 (19%).</P>
<P>OP: 29/64 (45%).</P>
<P>OC+OP: 41/64 (64%).</P>
<P>Number randomised: 64.</P>
<P>Number analysed: 56.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:38:55 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Accelerated radiotherapy versus conventional radiotherapy</B>
</P>
<P>Accelerated (n = 33): high fractional dose of 4 Gy per day to total dose of 40-48 Gy in 2-3 weeks. Bilateral neck regions irradiated to 28 Gy and spinal cord dose limited to 28 Gy.</P>
<P>Conventional (n = 31): 2 Gy per day to total of 60-70 Gy over 6-7 weeks. Bilateral neck regions irradiated to 44 Gy and spinal cord dose limited to 44 Gy.</P>
<P>Radiotherapy from 2 MeV van der Graff generator or 4 or 6 MeV linear accelerator.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:39:04 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: disease free survival at 5 years.</P>
<P>Secondary: disease free survival, regression, toxicity.</P>
<P>Duration of follow-up: 5-7 years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-09 15:18:22 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CT = chemotherapy; ECOG = Eastern Cooperative Oncology Group; EORTC = European Organisation for Research and Treatment of Cancer; HR = hazard ratio; N = node; OC = oral cavity; OP = oropharynx; RT = radiotherapy; RTOG = Radiation Therapy Oncology Group; T = tumour; WHO = World Health Organization.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-11-05 16:44:38 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-08-04 15:38:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arimoto-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-04 15:38:39 +0100" MODIFIED_BY="[Empty name]">
<P>Less than 50% of participants in trial have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-04 15:38:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Awwad-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-04 15:38:38 +0100" MODIFIED_BY="[Empty name]">
<P>Less than 50% of participants in trial have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-04 15:38:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Awwad-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-04 15:38:38 +0100" MODIFIED_BY="[Empty name]">
<P>Less than 50% of participants in trial have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-05 16:41:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baumann-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-05 16:41:19 +0000" MODIFIED_BY="[Empty name]">
<P>2 commentaries on Fu 2000; no additional data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-04 15:38:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Catterall-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-04 15:38:34 +0100" MODIFIED_BY="[Empty name]">
<P>Less than 50% of participants in trial have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-04 15:38:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CHART-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-04 15:38:34 +0100" MODIFIED_BY="[Empty name]">
<P>Less than 50% of participants in trial have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-04 15:38:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cummings-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-04 15:38:32 +0100" MODIFIED_BY="[Empty name]">
<P>Less than 50% of participants in trial have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-04 15:38:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DAHANCA-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-04 15:38:31 +0100" MODIFIED_BY="[Empty name]">
<P>Less than 50% of participants in trial have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-05 16:41:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Datta-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-05 16:41:41 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract only. No subsequent publication identified. Unclear percentage of oral cavity and oropharyngeal cancer patients included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-04 15:38:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dieckmann-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-04 15:38:31 +0100" MODIFIED_BY="[Empty name]">
<P>Uncertain if truly randomised - abstract only, no subsequent publication identified.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-04 15:38:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dvivedi-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-04 15:38:28 +0100" MODIFIED_BY="[Empty name]">
<P>59% of patients have squamous cell carcinoma of the head and neck but not stated how many of these have oral cavity or oropharyngeal cancer. No longer possible to contact authors.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-31 15:25:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flores-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-31 15:25:28 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear how many of these have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-05 16:42:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garden-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-05 16:42:01 +0000" MODIFIED_BY="[Empty name]">
<P>3 treatment groups, each with different chemotherapy regimen, therefore results cannot be attributed to radiotherapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-05 16:42:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giglio-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-05 16:42:08 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of radiotherapy regimen, but results confounded by use of chemotherapy in 1 arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-05 16:42:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hansen-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-05 16:42:14 +0000" MODIFIED_BY="[Empty name]">
<P>Reanalysis of data from 2 DAHANCA studies.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-09 15:34:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hering-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-09 15:34:45 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-01 22:00:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hintz-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-01 22:00:20 +0000" MODIFIED_BY="[Empty name]">
<P>Less than 50% of participants in trial have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-05 16:42:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Holsti-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-05 16:42:35 +0000" MODIFIED_BY="[Empty name]">
<P>Inadequate randomisation - odd versus even birth dates.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-04 15:38:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jackson-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-04 15:38:24 +0100" MODIFIED_BY="[Empty name]">
<P>Some trial participants are randomly allocated to treatment, and some are not. Minority of participants have oral cavity or oropharyngeal cancer. Attempts to contact author failed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-04 15:38:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Janot-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-04 15:38:25 +0100" MODIFIED_BY="[Empty name]">
<P>Patients had recurrent disease.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-05 16:42:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-05 16:42:46 +0000" MODIFIED_BY="[Empty name]">
<P>Conference abstract. No information on proportion of included participants with oral cavity or oropharyngeal cancer. No subsequent publication identified.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-11 12:15:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Katori-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-11 12:15:49 +0100" MODIFIED_BY="[Empty name]">
<P>Less than 50% of participants in trial have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-11 12:15:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klima-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-11 12:15:51 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with metastatic disease included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-03 22:18:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kokal-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-03 22:18:21 +0000" MODIFIED_BY="[Empty name]">
<P>Less than 50% of participants in trial have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-03 22:03:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kramer-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-03 22:03:52 +0000" MODIFIED_BY="[Empty name]">
<P>Less than 50% of participants in trial have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-12 17:03:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maor-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-12 17:03:04 +0100" MODIFIED_BY="[Empty name]">
<P>Includes recurrent cancer patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-05 16:43:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mishra-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-05 16:43:28 +0000" MODIFIED_BY="[Empty name]">
<P>Only some of the patients are randomised but all are analysed together. "However some surgeons preferred to put more clinically node-positive cases into the post-operative radiotherapy group."<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-05 16:43:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nissenbaum-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-05 16:43:34 +0000" MODIFIED_BY="[Empty name]">
<P>Less than 6 months follow-up.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-05 16:43:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Noel-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-05 16:43:39 +0000" MODIFIED_BY="[Empty name]">
<P>Unclear how many patients have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-05 16:43:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Noel-1997a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-05 16:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>Unclear how many patients have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-05 16:43:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Noel-1997b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-05 16:43:43 +0000" MODIFIED_BY="[Empty name]">
<P>Unclear how many patients have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-11 12:06:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Noel-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-11 12:06:02 +0100" MODIFIED_BY="[Empty name]">
<P>Commentary on 4 trials - no data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-09 15:34:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rink-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-09 15:34:49 +0100" MODIFIED_BY="[Empty name]">
<P>3 groups but not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-05 16:44:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Robertson-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-05 16:44:11 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of 2 different radiotherapy regimens, 1 of which includes surgery. Results confounded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-08 15:24:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanchiz-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-08 15:24:45 +0000" MODIFIED_BY="[Empty name]">
<P>Less than 50% of participants in trial have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-02 15:29:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Singh-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-02 15:29:17 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear if true RCT. Data presented as percentages; unclear denominator.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-08 12:51:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Snow-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-08 12:51:53 +0000" MODIFIED_BY="[Empty name]">
<P>Less than 50% of participants in trial have oral cavity or oropharyngeal cancer. Authors have not responded to request for separate data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-09 15:34:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Srivastava-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-09 15:34:57 +0100" MODIFIED_BY="[Empty name]">
<P>Less than 50% of participants in trial have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-09 15:34:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strong-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-09 15:34:57 +0100" MODIFIED_BY="[Empty name]">
<P>Less than 50% of participants in trial have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-09 15:34:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Suwinski-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-09 15:34:58 +0100" MODIFIED_BY="[Empty name]">
<P>Less than 50% of participants in trial have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-09 15:34:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tupchong-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-09 15:34:59 +0100" MODIFIED_BY="[Empty name]">
<P>Less than 50% of participants in trial have oral cavity or oropharyngeal cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT = randomised controlled trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-11-05 16:47:08 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2010-11-05 16:44:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ang-2007">
<CHAR_METHODS MODIFIED="2010-08-11 12:10:50 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_PARTICIPANTS MODIFIED="2010-08-11 12:10:56 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_INTERVENTIONS MODIFIED="2010-08-11 12:10:56 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_OUTCOMES MODIFIED="2010-08-11 12:10:45 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_NOTES MODIFIED="2010-11-05 16:44:54 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract only - full text due maybe in 2010.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-11-05 16:44:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghosh-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2010-11-05 16:44:57 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract only - awaiting full paper.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-11-05 16:45:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nutting-2009a">
<CHAR_METHODS MODIFIED="2010-11-05 16:45:04 +0000" MODIFIED_BY="[Empty name]">
<P>PARSPORT study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2010-11-05 16:45:35 +0000" MODIFIED_BY="[Empty name]">
<P>American Society of Clinical Oncology (ASCO) abstract 2009 - outcome = xerostomia, full report due in 2010 or 2011.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-11-05 16:46:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rodrigo-2004">
<CHAR_METHODS MODIFIED="2010-11-05 16:45:36 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:45:37 +0000" MODIFIED_BY="[Empty name]">
<P>Head and neck cancer patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:45:46 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative radiotherapy versus surgery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:46:00 +0000" MODIFIED_BY="[Empty name]">
<P>Total mortality, disease specific survival, locoregional control.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 16:45:39 +0000" MODIFIED_BY="[Empty name]">
<P>Awaiting translation.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-11-05 16:46:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rosenthal-2006">
<CHAR_METHODS MODIFIED="2010-08-11 12:08:33 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_PARTICIPANTS MODIFIED="2010-08-11 12:08:33 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_INTERVENTIONS MODIFIED="2010-10-29 16:57:38 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_OUTCOMES MODIFIED="2010-08-11 12:08:28 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_NOTES MODIFIED="2010-11-05 16:46:32 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract only - unclear of oral cavity/oropharyngeal percentages in full group.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-11-05 16:47:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Skladowski-2001">
<CHAR_METHODS MODIFIED="2010-11-05 16:46:47 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:47:05 +0000" MODIFIED_BY="[Empty name]">
<P>Head and neck cancer patients (oral cavity, oro-hypopharynx and larynx in Stage T2-4, N0-1, M0).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:47:06 +0000" MODIFIED_BY="[Empty name]">
<P>7 fractions in 7 days versus 7 fractions in 5 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:47:07 +0000" MODIFIED_BY="[Empty name]">
<P>Toxicity (additional outcomes unclear).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-05 16:47:08 +0000" MODIFIED_BY="[Empty name]">
<P>Information taken from published abstracts.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-11-05 16:48:55 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2010-11-05 16:48:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moergel-2009">
<CHAR_STUDY_NAME/>
<CHAR_METHODS MODIFIED="2010-11-05 16:47:56 +0000" MODIFIED_BY="[Empty name]">
<P>Non-blinded, multicentre randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-05 16:48:30 +0000" MODIFIED_BY="[Empty name]">
<P>Histologically verified diagnosis of a primary squamous cell carcinoma of the oral cavity or the oropharynx are eligible.</P>
<P>"- Maximum tumor diameter less than 4 cm in the pathohistological specimen irrespective of histological grading (pT1 or pT2)</P>
<P>- Concomitant histological verification of a singular ipsilateral lymph node metastasis less than 3 cm in diameter (pN1) without penetration of the lymph node's capsule and without presence of lymphangiosis carcinomatosa</P>
<P>- Radical resection of the tumor within adequate resection margins (R0)</P>
<P>- Written informed consent from the patient</P>
<P>- Adequate performance status ECOG Index greater or equal to 2</P>
<P>Patients younger than 18 and pregnant women are to be excluded."</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 16:48:36 +0000" MODIFIED_BY="[Empty name]">
<P>Surgery plus radiotherapy versus surgery alone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-05 16:48:45 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: overall survival.</P>
<P>Secondary outcomes: incidence and time to tumour relapse, quality of life and time from surgery to orofacial rehabilitation.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-11-05 16:48:49 +0000" MODIFIED_BY="[Empty name]">
<P>September 2009.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-11-05 16:48:55 +0000" MODIFIED_BY="[Empty name]">
<P>Maximilian Moergel (moergel@mkg.klinik.uni-mainz.de).</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-11-10 12:43:44 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-11-10 12:43:44 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:25:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ang-2001">
<DESCRIPTION>
<P>"Randomized trial."</P>
<P>Not explicitly reported but undertaken by third party (data provided by author).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 13:49:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bartelink-2002">
<DESCRIPTION>
<P>"Patients were randomised between" - method of sequence generation not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 09:14:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bergermann-1992">
<DESCRIPTION>
<P>"Randomly allocated to treatment groups". No further information on method of sequence generation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-19 09:49:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bjarnason-2009">
<DESCRIPTION>
<P>A minimisation procedure was used to randomise patients. Patients were stratified by treatment centre, pretreatment smoking status and planned total radiation dose.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:36:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bourhis-2006">
<DESCRIPTION>
<P>"Centrally randomised at Institute Gustave Roussy Villejeuf, France from a computer generated list.... randomisation stratified by centre."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:38:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cox-1990">
<DESCRIPTION>
<P>"Randomized to 1 of 3 total doses". No details of method of sequence generation given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:40:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dobrowsky-2000">
<DESCRIPTION>
<P>"Patients were randomised by the Documentation Office of the 1st Surgical University Clinic". Randomisation was stratified by site, age, performance status &amp; gender.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:42:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fu-1995">
<DESCRIPTION>
<P>"Stratified by Karnofsky performance status (60-80 versus 90-100) and randomised". No details of sequence generation given but assumed to be adequate as for other RTOG trials.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:48:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fu-2000">
<DESCRIPTION>
<P>Stratified by Karnofsky performance status (90-100 versus 60-80), N stage (N+ versus N-) and primary site. Randomisation was according to the scheme of Zelen, used to achieve balance in treatment assignment among the institutions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 17:08:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ghoshal-2008">
<DESCRIPTION>
<P>Permuted block randomisation using a computer generated in house system. Randomisation was not stratified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:52:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Griffin-1984">
<DESCRIPTION>
<P>Randomisation stratified by region and stage of primary tumour and institution where treatment given. Randomised groups were "intentionally unbalanced" to give a greater proportion of patients in the mixed beam group. Method of sequence generation not described but assumed adequate as for other RTOG trials.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:54:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Griffin-1989">
<DESCRIPTION>
<P>Randomisation stratified by region and stage of primary tumour and institution where treatment given. Randomised groups were "intentionally unbalanced" to give a greater proportion of patients in the mixed beam group. Method of sequence generation not described but assumed adequate as for other RTOG trials.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:55:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Horiot-1992">
<DESCRIPTION>
<P>"Randomised". No further information regarding generation of random sequence presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:58:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horiot-1997">
<DESCRIPTION>
<P>"Randomisation performed centrally at the EORTC data centre in Bristol" Randomisation used the minimisation techniques and was stratified by institution, site of primary tumour and stage (T2 versus T3-4).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:00:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hukku-1991">
<DESCRIPTION>
<P>"Randomisation of patients...". No details of method of sequence generation provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:01:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inoue-2001">
<DESCRIPTION>
<P>"Randomly allocated into LDR &amp; HDR groups according to Peto's balanced randomisation list."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:10:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ketcham-1969">
<DESCRIPTION>
<P>"Sealed envelope selected randomly from 3 groups based on type of surgery patient required." Not clear how the envelopes were prepared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 09:32:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lawrence-1974">
<DESCRIPTION>
<P>"Patients...randomly assigned". Randomisation stratified by site of primary tumour and stage of disease, but method of sequence generation not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:14:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacDougall-1990">
<DESCRIPTION>
<P>Randomisation stratified on site of primary tumour and presence/absence of malignant lymph nodes. Envelopes containing treatment allocation prepared by trial statistician in Edinburgh, and held by Neutron Clinic secretary.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 17:52:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maor-1986">
<DESCRIPTION>
<P>Randomisation stratified by institution, T stage and region and performed by central office. No details given but assumed adequate as for other RTOG trials.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 11:50:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maor-1995">
<DESCRIPTION>
<P>"Patients...randomized to receive". Details of sequence generation not described. Stratification by site and stage of primary tumour and treating institution.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 11:50:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marcial-1987">
<DESCRIPTION>
<P>Randomisation was undertaken at RTOG headquarters in Philadelphia, and was stratified by site of primary tumour and stage of disease. No details on method of sequence generation are provided but it is assumed to be adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 09:21:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marcial-1993">
<DESCRIPTION>
<P>Randomisation done at RTOG headquarters in Philadelphia and was stratified by institution, T stage, N stage and gender. No details on method of sequence generation provided but it is assumed to be adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:24:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olmi-2003">
<DESCRIPTION>
<P>Randomisation performed by the Instituto Mario Negri, Milan. Patients were stratified by centre and disease stage (Stage III &amp; IV N0-N1 versus Stage IV N2-3). No details on sequence generation given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:43:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pinto-1991">
<DESCRIPTION>
<P>"...randomly allocated .... after stratification by site of primary tumour, T stage (T1-2 vs T3-4) N stage (N0 vs N1 vs N2-3) and lymph node size (&gt; or &lt; 6 cm)". No details on method of sequence generation provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 14:13:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poulsen-2001">
<DESCRIPTION>
<P>Randomisation done by Data Management Office of Queensland Radium Institute, stratified by primary tumour site and stage (4 groups). No details of the method of sequence generation provided but assumed to be adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:32:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanguineti-2005">
<DESCRIPTION>
<P>"Computer generated list and stratified according to center and balanced by variable blocks."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 14:36:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Skladowski-2006">
<DESCRIPTION>
<P>"Simple randomisation stratified by site of primary tumour, TNM Stage with 1:1 arm allocation, was made at Bureau of Trials at the Instiute using random numbers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-19 12:03:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Terz-1981">
<DESCRIPTION>
<P>No details on method of sequence generation used. Randomisation was stratified on site of primary tumour and stage of disease. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:39:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weissberg-1983">
<DESCRIPTION>
<P>"Randomized" but no details on method of sequence generation used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-11-05 16:39:18 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ang-2001">
<DESCRIPTION>
<P>Third party allocation (data provided by author).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 13:49:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bartelink-2002">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 09:21:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bergermann-1992">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 13:59:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bjarnason-2009">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 17:25:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bourhis-2006">
<DESCRIPTION>
<P>Treatment allocation made by telephone call to randomisation centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 12:28:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cox-1990">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:40:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dobrowsky-2000">
<DESCRIPTION>
<P>Allocation was made by telephone call to the randomisation centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 10:14:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fu-1995">
<DESCRIPTION>
<P>Patients entered into study by a telephone call to RTOG headquarters.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 10:57:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fu-2000">
<DESCRIPTION>
<P>Patients were enrolled by means of a telephone call to RTOG headquarters.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 17:18:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghoshal-2008">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 18:12:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Griffin-1984">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 13:34:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Griffin-1989">
<DESCRIPTION>
<P>Eligible patients were randomised by means of a phone call to the central office.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 15:25:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Horiot-1992">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 15:17:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horiot-1997">
<DESCRIPTION>
<P>Allocation to treatment group obtained by a telephone call to randomisation centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 09:48:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hukku-1991">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:01:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inoue-2001">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 11:23:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ketcham-1969">
<DESCRIPTION>
<P>Sealed envelope selected and taken by the patient to the radiotherapist, who opened it and delivered either RT or sham depending on envelope contents.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 09:32:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lawrence-1974">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-16 09:22:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacDougall-1990">
<DESCRIPTION>
<P>Sequentially numbered sealed envelopes were drawn. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 17:52:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maor-1986">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 11:50:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maor-1995">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 11:50:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marcial-1987">
<DESCRIPTION>
<P>Treatment allocation made by phone call to RTOG headquarters.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 11:09:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marcial-1993">
<DESCRIPTION>
<P>Treatment allocation made by telephone call to RTOG headquarters.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 13:51:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olmi-2003">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:27:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pinto-1991">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 14:13:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poulsen-2001">
<DESCRIPTION>
<P>Allocation made by telephone call to randomisation centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:32:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanguineti-2005">
<DESCRIPTION>
<P>"A centralized telephone call procedure to the unit of clinical epidemiology and trials in Genoa."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 14:36:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Skladowski-2006">
<DESCRIPTION>
<P>Sealed envelope method used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:37:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Terz-1981">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:39:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weissberg-1983">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-02-08 16:00:09 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-02-08 16:00:09 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-02-08 16:00:09 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2010-02-11 14:26:32 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding - Patients</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2010-02-11 14:26:32 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding - Carers</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2010-11-05 16:39:21 +0000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Blinding - Outcome Assessors</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-31 16:06:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ang-2001">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 13:49:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bartelink-2002">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 09:21:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bergermann-1992">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 13:59:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bjarnason-2009">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 17:25:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bourhis-2006">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 12:28:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cox-1990">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:40:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dobrowsky-2000">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 10:14:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fu-1995">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 10:57:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fu-2000">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 17:18:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ghoshal-2008">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 18:12:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Griffin-1984">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 13:34:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Griffin-1989">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 15:25:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Horiot-1992">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 15:17:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Horiot-1997">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 09:48:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hukku-1991">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:01:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Inoue-2001">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:10:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ketcham-1969">
<DESCRIPTION>
<P>Double blinded - both the patient and the surgeon were blinded to the treatment. Surgeons were asked to record whether they thought each patient has had RT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 09:32:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lawrence-1974">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 09:53:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-MacDougall-1990">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 17:52:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maor-1986">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 11:50:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maor-1995">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:19:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marcial-1987">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 09:21:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marcial-1993">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:25:02 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Olmi-2003">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:28:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pinto-1991">
<DESCRIPTION>
<P>Assessment of late radiation induced fibrosis conducted by clinician blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 14:13:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Poulsen-2001">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-31 15:10:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sanguineti-2005">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 14:36:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Skladowski-2006">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:37:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terz-1981">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:39:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weissberg-1983">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2010-11-05 16:39:41 +0000" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-31 16:14:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ang-2001">
<DESCRIPTION>
<P>All randomised participants included in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 13:49:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bartelink-2002">
<DESCRIPTION>
<P>3/28 (11%) patients in Gr A and 1/25 (4%) in Gr B did not receive allocated treatment. In this small trial this may have resulted in differences between groups with regard to prognostic factors and introduced bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 09:18:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bergermann-1992">
<DESCRIPTION>
<P>15/100 randomised patients excluded from analysis (6 receiving radiotherapy; 9 not receiving radiotherapy). Reasons unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 14:02:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bjarnason-2009">
<DESCRIPTION>
<P>Gr A 4/108 (4%) patients and Gr B 3/108 (3%) were found to be ineligible. In addition, Gr B 3/108 did not receive RT &amp; 1/108 had no mucositis assessments recorded (4%). All randomised patients were included in survival outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 17:26:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bourhis-2006">
<DESCRIPTION>
<P>1 patient had missing data, 1 refused treatment, and remainders of those randomised included in outcome evaluation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 11:37:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cox-1990">
<DESCRIPTION>
<P>9% of patients randomised are excluded from analysis, but reasons and group allocation not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:40:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dobrowsky-2000">
<DESCRIPTION>
<P>All randomised patients included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:45:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fu-1995">
<DESCRIPTION>
<P>5 patients excluded post-randomisation (1 ineligible due to metastasis, 1 had prior CT, 3 refused treatment) but not ascribed to treatment groups. Unclear from paper how many patients are included in percentage figures given for locoregional control, disease free survival and overall survival.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:48:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fu-2000">
<DESCRIPTION>
<P>1113 patients randomised, 28 were found to be ineligible, 5 refused protocol treatment or died before treatment started, 7 had inadequate data, total 40/1113 = 4% excluded. Exclusions not described by treatment group; appears likely that more excluded from hyperfractionated group (A) and fewer from split accelerated group (B).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:50:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ghoshal-2008">
<DESCRIPTION>
<P>2 in each group did not receive treatment, 2 &amp; 3 were lost to follow-up and 2 &amp; 3 discontinued treatment due to grade 3 mucositis. Remainder were included in outcome evaluation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 18:14:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Griffin-1984">
<DESCRIPTION>
<P>5/40 excluded (3 from neutron group; 2 from photon group) due to ineligibility or cancelled. Unclear how many patients included in outcome evaluation. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 13:34:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Griffin-1989">
<DESCRIPTION>
<P>After randomisation 16 patients were found to be ineligible, 6 cancelled and 8 had inadequate data. Total of 15 patients per group excluded for these reasons; unlikely to have resulted in bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 15:26:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Horiot-1992">
<DESCRIPTION>
<P>29 patients (8%) found to be ineligible. Reasons given in Table 3 but not per randomised group. Seems likely that more were excluded from conventional radiotherapy group and that this may have introduced a bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 15:18:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horiot-1997">
<DESCRIPTION>
<P>10/257 and 2/255 excluded from Gr A and Gr B respectively, due to ineligibility. These patients were included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:00:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hukku-1991">
<DESCRIPTION>
<P>All randomised patients included in the outcome analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:02:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inoue-2001">
<DESCRIPTION>
<P>8 patients were excluded; 3 (10%) from low dose rate and 5 (20%) from high dose rate but reasons are not given for each treatment group. This is a possible cause of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:10:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ketcham-1969">
<DESCRIPTION>
<P>Unclear from the paper how many patients in total were randomised, how many were excluded post-randomisation and how many were included in the outcome analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 09:33:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lawrence-1974">
<DESCRIPTION>
<P>All randomised patients are included in the analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-16 09:24:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacDougall-1990">
<DESCRIPTION>
<P>All randomised patients included in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:15:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maor-1986">
<DESCRIPTION>
<P>3/118 excluded from the analysis. Unlikely to affect results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:17:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maor-1995">
<DESCRIPTION>
<P>6/178 patients died before treatment started, 2 had other cancers and 1 was lost to follow-up (total 9 excluded 5% - reasons not described by treatment group). All remaining patients included in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:19:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marcial-1987">
<DESCRIPTION>
<P>23 patients (11%) excluded. 10 were ineligible, 2 cancelled before treatment started and 11 had insufficient data. It is not stated which treatment groups these patients are from, and this may result in bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:22:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marcial-1993">
<DESCRIPTION>
<P>10 patients (7%) excluded. 17 reasons for exclusions (3 cancellation, 3 ineligible, 11 no data) for 10 people - unclear how many and which treatment group they were from.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 13:52:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olmi-2003">
<DESCRIPTION>
<P>10 patients are excluded from analysis (across groups), 8 of these are due to death during treatment, reasons for other unclear. Unlikely to have introduced bias to results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:28:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pinto-1991">
<DESCRIPTION>
<P>14 patients (12%) excluded from the analyses. In hyperfractionated group 2 died during treatment and 4 stopped treatment early and in conventional RT group 3 died and 5 stopped treatment early. This is unlikely to have resulted in bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:31:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poulsen-2001">
<DESCRIPTION>
<P>7 (2%) patients excluded from analysis: 3 refused treatment, 3 found to be ineligible, 1 died before treatment started. Not stated which groups these were from but numbers small and unlikely to have introduced a bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-25 12:25:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanguineti-2005">
<DESCRIPTION>
<P>All randomised participants included in analysis for locoregional control and overall survival. For acute toxicity 221/226 participants analysed and for late toxicity 214/226 participants analysed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:35:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Skladowski-2006">
<DESCRIPTION>
<P>No drop outs post-randomisation. 2 in accelerated group and 1 in conventional group did not complete treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:37:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Terz-1981">
<DESCRIPTION>
<P>Unclear how many patients are included in the analysis as only percentages are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:39:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weissberg-1983">
<DESCRIPTION>
<P>Gr A 1 patient withdrew and 2 died during treatment; Gr B 3 died during treatment, 1 stroke and 1 withdrew due to metastatic disease. Total 13% post-randomisation exclusion but numbers and reasons similar in each group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2010-11-05 16:39:42 +0000" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-25 12:25:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ang-2001">
<DESCRIPTION>
<P>Important outcomes of locoregional control, overall survival and toxicity reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 13:48:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bartelink-2002">
<DESCRIPTION>
<P>Primary outcomes are acute and late side effects, but also planned and reported treatment compliance, locoregional control and overall survival.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 09:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bergermann-1992">
<DESCRIPTION>
<P>Trial reports outcomes of overall survival, local relapse, regional metastases, distant metastases, secondary tumours. No reporting of toxicity.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 14:01:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bjarnason-2009">
<DESCRIPTION>
<P>Primary endpoint of study is toxicity, overall survival is a secondary outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 17:26:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bourhis-2006">
<DESCRIPTION>
<P>Important outcomes planned and reported - locoregional control, toxicity and overall survival.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 12:28:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cox-1990">
<DESCRIPTION>
<P>Multiple publications addressing different outcomes and exposures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:40:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dobrowsky-2000">
<DESCRIPTION>
<P>Primary outcome of overall survival and secondary outcomes of toxicity, locoregional response and recurrence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:43:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fu-1995">
<DESCRIPTION>
<P>Trial planned to report locoregional control (success/failure) and tolerability and not powered for survival outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 10:58:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fu-2000">
<DESCRIPTION>
<P>Important outcomes reported - locoregional control, overall survival and disease free survival.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 17:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ghoshal-2008">
<DESCRIPTION>
<P>Disease free survival and locoregional control were planned and reported. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-25 12:25:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Griffin-1984">
<DESCRIPTION>
<P>Important outcomes of overall survival, locoregional control and disease free survival planned and reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 13:34:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Griffin-1989">
<DESCRIPTION>
<P>Main outcomes are reported but it is not clear if the subgroup analyses were preplanned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 15:26:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horiot-1992">
<DESCRIPTION>
<P>Important outcomes of locoregional control, tolerance, survival and adverse effects reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 15:18:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horiot-1997">
<DESCRIPTION>
<P>Important outcomes of locoregional control, survival, time to progression and toxicity were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:00:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hukku-1991">
<DESCRIPTION>
<P>Important outcomes of overall survival, disease free survival, locoregional control and adverse events reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:02:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inoue-2001">
<DESCRIPTION>
<P>Some important outcomes, locoregional control, survival and cause specific survival are reported but there are no data on toxicity.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 11:27:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ketcham-1969">
<DESCRIPTION>
<P>Outcomes reported are surgical complications, recurrent disease and metastases but not survival, or numbers of patients who had positive margins or tumours inadvertently cut.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:12:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lawrence-1974">
<DESCRIPTION>
<P>Important outcomes of surgical complications, mortality and local recurrence reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:14:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MacDougall-1990">
<DESCRIPTION>
<P>No planned outcomes listed in methods section. Important outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:15:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maor-1986">
<DESCRIPTION>
<P>Important outcomes of overall survival, local clearance, locoregional control planned and reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 11:51:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maor-1995">
<DESCRIPTION>
<P>Important outcomes of locoregional control, survival and toxicity reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 11:52:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marcial-1987">
<DESCRIPTION>
<P>Important outcomes of locoregional control, survival and toxicity are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 09:21:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marcial-1993">
<DESCRIPTION>
<P>Important outcomes of tumour response, locoregional control, overall survival and toxicity reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-16 09:00:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olmi-2003">
<DESCRIPTION>
<P>Important outcomes of locoregional control, mortality, acute and late toxicity reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:27:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pinto-1991">
<DESCRIPTION>
<P>Important outcomes of overall survival, locoregional control and toxicity reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 15:36:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poulsen-2001">
<DESCRIPTION>
<P>Important outcomes of disease free survival, survival, locoregional control and toxicity were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-31 15:12:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanguineti-2005">
<DESCRIPTION>
<P>Important outcomes of overall survival, locoregional control and toxicity were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 14:36:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Skladowski-2006">
<DESCRIPTION>
<P>Important outcomes of response, survival and toxicity reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:37:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Terz-1981">
<DESCRIPTION>
<P>Many outcomes reported - complications, operative mortality, locoregional recurrence, disease free survival. Subgroup analyses were also undertaken and it is not clear if these were preplanned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:39:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weissberg-1983">
<DESCRIPTION>
<P>Tumour regression, survival and toxicity reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2010-11-05 16:39:53 +0000" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Free of other bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-31 16:16:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ang-2001">
<DESCRIPTION>
<P>Groups appear comparable. No other bias apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-09 16:26:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bartelink-2002">
<DESCRIPTION>
<P>There appear to be differences between treatment groups at baseline eg T stage, location of primary tumour and degree of tumour differentiation. No other bias apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 09:21:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bergermann-1992">
<DESCRIPTION>
<P>Substantial differences between groups in location of primary tumour.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 14:01:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bjarnason-2009">
<DESCRIPTION>
<P>Groups appear comparable at baseline. Possible co-interventions clearly proscribed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 17:26:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bourhis-2006">
<DESCRIPTION>
<P>Distribution of important patient and tumour characteristics well balanced between treatment arms. No other apparent bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 12:28:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cox-1990">
<DESCRIPTION>
<P>Possible contamination due to some patients having had prior chemotherapy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 17:46:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dobrowsky-2000">
<DESCRIPTION>
<P>Groups appear similar at baseline. No other apparent bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 15:45:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fu-1995">
<DESCRIPTION>
<P>Some imbalance between the groups at baseline. The split course arm had higher percentage of OP primaries (63% versus 44%) and Stage IV disease (82% versus 50%), and a lower proportion of oral cavity lesions (3% versus 22%) and N0 disease 16% versus 31%. This imbalance has the potential to result in bias in the outcomes locoregional control, disease free survival and overall survival.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 10:58:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fu-2000">
<DESCRIPTION>
<P>Appears to be some difference between groups at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 17:09:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ghoshal-2008">
<DESCRIPTION>
<P>Groups appear comparable at baseline. No other apparent bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 18:15:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Griffin-1984">
<DESCRIPTION>
<P>Differences at baseline for age, gender and primary tumour.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 11:35:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Griffin-1989">
<DESCRIPTION>
<P>Groups appear similar at baseline. No other apparent bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 15:26:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Horiot-1992">
<DESCRIPTION>
<P>Little information presented on groups at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 15:19:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horiot-1997">
<DESCRIPTION>
<P>Groups appear comparable at baseline. No other apparent bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-05 09:49:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hukku-1991">
<DESCRIPTION>
<P>Groups appear similar at baseline. No other apparent bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:03:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inoue-2001">
<DESCRIPTION>
<P>At baseline there is some difference between groups with regard to tumour thickness. Low dose rate group has more medium thickness tumours and high dose rate more very thick tumours. Tumour thickness is likely to be an important prognostic factor linked to outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:10:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ketcham-1969">
<DESCRIPTION>
<P>Randomised treatment was pre-operative, yet 2 of the exclusion criteria related to the surgery. It is possible that the large imbalance in number in the treatment and placebo groups is related to surgical exclusions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 09:33:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lawrence-1974">
<DESCRIPTION>
<P>Groups appear comparable at baseline. No other apparent bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:14:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MacDougall-1990">
<DESCRIPTION>
<P>Gender imbalance between the groups, unclear if this would introduce a bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:16:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maor-1986">
<DESCRIPTION>
<P>1 patient in neutron boost group and 5 in photon boost group received interstitial implants to deliver boost.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:17:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maor-1995">
<DESCRIPTION>
<P>Characteristics of the treatment groups at baseline differed with regard to number of patients with hypopharynx (more in photon group) and supraglottic larynx (more in neutron group). Paper states that this is likely to mean more patients in the neutron group have worse prognosis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 11:57:17 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marcial-1987">
<DESCRIPTION>
<P>Groups are not balanced at baseline in the distribution of Karnofsky performance scores, which are likely to be linked with prognosis. Randomisation was not stratified by treating institution. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 09:22:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marcial-1993">
<DESCRIPTION>
<P>No significant differences between the groups at baseline. No other apparent bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 13:52:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olmi-2003">
<DESCRIPTION>
<P>Groups appear similar at baseline. No other apparent bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:27:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pinto-1991">
<DESCRIPTION>
<P>Groups well balanced at baseline for main prognostic factors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 14:13:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poulsen-2001">
<DESCRIPTION>
<P>Authors state that groups were comparable at baseline for the variables examined. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-31 15:12:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sanguineti-2005">
<DESCRIPTION>
<P>Groups appear similar at baseline. No other apparent bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 14:37:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Skladowski-2006">
<DESCRIPTION>
<P>Fraction size reduced in both groups from 2 Gy to 1.8 Gy in 1995 in response to planned interim analysis. Accelerated group were hospitalised throughout treatment and received a higher rate of systemic corticosteroids and/or antibiotics for severe mucositis - 90% compared to 48% in control group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 14:54:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Terz-1981">
<DESCRIPTION>
<P>Groups appear similar at baseline. No other apparent bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 16:39:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weissberg-1983">
<DESCRIPTION>
<P>Imbalance between groups with regard to oral cancer primaries (10 versus 2). Unclear whether this indicates bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-11-10 12:14:41 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2010-11-10 12:14:41 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-10-07 10:44:22 +0100" MODIFIED_BY="Helen Worthington">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="19">
<TR>
<TD COLSPAN="7">
<P>
<B>Altered fractionation compared with conventional radiotherapy for the treatment of oral cavity and oropharyngeal cancer</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>people with oral cavity and oropharyngeal cancer</P>
<P>
<B>Settings: </B>hospital</P>
<P>
<B>Intervention:</B> altered fractionation</P>
<P>
<B>Comparison: </B>conventional</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Conventional </B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Altered fractionation</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P>Mortality</P>
<P>(follow-up: 5 years)</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P>HR 0.86 (0.76 to 0.98)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P>[3751]<BR/>(13)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P>+OOO<BR/>very low<SUP>2,3,4</SUP>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P>Analysis conducted on all included studies</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>200 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>175 per 1000<BR/>(156 to 196)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>500 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>449 per 1000<BR/>(410 to 493)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>700 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>645 per 1000<BR/>(599 to 693)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="6">
<P>Mortality</P>
<P>(follow-up: 5 years)</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Low risk population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P>HR 0.93 (0.80 to 1.07)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P>[1511]<BR/>(5)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P>+++O<BR/>moderate<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="6" VALIGN="MIDDLE">
<P>Analysis conducted for studies at low risk of bias</P>
</TD>
</TR>
<TR>
<TD>
<P>200 per 1000<SUP>1</SUP>
</P>
</TD>
<TD>
<P>187 per 1000</P>
<P>(163 to 212)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>500 per 1000</P>
</TD>
<TD>
<P>475 per 1000</P>
<P>(426 to 524)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>700 per 1000<SUP>1</SUP>
</P>
</TD>
<TD>
<P>674 per 1000</P>
<P>(618 to 724)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: confidence interval; HR: hazard ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Based on data presented by <LINK REF="REF-McGurk-2005" TYPE="REFERENCE">McGurk 2005</LINK>
</P>
<P>
<SUP>2</SUP>Studies included patients with other head and neck cancers</P>
<P>
<SUP>3</SUP>Heterogeneity due to one study</P>
<P>
<SUP>4</SUP>Assessed as<SUP> </SUP>unclear regarding allocation concealment, incomplete outcome data, selective reporting and/or other biases for 8 included trials</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2010-11-05 17:09:43 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2010-11-05 16:53:49 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-11-05 16:52:44 +0000" MODIFIED_BY="[Empty name]">Percentage of patients with oral cavity (OC) or oropharyngeal (OP) cancer in studies included in this review</TITLE>
<TABLE COLS="4" ROWS="31">
<TR>
<TH ALIGN="CENTER">
<P>
<B>Trial ID</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>%OC</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>%OP</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Total % OC/OP</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Ang 2001*</P>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>51</P>
</TD>
<TD>
<P>100</P>
</TD>
</TR>
<TR>
<TD>
<P>Bergermann 1992</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>100</P>
</TD>
</TR>
<TR>
<TD>
<P>Horiot 1992</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>100</P>
</TD>
</TR>
<TR>
<TD>
<P>Inoue 2001</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>100</P>
</TD>
</TR>
<TR>
<TD>
<P>Marcial 1993</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>100</P>
</TD>
</TR>
<TR>
<TD>
<P>Olmi 2003</P>
</TD>
<TD>
<P> 0</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>100</P>
</TD>
</TR>
<TR>
<TD>
<P>Pinto 1991</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>100</P>
</TD>
</TR>
<TR>
<TD>
<P>Sanguineti 2005*</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>100</P>
</TD>
</TR>
<TR>
<TD>
<P>Bourhis 2006</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>77</P>
</TD>
<TD>
<P>91</P>
</TD>
</TR>
<TR>
<TD>
<P>Bartelink 2002</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>80</P>
</TD>
</TR>
<TR>
<TD>
<P>Horiot 1997</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P>80</P>
</TD>
</TR>
<TR>
<TD>
<P>Griffin 1989</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>79</P>
</TD>
</TR>
<TR>
<TD>
<P>Poulsen 2001</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P>78</P>
</TD>
</TR>
<TR>
<TD>
<P>Maor 1986</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>51</P>
</TD>
<TD>
<P>77</P>
</TD>
</TR>
<TR>
<TD>
<P>Maor 1995</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>51</P>
</TD>
<TD>
<P>75</P>
</TD>
</TR>
<TR>
<TD>
<P>Hukku 1991</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>62</P>
</TD>
<TD>
<P>72</P>
</TD>
</TR>
<TR>
<TD>
<P>Dobrowsky 2000</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>71</P>
</TD>
</TR>
<TR>
<TD>
<P>Fu 2000</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>71</P>
</TD>
</TR>
<TR>
<TD>
<P>Lawrence 1974</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>71</P>
</TD>
</TR>
<TR>
<TD>
<P>Terz 1981</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>67</P>
</TD>
</TR>
<TR>
<TD>
<P>Ghoshal 2008</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>65</P>
</TD>
</TR>
<TR>
<TD>
<P>Cox 1990</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>64</P>
</TD>
</TR>
<TR>
<TD>
<P>Weissberg 1983</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>64</P>
</TD>
</TR>
<TR>
<TD>
<P>Fu 1995</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>51</P>
</TD>
<TD>
<P>61</P>
</TD>
</TR>
<TR>
<TD>
<P>MacDougall 1990</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>61</P>
</TD>
</TR>
<TR>
<TD>
<P>Marcial 1987</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>61</P>
</TD>
</TR>
<TR>
<TD>
<P>Griffin 1984</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>58</P>
</TD>
</TR>
<TR>
<TD>
<P>Ketcham 1969</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>&gt;56</P>
</TD>
</TR>
<TR>
<TD>
<P>Bjarnason 2009</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>54</P>
</TD>
</TR>
<TR>
<TD>
<P>Skladowski 2006</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>50</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*Data were available from the authors for those participants with cancer of the oral cavity or oropharynx only.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2010-11-05 17:09:43 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-11-05 16:54:06 +0000" MODIFIED_BY="[Empty name]">Results from comparisons where there are data from a single study only</TITLE>
<TABLE COLS="5" ROWS="21">
<TR>
<TH ALIGN="CENTER">
<P/>
</TH>
<TH ALIGN="CENTER">
<P>Total mortality</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>Locoregional control</P>
</TH>
<TH ALIGN="CENTER">
<P>Disease free survival</P>
</TH>
</TR>
<TR>
<TD COLSPAN="5">
<P>
<B>Accelerated/split versus conventional</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Marcial-1993" TYPE="STUDY">Marcial 1993</LINK>
</P>
</TD>
<TD>
<P>5 years</P>
<P>RR 1.17 (95% CI 0.57 to 2.43)</P>
</TD>
<TD COLSPAN="2">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>
<B>Split course versus accelerated</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hukku-1991" TYPE="STUDY">Hukku 1991</LINK>
</P>
</TD>
<TD COLSPAN="2">
<P>2 years</P>
<P>RR 1.00 (95% CI 0.82 to 1.22)</P>
</TD>
<TD>
<P>2 years</P>
<P>RR 1.33 (95% CI 0.67 to 2.67)</P>
</TD>
<TD>
<P>2 years</P>
<P>RR 0.83 (95% CI 0.29 to 2.42)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>
<B>Variable total dose/duration of radiotherapy</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Cox-1990" TYPE="STUDY">Cox 1990</LINK>
</P>
</TD>
<TD>
<P>High versus standard</P>
<P>HR 1.08 (95% CI 0.69 to 1.70)</P>
</TD>
<TD COLSPAN="2">
<P>High versus standard</P>
<P>HR 0.78 (95% CI 0.55 to 1.11)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Low versus standard</P>
<P>HR 1.38 (95% CI 0.83 to 2.29)</P>
</TD>
<TD COLSPAN="2">
<P>Low versus standard</P>
<P>HR 1.13 (95% CI 0.78 to 1.64)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>
<B>Morning versus afternoon radiotherapy</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>
</P>
</TD>
<TD>
<P>2 years</P>
<P>RR 1.09 (95% CI 0.74 to 1.59)</P>
</TD>
<TD COLSPAN="2">
<P/>
<P>HR 0.92 (95% CI 0.60 to 1.42)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>
<B>Mixed beam versus photon</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Griffin-1989" TYPE="STUDY">Griffin 1989</LINK>
</P>
</TD>
<TD>
<P>HR 1.12 (95% CI 0.92 to 1.36)</P>
</TD>
<TD COLSPAN="2">
<P>HR 1.04 (95% CI 0.84 to 1.29)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>
<B>Neutron versus photon</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-MacDougall-1990" TYPE="STUDY">MacDougall 1990</LINK>
</P>
</TD>
<TD>
<P>5 years</P>
<P>RR 1.15 (95% CI 0.95 to 1.40)</P>
</TD>
<TD COLSPAN="2">
<P>5 years</P>
<P>RR 0.97 (95% CI 0.69 to 1.36)</P>
</TD>
<TD>
<P>5 years</P>
<P>RR 0.63 (95% CI 0.36 to 1.09)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>
<B>Pre-operative radiotherapy versus surgery alone</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ketcham-1969" TYPE="STUDY">Ketcham 1969</LINK>
</P>
</TD>
<TD>
<P/>
</TD>
<TD COLSPAN="2">
<P>Timing unclear</P>
<P>RR 0.63 (95% CI 0.28 to 1.46)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Terz-1981" TYPE="STUDY">Terz 1981</LINK>
</P>
</TD>
<TD>
<P>HR 0.83 (95% CI 0.64 to 1.07)</P>
</TD>
<TD COLSPAN="2">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>
<B>Pre-operative and post-operative radiotherapy versus post-operative radiotherapy alone</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bergermann-1992" TYPE="STUDY">Bergermann 1992</LINK>
</P>
</TD>
<TD>
<P>HR 0.67 (95% CI 0.35 to 1.28)</P>
</TD>
<TD COLSPAN="2">
<P>HR 1.13 (95% CI 0.78 to 1.64)</P>
</TD>
<TD>
<P>HR 1.13 (95% CI 0.78 to 1.64)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>
<B>Low dose rate interstitial radiotherapy versus high dose rate interstitial radiotherapy</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Inoue-2001" TYPE="STUDY">Inoue 2001</LINK>
</P>
</TD>
<TD>
<P/>
</TD>
<TD COLSPAN="2">
<P>HR 1.00 (95% CI 0.16 to 6.44)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CI = confidence interval; HR = hazard ratio; RR = risk ratio.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2010-11-05 17:01:57 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-10-29 17:03:33 +0100" MODIFIED_BY="[Empty name]">Sensitivity analyses: altered fractionation versus conventional radiotherapy</TITLE>
<TABLE COLS="3" ROWS="4">
<TR>
<TH>
<P/>
</TH>
<TH ALIGN="CENTER">
<P>All trials</P>
</TH>
<TH ALIGN="CENTER">
<P>Trials assessed as being at low risk of bias</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Total mortality</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>HR 0.86 (95% CI 0.76 to 0.98)</P>
<P>(13 trials)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>HR 0.93 (95% CI 0.80 to 1.07)</P>
<P>(5 trials)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Locoregional control</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>HR 0.79 (95% CI 0.70 to 0.89)</P>
<P>(11 trials)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>HR 0.79 (95% CI 0.68 to 0.91)</P>
<P>(4 trials)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Disease free survival</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>HR 0.85 (95% CI 0.70 to 1.03)</P>
<P>(8 trials)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>HR 0.95 (95% CI 0.0.74 to 1.22)*</P>
<P>(2 trials)</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*Fixed-effect model due to limited number of trials.<BR/>CI = confidence interval; HR = hazard ratio.<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-11-05 17:27:45 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-11-05 17:27:45 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Altered fractionation versus conventional radiotherapy</NAME>
<IV_OUTCOME CHI2="34.33968680993961" CI_END="0.9483707326388677" CI_START="0.8198979902345005" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_SIZE="0.8817977419384949" ESTIMABLE="YES" I2="59.23084541368704" I2_Q="84.84319864486602" ID="CMP-001.01" LOG_CI_END="-0.023021857107986182" LOG_CI_START="-0.08624017814571579" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.054631017626850985" MODIFIED="2010-11-01 21:41:10 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.001839221877154018" P_Q="2.6391453455176794E-5" P_Z="7.054251390854396E-4" Q="26.390792531203164" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="3.3874619012262936">
<NAME>Total mortality (using IPD where available)</NAME>
<GROUP_LABEL_1>Altered fraction</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours altered fraction</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="2.653091414080426" CI_END="0.8987374302475523" CI_START="0.6763349591569359" DF="2" EFFECT_SIZE="0.7796457805819819" ESTIMABLE="YES" I2="24.616242418725342" ID="CMP-001.01.01" LOG_CI_END="-0.04636717061440329" LOG_CI_START="-0.16983816369611862" LOG_EFFECT_SIZE="-0.10810266715526094" MODIFIED="2010-08-20 11:27:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.26539259008041793" P_Z="5.991078328163544E-4" STUDIES="3" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="26.215372481806853" Z="3.4320179820179826">
<NAME>Hyperfractionated versus conventional</NAME>
<IV_DATA CI_END="1.0263372520659664" CI_START="0.6935052988964894" EFFECT_SIZE="0.8436648165963837" ESTIMABLE="YES" ESTIMATE="-0.17" LOG_CI_END="0.011290092397932744" LOG_CI_START="-0.15895021624503847" LOG_EFFECT_SIZE="-0.0738300619235528" MODIFIED="2010-08-20 11:27:32 +0100" MODIFIED_BY="[Empty name]" ORDER="81" SE="0.1" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.789900076168413"/>
<IV_DATA CI_END="0.9657943826217257" CI_START="0.603387494129002" EFFECT_SIZE="0.7633794943368531" ESTIMABLE="YES" ESTIMATE="-0.27" LOG_CI_END="-0.015115324928095291" LOG_CI_START="-0.2194036952996607" LOG_EFFECT_SIZE="-0.117259510113878" MODIFIED="2010-08-20 11:27:40 +0100" MODIFIED_BY="[Empty name]" ORDER="80" SE="0.12" STUDY_ID="STD-Horiot-1992" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.576319497339178"/>
<IV_DATA CI_END="0.8791428120905453" CI_START="0.37113400705303723" EFFECT_SIZE="0.5712090638488149" ESTIMABLE="YES" ESTIMATE="-0.56" LOG_CI_END="-0.05594057035855272" LOG_CI_START="-0.4304692493730894" LOG_EFFECT_SIZE="-0.24320490986582105" MODIFIED="2010-08-20 11:27:51 +0100" MODIFIED_BY="[Empty name]" ORDER="82" SE="0.22" STUDY_ID="STD-Pinto-1991" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.8491529082992595"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.5292408766319427" CI_END="1.0029141270373176" CI_START="0.7471872096762784" DF="3" EFFECT_SIZE="0.8656584823854809" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.0012637488225925627" LOG_CI_START="-0.1265705709516206" LOG_EFFECT_SIZE="-0.06265341106451401" MODIFIED="2010-08-20 11:30:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9124220005961052" P_Z="0.05470495711607508" STUDIES="4" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="24.4563130854496" Z="1.9212122286397417">
<NAME>Hyperfractionated/accelerated versus conventional</NAME>
<IV_DATA CI_END="1.0772321827790021" CI_START="0.6222614369971509" EFFECT_SIZE="0.8187307530779818" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.03230931966942949" LOG_CI_START="-0.20602711243073019" LOG_EFFECT_SIZE="-0.08685889638065038" MODIFIED="2010-08-20 11:30:23 +0100" MODIFIED_BY="[Empty name]" ORDER="95" SE="0.14" STUDY_ID="STD-Bourhis-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="7.035663304167558"/>
<IV_DATA CI_END="1.2876173785643727" CI_START="0.6358494120286142" EFFECT_SIZE="0.9048374180359595" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.10978682958834891" LOG_CI_START="-0.1966457259689992" LOG_EFFECT_SIZE="-0.04342944819032521" MODIFIED="2010-08-20 11:28:04 +0100" MODIFIED_BY="[Empty name]" ORDER="93" SE="0.18" STUDY_ID="STD-Dobrowsky-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.256141998817412"/>
<IV_DATA CI_END="1.25106426076189" CI_START="0.6948949487769496" EFFECT_SIZE="0.9323938199059483" ESTIMABLE="YES" ESTIMATE="-0.07" LOG_CI_END="0.09727961774900074" LOG_CI_START="-0.15808084521545596" LOG_EFFECT_SIZE="-0.030400613733227607" MODIFIED="2010-08-20 11:28:24 +0100" MODIFIED_BY="[Empty name]" ORDER="94" SE="0.15" STUDY_ID="STD-Marcial-1987" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.128844478297073"/>
<IV_DATA CI_END="1.098993716391085" CI_START="0.634831951871468" EFFECT_SIZE="0.835270211411272" ESTIMABLE="YES" ESTIMATE="-0.18" LOG_CI_END="0.040995209307494486" LOG_CI_START="-0.19734122279266514" LOG_EFFECT_SIZE="-0.07817300674258533" MODIFIED="2010-08-20 10:32:18 +0100" MODIFIED_BY="[Empty name]" ORDER="92" SE="0.14" STUDY_ID="STD-Poulsen-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="7.035663304167558"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.0103547405152573" CI_END="1.1704779612514429" CI_START="0.8972339073960176" DF="3" EFFECT_SIZE="1.0247890098427854" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.06836324084597577" LOG_CI_START="-0.04709432234193306" LOG_EFFECT_SIZE="0.01063445925202135" MODIFIED="2010-11-01 21:41:10 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7987464512098581" P_Z="0.7180597327748512" STUDIES="4" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="29.980656657720875" Z="0.36105312728795497">
<NAME>Hyperfractionated/accelerated/split versus conventional</NAME>
<IV_DATA CI_END="2.0692546605138062" CI_START="0.5902621757811527" EFFECT_SIZE="1.1051709180756477" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.3158139420190791" LOG_CI_START="-0.22895504563842872" LOG_EFFECT_SIZE="0.043429448190325216" MODIFIED="2010-08-20 10:28:29 +0100" MODIFIED_BY="[Empty name]" ORDER="90" SE="0.32" STUDY_ID="STD-Bartelink-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="1.3466699293133217"/>
<IV_DATA CI_END="1.228748778592101" CI_START="0.8302765852558579" EFFECT_SIZE="1.010050167084168" ESTIMABLE="YES" ESTIMATE="0.01" LOG_CI_END="0.0894630991405181" LOG_CI_START="-0.08077720950245307" LOG_EFFECT_SIZE="0.004342944819032472" MODIFIED="2010-08-20 10:32:18 +0100" MODIFIED_BY="[Empty name]" ORDER="87" SE="0.1" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.789900076168413"/>
<IV_DATA CI_END="1.21603557430296" CI_START="0.7900997795258206" EFFECT_SIZE="0.9801986733067553" ESTIMABLE="YES" ESTIMATE="-0.02" LOG_CI_END="0.08494628011556914" LOG_CI_START="-0.10231805939169916" LOG_EFFECT_SIZE="-0.008685889638065058" MODIFIED="2010-08-20 11:28:57 +0100" MODIFIED_BY="[Empty name]" ORDER="91" SE="0.11" STUDY_ID="STD-Horiot-1997" TOTAL_1="0" TOTAL_2="0" WEIGHT="11.396611633197038"/>
<IV_DATA CI_END="1.8075869823497992" CI_START="0.8253128132743858" EFFECT_SIZE="1.2214027581601699" ESTIMABLE="YES" ESTIMATE="0.2" LOG_CI_END="0.25709920502362155" LOG_CI_START="-0.08338141226232083" LOG_EFFECT_SIZE="0.08685889638065036" MODIFIED="2010-08-20 10:32:18 +0100" MODIFIED_BY="[Empty name]" ORDER="89" SE="0.2" STUDY_ID="STD-Olmi-2003" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.4474750190421033"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.46710085346034463" CI_START="0.1558611214004479" DF="0" EFFECT_SIZE="0.26982005638468687" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="-0.3305893391931002" LOG_CI_START="-0.8072622033934196" LOG_EFFECT_SIZE="-0.5689257712932598" MODIFIED="2010-09-09 14:39:58 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="2.8888053726575197E-6" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="1.7589158260418896" Z="4.678571428571428">
<NAME>Accelerated versus conventional</NAME>
<IV_DATA CI_END="0.46710085346034463" CI_START="0.1558611214004479" EFFECT_SIZE="0.26982005638468687" ESTIMABLE="YES" ESTIMATE="-1.31" LOG_CI_END="-0.3305893391931002" LOG_CI_START="-0.8072622033934196" LOG_EFFECT_SIZE="-0.5689257712932598" MODIFIED="2010-08-20 11:29:17 +0100" MODIFIED_BY="[Empty name]" ORDER="85" SE="0.28" STUDY_ID="STD-Skladowski-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="1.7589158260418896"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="3.7562072475088164" CI_END="1.126611151889297" CI_START="0.7962236386346708" DF="2" EFFECT_SIZE="0.9471190161134416" ESTIMABLE="YES" I2="46.75480163331148" ID="CMP-001.01.05" LOG_CI_END="0.05177404583419252" LOG_CI_START="-0.09896493303651882" LOG_EFFECT_SIZE="-0.023595443601163175" MODIFIED="2010-09-10 10:36:02 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.15287985096110435" P_Z="0.5394840635649839" STUDIES="3" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="17.58874194898078" Z="0.6135933784876073">
<NAME>Accelerated/boost versus conventional</NAME>
<IV_DATA CI_END="2.4585964442014543" CI_START="0.8872835843569024" EFFECT_SIZE="1.4769807938826425" ESTIMABLE="YES" ESTIMATE="0.39" LOG_CI_END="0.3906872491781308" LOG_CI_START="-0.051937553293594334" LOG_EFFECT_SIZE="0.16937484794226818" MODIFIED="2010-08-31 22:05:49 +0100" MODIFIED_BY="[Empty name]" ORDER="118" SE="0.26" STUDY_ID="STD-Ang-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.0399260467704754"/>
<IV_DATA CI_END="1.1118178722361156" CI_START="0.7512653216586237" EFFECT_SIZE="0.9139311852712282" ESTIMABLE="YES" ESTIMATE="-0.09" LOG_CI_END="0.04603365095019293" LOG_CI_START="-0.12420665769277828" LOG_EFFECT_SIZE="-0.039086503371292665" MODIFIED="2010-08-20 11:29:21 +0100" MODIFIED_BY="[Empty name]" ORDER="84" SE="0.1" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.789900076168413"/>
<IV_DATA CI_END="1.2953616410594826" CI_START="0.43223324577332584" EFFECT_SIZE="0.7482635675785652" ESTIMABLE="YES" ESTIMATE="-0.29" LOG_CI_END="0.11239103234821667" LOG_CI_START="-0.3642818318521027" LOG_EFFECT_SIZE="-0.12594539975194308" MODIFIED="2010-08-31 14:30:18 +0100" MODIFIED_BY="[Empty name]" ORDER="339" SE="0.28" STUDY_ID="STD-Sanguineti-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="1.7589158260418896"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="21.593921688705578" CI_END="0.8694977712006858" CI_START="0.7309228509668266" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_SIZE="0.7972049860828185" ESTIMABLE="YES" I2="44.42880652717915" I2_Q="71.31603681117802" ID="CMP-001.02" LOG_CI_END="-0.06073152689471785" LOG_CI_START="-0.13612846048068877" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.09842999368770329" MODIFIED="2010-11-05 17:24:35 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.04233119066813973" P_Q="0.007472461146347031" P_Z="3.097279251469002E-7" Q="13.945074373679237" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="5.117429408622522">
<NAME>Locoregional control (using IPD where available)</NAME>
<GROUP_LABEL_1>Altered</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours altered fraction</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.6692387882541158" CI_END="0.8885001439751788" CI_START="0.6231062434920251" DF="2" EFFECT_SIZE="0.7440631606621155" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-0.05134249748431766" LOG_CI_START="-0.20543789711540428" LOG_EFFECT_SIZE="-0.12839019729986098" MODIFIED="2010-08-31 12:16:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7156104696418499" P_Z="0.0010906637589746377" STUDIES="3" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="23.940213534010976" Z="3.2660308260747626">
<NAME>Hyperfractionated versus conventional</NAME>
<IV_DATA CI_END="0.9853047233409978" CI_START="0.6155767300657942" EFFECT_SIZE="0.7788007830714049" ESTIMABLE="YES" ESTIMATE="-0.25" LOG_CI_END="-0.006429435290030267" LOG_CI_START="-0.21071780566159565" LOG_EFFECT_SIZE="-0.10857362047581295" MODIFIED="2010-08-31 12:16:30 +0100" MODIFIED_BY="[Empty name]" ORDER="216" SE="0.12" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.621347691204573"/>
<IV_DATA CI_END="0.9084591082695554" CI_START="0.5045972979217537" EFFECT_SIZE="0.6770568744981647" ESTIMABLE="YES" ESTIMATE="-0.39" LOG_CI_END="-0.041694616460039836" LOG_CI_START="-0.2970550794244966" LOG_EFFECT_SIZE="-0.16937484794226823" MODIFIED="2010-08-31 12:16:44 +0100" MODIFIED_BY="[Empty name]" ORDER="218" SE="0.15" STUDY_ID="STD-Horiot-1992" TOTAL_1="0" TOTAL_2="0" WEIGHT="8.717662522370926"/>
<IV_DATA CI_END="1.6752918595220854" CI_START="0.424863476006896" EFFECT_SIZE="0.8436648165963837" ESTIMABLE="YES" ESTIMATE="-0.17" LOG_CI_END="0.2240904782016467" LOG_CI_START="-0.3717506020487524" LOG_EFFECT_SIZE="-0.0738300619235528" MODIFIED="2010-08-31 12:16:59 +0100" MODIFIED_BY="[Empty name]" ORDER="217" SE="0.35" STUDY_ID="STD-Pinto-1991" TOTAL_1="0" TOTAL_2="0" WEIGHT="1.6012033204354768"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="3.6744190300225243" CI_END="0.9876984371036306" CI_START="0.7213912130837626" DF="3" EFFECT_SIZE="0.844107205100824" ESTIMABLE="YES" I2="18.35443983149603" ID="CMP-001.02.02" LOG_CI_END="-0.005375633441890468" LOG_CI_START="-0.14182915191573695" LOG_EFFECT_SIZE="-0.07360239267881367" MODIFIED="2010-08-31 12:18:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2988353050157001" P_Z="0.03448189430245581" STUDIES="4" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="30.53077929149722" Z="2.114390899405042">
<NAME>Hyperfractionated/accelerated versus conventional</NAME>
<IV_DATA CI_END="0.8994197891101908" CI_START="0.4995764709177116" EFFECT_SIZE="0.6703200460356393" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="-0.04603756127907235" LOG_CI_START="-0.30139802424352913" LOG_EFFECT_SIZE="-0.1737177927613007" MODIFIED="2010-08-31 12:17:32 +0100" MODIFIED_BY="[Empty name]" ORDER="222" SE="0.15" STUDY_ID="STD-Bourhis-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="8.717662522370926"/>
<IV_DATA CI_END="1.2243292671983141" CI_START="0.5813553117058001" EFFECT_SIZE="0.8436648165963837" ESTIMABLE="YES" ESTIMATE="-0.17" LOG_CI_END="0.08789823128726985" LOG_CI_START="-0.23555835513437545" LOG_EFFECT_SIZE="-0.0738300619235528" MODIFIED="2010-08-31 12:17:45 +0100" MODIFIED_BY="[Empty name]" ORDER="220" SE="0.19" STUDY_ID="STD-Dobrowsky-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.433446170452793"/>
<IV_DATA CI_END="1.3412395685540437" CI_START="0.7163443889357706" EFFECT_SIZE="0.9801986733067553" ESTIMABLE="YES" ESTIMATE="-0.02" LOG_CI_END="0.12750635727631185" LOG_CI_START="-0.14487813655244206" LOG_EFFECT_SIZE="-0.008685889638065058" MODIFIED="2010-08-31 12:17:52 +0100" MODIFIED_BY="[Empty name]" ORDER="221" SE="0.16" STUDY_ID="STD-Marcial-1987" TOTAL_1="0" TOTAL_2="0" WEIGHT="7.662008076302572"/>
<IV_DATA CI_END="1.25106426076189" CI_START="0.6948949487769496" EFFECT_SIZE="0.9323938199059483" ESTIMABLE="YES" ESTIMATE="-0.07" LOG_CI_END="0.09727961774900074" LOG_CI_START="-0.15808084521545596" LOG_EFFECT_SIZE="-0.030400613733227607" MODIFIED="2010-08-31 12:18:22 +0100" MODIFIED_BY="[Empty name]" ORDER="219" SE="0.15" STUDY_ID="STD-Poulsen-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="8.717662522370926"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="3.3051894967497017" CI_END="1.0098539198273955" CI_START="0.7355043093395301" DF="3" EFFECT_SIZE="0.8618305574975081" ESTIMABLE="YES" I2="9.233645969461744" ID="CMP-001.02.03" LOG_CI_END="0.004258555563596662" LOG_CI_START="-0.13341477838594676" LOG_EFFECT_SIZE="-0.06457811141117507" MODIFIED="2010-09-09 14:40:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3469210842531987" P_Z="0.06595762812288437" STUDIES="4" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="29.992157464211598" Z="1.8387115198634727">
<NAME>Hyperfractionated/accelerated/split versus conventional</NAME>
<IV_DATA CI_END="1.2179735767085242" CI_START="0.3474312500779454" EFFECT_SIZE="0.6505090947233165" ESTIMABLE="YES" ESTIMATE="-0.43" LOG_CI_END="0.08563786661035566" LOG_CI_START="-0.45913112104715215" LOG_EFFECT_SIZE="-0.1867466272183983" MODIFIED="2010-08-31 12:15:31 +0100" MODIFIED_BY="[Empty name]" ORDER="223" SE="0.32" STUDY_ID="STD-Bartelink-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="1.915502019075643"/>
<IV_DATA CI_END="1.1678864686049555" CI_START="0.7296460845069129" EFFECT_SIZE="0.9231163463866358" ESTIMABLE="YES" ESTIMATE="-0.08" LOG_CI_END="0.06740062663352261" LOG_CI_START="-0.13688774373804286" LOG_EFFECT_SIZE="-0.034743558552260155" MODIFIED="2010-08-31 12:19:07 +0100" MODIFIED_BY="[Empty name]" ORDER="225" SE="0.12" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.621347691204573"/>
<IV_DATA CI_END="0.9845160856195257" CI_START="0.5687041326633838" EFFECT_SIZE="0.7482635675785652" ESTIMABLE="YES" ESTIMATE="-0.29" LOG_CI_END="-0.0067771837018631665" LOG_CI_START="-0.24511361580202284" LOG_EFFECT_SIZE="-0.12594539975194308" MODIFIED="2010-08-31 12:19:29 +0100" MODIFIED_BY="[Empty name]" ORDER="227" SE="0.14" STUDY_ID="STD-Horiot-1997" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.007520752721726"/>
<IV_DATA CI_END="1.634917651054735" CI_START="0.7177798039153488" EFFECT_SIZE="1.0832870676749586" ESTIMABLE="YES" ESTIMATE="0.08" LOG_CI_END="0.21349588262737992" LOG_CI_START="-0.1440087655228596" LOG_EFFECT_SIZE="0.034743558552260176" MODIFIED="2010-08-31 14:35:20 +0100" MODIFIED_BY="[Empty name]" ORDER="224" SE="0.21" STUDY_ID="STD-Olmi-2003" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.447787001209657"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.4951911026554251" CI_START="0.14125500512744124" DF="0" EFFECT_SIZE="0.26447726129982396" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="-0.3052271671025711" LOG_CI_START="-0.8499961547600788" LOG_EFFECT_SIZE="-0.5776116609313249" MODIFIED="2010-09-09 14:40:38 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="3.235138133748605E-5" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="1.915502019075643" Z="4.15625">
<NAME>Accelerated versus conventional</NAME>
<IV_DATA CI_END="0.4951911026554251" CI_START="0.14125500512744124" EFFECT_SIZE="0.26447726129982396" ESTIMABLE="YES" ESTIMATE="-1.33" LOG_CI_END="-0.3052271671025711" LOG_CI_START="-0.8499961547600788" LOG_EFFECT_SIZE="-0.5776116609313249" MODIFIED="2010-08-31 12:20:46 +0100" MODIFIED_BY="[Empty name]" ORDER="228" SE="0.32" STUDY_ID="STD-Skladowski-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="1.915502019075643"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.9853047233409978" CI_START="0.6155767300657942" DF="0" EFFECT_SIZE="0.7788007830714049" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.05" LOG_CI_END="-0.006429435290030267" LOG_CI_START="-0.21071780566159565" LOG_EFFECT_SIZE="-0.10857362047581295" MODIFIED="2010-09-09 14:40:53 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.03722085038083199" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.621347691204573" Z="2.0833333333333335">
<NAME>Accelerated/boost versus conventional</NAME>
<IV_DATA CI_END="0.9853047233409978" CI_START="0.6155767300657942" EFFECT_SIZE="0.7788007830714049" ESTIMABLE="YES" ESTIMATE="-0.25" LOG_CI_END="-0.006429435290030267" LOG_CI_START="-0.21071780566159565" LOG_EFFECT_SIZE="-0.10857362047581295" MODIFIED="2010-08-31 12:20:59 +0100" MODIFIED_BY="[Empty name]" ORDER="230" SE="0.12" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.621347691204573"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="33.61688106311019" CI_END="0.9620522672236965" CI_START="0.8024861266993" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_SIZE="0.8786544244506052" ESTIMABLE="YES" I2="73.22773643663142" I2_Q="47.45325117770622" ID="CMP-001.03" LOG_CI_END="-0.01680133258774938" LOG_CI_START="-0.0955624668981933" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.056181899742971324" MODIFIED="2010-11-05 17:27:45 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0423810783399823E-4" P_Q="0.10685950595462812" P_Z="0.0051713249486238285" Q="7.612269245291419" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="2.7961633880293806">
<NAME>Disease free survival</NAME>
<GROUP_LABEL_1>Altered</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours altered fraction</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="1.068222869905267" CI_START="0.7218077870509788" DF="0" EFFECT_SIZE="0.8780954309205613" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.028661871674062887" LOG_CI_START="-0.14157843696890832" LOG_EFFECT_SIZE="-0.05645828264742275" MODIFIED="2010-10-08 12:13:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1936009691719703" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="21.40420631034137" Z="1.3">
<NAME>Hyperfractionated versus conventional</NAME>
<IV_DATA CI_END="1.068222869905267" CI_START="0.7218077870509788" EFFECT_SIZE="0.8780954309205613" ESTIMABLE="YES" ESTIMATE="-0.13" LOG_CI_END="0.028661871674062887" LOG_CI_START="-0.14157843696890832" LOG_EFFECT_SIZE="-0.05645828264742275" MODIFIED="2010-08-17 16:19:16 +0100" MODIFIED_BY="[Empty name]" ORDER="76" SE="0.1" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="21.40420631034137"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.1438445007895752" CI_START="0.6607399353094076" DF="0" EFFECT_SIZE="0.8693582353988059" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.058366988583624595" LOG_CI_START="-0.17996944351653507" LOG_EFFECT_SIZE="-0.060801227466455235" MODIFIED="2010-10-08 12:17:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.31731052126128756" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.920513423643557" Z="1.0">
<NAME>Hyperfractionated/accelerated versus conventional</NAME>
<IV_DATA CI_END="1.1438445007895752" CI_START="0.6607399353094076" EFFECT_SIZE="0.8693582353988059" ESTIMABLE="YES" ESTIMATE="-0.14" LOG_CI_END="0.058366988583624595" LOG_CI_START="-0.17996944351653507" LOG_EFFECT_SIZE="-0.060801227466455235" MODIFIED="2010-08-17 16:19:16 +0100" MODIFIED_BY="[Empty name]" ORDER="83" SE="0.14" STUDY_ID="STD-Poulsen-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.920513423643557"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="5.433962264150943" CI_END="1.239290731165341" CI_START="0.8797441691665866" DF="1" EFFECT_SIZE="1.0441545836919477" ESTIMABLE="YES" I2="81.59722222222221" ID="CMP-001.03.03" LOG_CI_END="0.09317320155713829" LOG_CI_START="-0.05564360293229125" LOG_EFFECT_SIZE="0.018764799312423534" MODIFIED="2010-11-05 17:27:45 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.01974890305174426" P_Z="0.6211108622495707" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="28.01044282587883" Z="0.4942765832884745">
<NAME>Hyperfractionated/accelerated/split versus conventional</NAME>
<IV_DATA CI_END="1.1342780831209816" CI_START="0.7664418878717596" EFFECT_SIZE="0.9323938199059483" ESTIMABLE="YES" ESTIMATE="-0.07" LOG_CI_END="0.054719540588257974" LOG_CI_START="-0.11552076805471326" LOG_EFFECT_SIZE="-0.030400613733227607" MODIFIED="2010-08-17 16:20:12 +0100" MODIFIED_BY="[Empty name]" ORDER="85" SE="0.1" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="21.40420631034137"/>
<IV_DATA CI_END="2.144257882982554" CI_START="1.0588744271627701" EFFECT_SIZE="1.5068177851128535" ESTIMABLE="YES" ESTIMATE="0.41" LOG_CI_END="0.33127701535900733" LOG_CI_START="0.024844459801659193" LOG_EFFECT_SIZE="0.17806073758033322" MODIFIED="2010-08-17 16:21:08 +0100" MODIFIED_BY="[Empty name]" ORDER="87" SE="0.18" STUDY_ID="STD-Olmi-2003" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.606236515537461"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="12.543999999999997" CI_END="0.9113612437859435" CI_START="0.5102042847571276" DF="1" EFFECT_SIZE="0.6818947217431541" ESTIMABLE="YES" I2="92.02806122448979" ID="CMP-001.03.04" LOG_CI_END="-0.040309444008767036" LOG_CI_START="-0.2922558984534671" LOG_EFFECT_SIZE="-0.16628267123111706" MODIFIED="2010-08-31 16:29:38 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="3.9748728106092646E-4" P_Z="0.009678145399320376" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.77253922416784" Z="2.587121518216387">
<NAME>Accelerated versus conventional</NAME>
<IV_DATA CI_END="0.5323738217059241" CI_START="0.1921285430372605" EFFECT_SIZE="0.31981902181630395" ESTIMABLE="YES" ESTIMATE="-1.14" LOG_CI_END="-0.2737833081338445" LOG_CI_START="-0.7164081106055696" LOG_EFFECT_SIZE="-0.49509570936970704" MODIFIED="2010-08-20 10:03:22 +0100" MODIFIED_BY="[Empty name]" ORDER="79" SE="0.26" STUDY_ID="STD-Skladowski-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.16630270863038"/>
<IV_DATA CI_END="1.3948592543123164" CI_START="0.688807445039324" EFFECT_SIZE="0.9801986733067553" ESTIMABLE="YES" ESTIMATE="-0.02" LOG_CI_END="0.14453038814060906" LOG_CI_START="-0.16190216741673907" LOG_EFFECT_SIZE="-0.008685889638065058" MODIFIED="2010-08-18 11:44:41 +0100" MODIFIED_BY="[Empty name]" ORDER="275" SE="0.18" STUDY_ID="STD-Weissberg-1983" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.606236515537461"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="8.026649553667834" CI_END="0.9627154958944812" CI_START="0.6909420826154912" DF="3" EFFECT_SIZE="0.8155860774311552" ESTIMABLE="YES" I2="62.6245050323752" ID="CMP-001.03.05" LOG_CI_END="-0.01650203771292772" LOG_CI_START="-0.16055835530986426" LOG_EFFECT_SIZE="-0.08853019651139597" MODIFIED="2010-08-31 16:29:38 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.04546425815539279" P_Z="0.015996199300682173" STUDIES="4" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="29.89229821596841" Z="2.4090022513567244">
<NAME>Accelerated/boost versus conventional</NAME>
<IV_DATA CI_END="2.6315916025191424" CI_START="0.780680865783749" EFFECT_SIZE="1.4333294145603404" ESTIMABLE="YES" ESTIMATE="0.36" LOG_CI_END="0.42021849188177596" LOG_CI_START="-0.10752646491143471" LOG_EFFECT_SIZE="0.15634601348517066" MODIFIED="2010-08-31 16:29:38 +0100" MODIFIED_BY="[Empty name]" ORDER="454" SE="0.31" STUDY_ID="STD-Ang-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.22728473572751"/>
<IV_DATA CI_END="1.0470706398770773" CI_START="0.7075150352498544" EFFECT_SIZE="0.8607079764250578" ESTIMABLE="YES" ESTIMATE="-0.15" LOG_CI_END="0.01997598203599783" LOG_CI_START="-0.15026432660697336" LOG_EFFECT_SIZE="-0.06514417228548777" MODIFIED="2010-08-17 16:25:04 +0100" MODIFIED_BY="[Empty name]" ORDER="80" SE="0.1" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="21.40420631034137"/>
<IV_DATA CI_END="0.8118760784229532" CI_START="0.3564389019826418" EFFECT_SIZE="0.5379444375946745" ESTIMABLE="YES" ESTIMATE="-0.62" LOG_CI_END="-0.09051025470489639" LOG_CI_START="-0.4480149028551359" LOG_EFFECT_SIZE="-0.26926257878001614" MODIFIED="2010-08-17 16:43:07 +0100" MODIFIED_BY="[Empty name]" ORDER="79" SE="0.21" STUDY_ID="STD-Ghoshal-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.853561521619359"/>
<IV_DATA CI_END="1.3289457436718481" CI_START="0.2881177713976399" EFFECT_SIZE="0.6187833918061408" ESTIMABLE="YES" ESTIMATE="-0.48" LOG_CI_END="0.12350725054023295" LOG_CI_START="-0.5404299531673546" LOG_EFFECT_SIZE="-0.2084613513135609" MODIFIED="2010-08-31 14:29:30 +0100" MODIFIED_BY="[Empty name]" ORDER="338" SE="0.39" STUDY_ID="STD-Sanguineti-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="1.407245648280169"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-11-05 17:25:42 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Summary analyses for altered fractionation versus conventional radiotherapy</NAME>
<IV_OUTCOME CHI2="34.33968680993961" CI_END="0.9777279615854997" CI_START="0.7647393114910582" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_SIZE="0.8647005309171788" ESTIMABLE="YES" I2="59.23084541368704" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.009781964452462384" LOG_CI_START="-0.11648658429149242" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.0631342743719774" MODIFIED="2010-10-29 17:04:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.001839221877154018" P_Q="1.0" P_Z="0.02037786999296386" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.03109185790457235" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="99.99999999999999" Z="2.3193167108568695">
<NAME>Total mortality</NAME>
<GROUP_LABEL_1>Altered fraction</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours altered fraction</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.4585964442014543" CI_START="0.8872835843569024" EFFECT_SIZE="1.4769807938826425" ESTIMABLE="YES" ESTIMATE="0.39" LOG_CI_END="0.3906872491781308" LOG_CI_START="-0.051937553293594334" LOG_EFFECT_SIZE="0.16937484794226818" MODIFIED="2010-10-29 16:53:11 +0100" MODIFIED_BY="[Empty name]" ORDER="611" SE="0.26" STUDY_ID="STD-Ang-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.980708030946296"/>
<IV_DATA CI_END="2.0692546605138062" CI_START="0.5902621757811527" EFFECT_SIZE="1.1051709180756477" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.3158139420190791" LOG_CI_START="-0.22895504563842872" LOG_EFFECT_SIZE="0.043429448190325216" MODIFIED="2010-10-29 17:04:29 +0100" MODIFIED_BY="[Empty name]" ORDER="618" SE="0.32" STUDY_ID="STD-Bartelink-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.9429770288355956"/>
<IV_DATA CI_END="1.0772321827790021" CI_START="0.6222614369971509" EFFECT_SIZE="0.8187307530779818" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.03230931966942949" LOG_CI_START="-0.20602711243073019" LOG_EFFECT_SIZE="-0.08685889638065038" MODIFIED="2010-10-07 11:54:49 +0100" MODIFIED_BY="Helen Worthington" ORDER="614" SE="0.14" STUDY_ID="STD-Bourhis-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="7.750031022522573"/>
<IV_DATA CI_END="1.2876173785643727" CI_START="0.6358494120286142" EFFECT_SIZE="0.9048374180359595" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.10978682958834891" LOG_CI_START="-0.1966457259689992" LOG_EFFECT_SIZE="-0.04342944819032521" MODIFIED="2010-09-01 16:05:51 +0100" MODIFIED_BY="[Empty name]" ORDER="615" SE="0.18" STUDY_ID="STD-Dobrowsky-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.187619709289526"/>
<IV_DATA CI_END="1.0263372520659664" CI_START="0.6935052988964894" EFFECT_SIZE="0.8436648165963837" ESTIMABLE="YES" ESTIMATE="-0.17" LOG_CI_END="0.011290092397932744" LOG_CI_START="-0.15895021624503847" LOG_EFFECT_SIZE="-0.0738300619235528" MODIFIED="2010-10-29 17:04:30 +0100" MODIFIED_BY="[Empty name]" ORDER="623" SE="0.1" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.560615931800623"/>
<IV_DATA CI_END="1.1118178722361156" CI_START="0.7512653216586237" EFFECT_SIZE="0.9139311852712282" ESTIMABLE="YES" ESTIMATE="-0.09" LOG_CI_END="0.04603365095019293" LOG_CI_START="-0.12420665769277828" LOG_EFFECT_SIZE="-0.039086503371292665" MODIFIED="2010-10-29 17:04:31 +0100" MODIFIED_BY="[Empty name]" ORDER="616" SE="0.1" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.560615931800623"/>
<IV_DATA CI_END="1.228748778592101" CI_START="0.8302765852558579" EFFECT_SIZE="1.010050167084168" ESTIMABLE="YES" ESTIMATE="0.01" LOG_CI_END="0.0894630991405181" LOG_CI_START="-0.08077720950245307" LOG_EFFECT_SIZE="0.004342944819032472" MODIFIED="2010-10-29 17:04:30 +0100" MODIFIED_BY="[Empty name]" ORDER="621" SE="0.1" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.560615931800623"/>
<IV_DATA CI_END="0.9657943826217257" CI_START="0.603387494129002" EFFECT_SIZE="0.7633794943368531" ESTIMABLE="YES" ESTIMATE="-0.27" LOG_CI_END="-0.015115324928095291" LOG_CI_START="-0.2194036952996607" LOG_EFFECT_SIZE="-0.117259510113878" MODIFIED="2010-10-29 17:04:31 +0100" MODIFIED_BY="[Empty name]" ORDER="620" SE="0.12" STUDY_ID="STD-Horiot-1992" TOTAL_1="0" TOTAL_2="0" WEIGHT="8.635907378719203"/>
<IV_DATA CI_END="1.21603557430296" CI_START="0.7900997795258206" EFFECT_SIZE="0.9801986733067553" ESTIMABLE="YES" ESTIMATE="-0.02" LOG_CI_END="0.08494628011556914" LOG_CI_START="-0.10231805939169916" LOG_EFFECT_SIZE="-0.008685889638065058" MODIFIED="2010-09-01 16:05:51 +0100" MODIFIED_BY="[Empty name]" ORDER="613" SE="0.11" STUDY_ID="STD-Horiot-1997" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.09577615803725"/>
<IV_DATA CI_END="1.25106426076189" CI_START="0.6948949487769496" EFFECT_SIZE="0.9323938199059483" ESTIMABLE="YES" ESTIMATE="-0.07" LOG_CI_END="0.09727961774900074" LOG_CI_START="-0.15808084521545596" LOG_EFFECT_SIZE="-0.030400613733227607" MODIFIED="2010-10-29 17:04:32 +0100" MODIFIED_BY="[Empty name]" ORDER="612" SE="0.15" STUDY_ID="STD-Marcial-1987" TOTAL_1="0" TOTAL_2="0" WEIGHT="7.330655937498736"/>
<IV_DATA CI_END="1.8075869823497992" CI_START="0.8253128132743858" EFFECT_SIZE="1.2214027581601699" ESTIMABLE="YES" ESTIMATE="0.2" LOG_CI_END="0.25709920502362155" LOG_CI_START="-0.08338141226232083" LOG_EFFECT_SIZE="0.08685889638065036" MODIFIED="2010-10-29 17:04:33 +0100" MODIFIED_BY="[Empty name]" ORDER="619" SE="0.2" STUDY_ID="STD-Olmi-2003" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.526138758071117"/>
<IV_DATA CI_END="0.8791428120905453" CI_START="0.37113400705303723" EFFECT_SIZE="0.5712090638488149" ESTIMABLE="YES" ESTIMATE="-0.56" LOG_CI_END="-0.05594057035855272" LOG_CI_START="-0.4304692493730894" LOG_EFFECT_SIZE="-0.24320490986582105" MODIFIED="2010-10-29 17:04:34 +0100" MODIFIED_BY="[Empty name]" ORDER="617" SE="0.22" STUDY_ID="STD-Pinto-1991" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.9421850451824"/>
<IV_DATA CI_END="1.098993716391085" CI_START="0.634831951871468" EFFECT_SIZE="0.835270211411272" ESTIMABLE="YES" ESTIMATE="-0.18" LOG_CI_END="0.040995209307494486" LOG_CI_START="-0.19734122279266514" LOG_EFFECT_SIZE="-0.07817300674258533" MODIFIED="2010-09-01 16:05:51 +0100" MODIFIED_BY="[Empty name]" ORDER="622" SE="0.14" STUDY_ID="STD-Poulsen-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="7.750031022522573"/>
<IV_DATA CI_END="1.2953616410594826" CI_START="0.43223324577332584" EFFECT_SIZE="0.7482635675785652" ESTIMABLE="YES" ESTIMATE="-0.29" LOG_CI_END="0.11239103234821667" LOG_CI_START="-0.3642818318521027" LOG_EFFECT_SIZE="-0.12594539975194308" MODIFIED="2010-10-29 17:04:35 +0100" MODIFIED_BY="[Empty name]" ORDER="625" SE="0.28" STUDY_ID="STD-Sanguineti-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.588061056486429"/>
<IV_DATA CI_END="0.46710085346034463" CI_START="0.1558611214004479" EFFECT_SIZE="0.26982005638468687" ESTIMABLE="YES" ESTIMATE="-1.31" LOG_CI_END="-0.3305893391931002" LOG_CI_START="-0.8072622033934196" LOG_EFFECT_SIZE="-0.5689257712932598" MODIFIED="2010-10-29 17:04:35 +0100" MODIFIED_BY="[Empty name]" ORDER="624" SE="0.28" STUDY_ID="STD-Skladowski-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.588061056486429"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="21.59392168870558" CI_END="0.8907776346694225" CI_START="0.6973323280681699" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_SIZE="0.7881421456660506" ESTIMABLE="YES" I2="44.42880652717916" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.05023069561374231" LOG_CI_START="-0.1565602005972193" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.10339544810548085" MODIFIED="2010-11-05 17:25:42 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.04233119066813973" P_Q="1.0" P_Z="1.3798000235585976E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.020915371931589627" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="99.99999999999999" Z="3.811761457623892">
<NAME>Locoregional control</NAME>
<GROUP_LABEL_1>Altered fraction</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours altered fraction</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.2179735767085242" CI_START="0.3474312500779454" EFFECT_SIZE="0.6505090947233165" ESTIMABLE="YES" ESTIMATE="-0.43" LOG_CI_END="0.08563786661035566" LOG_CI_START="-0.45913112104715215" LOG_EFFECT_SIZE="-0.1867466272183983" MODIFIED="2010-10-29 17:05:47 +0100" MODIFIED_BY="[Empty name]" ORDER="633" SE="0.32" STUDY_ID="STD-Bartelink-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.163483480494794"/>
<IV_DATA CI_END="0.8994197891101908" CI_START="0.4995764709177116" EFFECT_SIZE="0.6703200460356393" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="-0.04603756127907235" LOG_CI_START="-0.30139802424352913" LOG_EFFECT_SIZE="-0.1737177927613007" MODIFIED="2010-09-01 16:09:02 +0100" MODIFIED_BY="[Empty name]" ORDER="629" SE="0.15" STUDY_ID="STD-Bourhis-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="8.985438213252033"/>
<IV_DATA CI_END="1.2243292671983141" CI_START="0.5813553117058001" EFFECT_SIZE="0.8436648165963837" ESTIMABLE="YES" ESTIMATE="-0.17" LOG_CI_END="0.08789823128726985" LOG_CI_START="-0.23555835513437545" LOG_EFFECT_SIZE="-0.0738300619235528" MODIFIED="2010-09-01 16:09:02 +0100" MODIFIED_BY="[Empty name]" ORDER="631" SE="0.19" STUDY_ID="STD-Dobrowsky-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.842122199338229"/>
<IV_DATA CI_END="0.9853047233409978" CI_START="0.6155767300657942" EFFECT_SIZE="0.7788007830714049" ESTIMABLE="YES" ESTIMATE="-0.25" LOG_CI_END="-0.006429435290030267" LOG_CI_START="-0.21071780566159565" LOG_EFFECT_SIZE="-0.10857362047581295" MODIFIED="2010-10-29 17:05:47 +0100" MODIFIED_BY="[Empty name]" ORDER="641" SE="0.12" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="11.046355189245649"/>
<IV_DATA CI_END="1.1678864686049555" CI_START="0.7296460845069129" EFFECT_SIZE="0.9231163463866358" ESTIMABLE="YES" ESTIMATE="-0.08" LOG_CI_END="0.06740062663352261" LOG_CI_START="-0.13688774373804286" LOG_EFFECT_SIZE="-0.034743558552260155" MODIFIED="2010-10-29 17:05:48 +0100" MODIFIED_BY="[Empty name]" ORDER="637" SE="0.12" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="11.046355189245649"/>
<IV_DATA CI_END="0.9853047233409978" CI_START="0.6155767300657942" EFFECT_SIZE="0.7788007830714049" ESTIMABLE="YES" ESTIMATE="-0.25" LOG_CI_END="-0.006429435290030267" LOG_CI_START="-0.21071780566159565" LOG_EFFECT_SIZE="-0.10857362047581295" MODIFIED="2010-10-29 17:05:48 +0100" MODIFIED_BY="[Empty name]" ORDER="626" SE="0.12" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="11.046355189245649"/>
<IV_DATA CI_END="0.9084591082695554" CI_START="0.5045972979217537" EFFECT_SIZE="0.6770568744981647" ESTIMABLE="YES" ESTIMATE="-0.39" LOG_CI_END="-0.041694616460039836" LOG_CI_START="-0.2970550794244966" LOG_EFFECT_SIZE="-0.16937484794226823" MODIFIED="2010-10-29 17:05:49 +0100" MODIFIED_BY="[Empty name]" ORDER="627" SE="0.15" STUDY_ID="STD-Horiot-1992" TOTAL_1="0" TOTAL_2="0" WEIGHT="8.985438213252033"/>
<IV_DATA CI_END="0.9845160856195257" CI_START="0.5687041326633838" EFFECT_SIZE="0.7482635675785652" ESTIMABLE="YES" ESTIMATE="-0.29" LOG_CI_END="-0.0067771837018631665" LOG_CI_START="-0.24511361580202284" LOG_EFFECT_SIZE="-0.12594539975194308" MODIFIED="2010-09-01 16:09:14 +0100" MODIFIED_BY="[Empty name]" ORDER="634" SE="0.14" STUDY_ID="STD-Horiot-1997" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.628595848887947"/>
<IV_DATA CI_END="1.3412395685540437" CI_START="0.7163443889357706" EFFECT_SIZE="0.9801986733067553" ESTIMABLE="YES" ESTIMATE="-0.02" LOG_CI_END="0.12750635727631185" LOG_CI_START="-0.14487813655244206" LOG_EFFECT_SIZE="-0.008685889638065058" MODIFIED="2010-10-29 17:05:50 +0100" MODIFIED_BY="[Empty name]" ORDER="632" SE="0.16" STUDY_ID="STD-Marcial-1987" TOTAL_1="0" TOTAL_2="0" WEIGHT="8.38660696017622"/>
<IV_DATA CI_END="1.634917651054735" CI_START="0.7177798039153488" EFFECT_SIZE="1.0832870676749586" ESTIMABLE="YES" ESTIMATE="0.08" LOG_CI_END="0.21349588262737992" LOG_CI_START="-0.1440087655228596" LOG_EFFECT_SIZE="0.034743558552260176" MODIFIED="2010-10-29 17:05:50 +0100" MODIFIED_BY="[Empty name]" ORDER="636" SE="0.21" STUDY_ID="STD-Olmi-2003" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.000213955664701"/>
<IV_DATA CI_END="1.6752918595220854" CI_START="0.424863476006896" EFFECT_SIZE="0.8436648165963837" ESTIMABLE="YES" ESTIMATE="-0.17" LOG_CI_END="0.2240904782016467" LOG_CI_START="-0.3717506020487524" LOG_EFFECT_SIZE="-0.0738300619235528" MODIFIED="2010-10-29 17:05:51 +0100" MODIFIED_BY="[Empty name]" ORDER="628" SE="0.35" STUDY_ID="STD-Pinto-1991" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.7201138674502707"/>
<IV_DATA CI_END="1.25106426076189" CI_START="0.6948949487769496" EFFECT_SIZE="0.9323938199059483" ESTIMABLE="YES" ESTIMATE="-0.07" LOG_CI_END="0.09727961774900074" LOG_CI_START="-0.15808084521545596" LOG_EFFECT_SIZE="-0.030400613733227607" MODIFIED="2010-09-01 16:09:02 +0100" MODIFIED_BY="[Empty name]" ORDER="630" SE="0.15" STUDY_ID="STD-Poulsen-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="8.985438213252033"/>
<IV_DATA CI_END="0.4951911026554251" CI_START="0.14125500512744124" EFFECT_SIZE="0.26447726129982396" ESTIMABLE="YES" ESTIMATE="-1.33" LOG_CI_END="-0.3052271671025711" LOG_CI_START="-0.8499961547600788" LOG_EFFECT_SIZE="-0.5776116609313249" MODIFIED="2010-10-29 17:05:51 +0100" MODIFIED_BY="[Empty name]" ORDER="638" SE="0.32" STUDY_ID="STD-Skladowski-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.163483480494794"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="33.616881063110185" CI_END="1.0288777060358731" CI_START="0.6982078446420601" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_SIZE="0.8475673929143182" ESTIMABLE="YES" I2="73.22773643663142" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.012363756929461503" LOG_CI_START="-0.15601527602367288" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.07182575954710566" MODIFIED="2010-11-04 12:23:51 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0423810783444232E-4" P_Q="1.0" P_Z="0.09449848939108736" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.06288762068405476" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="99.99999999999999" Z="1.6721310178060447">
<NAME>Disease free survival</NAME>
<GROUP_LABEL_1>Altered fraction</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours altered fraction</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.6315916025191424" CI_START="0.780680865783749" EFFECT_SIZE="1.4333294145603404" ESTIMABLE="YES" ESTIMATE="0.36" LOG_CI_END="0.42021849188177596" LOG_CI_START="-0.10752646491143471" LOG_EFFECT_SIZE="0.15634601348517066" MODIFIED="2010-09-01 16:13:33 +0100" MODIFIED_BY="[Empty name]" ORDER="658" SE="0.31" STUDY_ID="STD-Ang-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.153014178954126"/>
<IV_DATA CI_END="1.1342780831209816" CI_START="0.7664418878717596" EFFECT_SIZE="0.9323938199059483" ESTIMABLE="YES" ESTIMATE="-0.07" LOG_CI_END="0.054719540588257974" LOG_CI_START="-0.11552076805471326" LOG_EFFECT_SIZE="-0.030400613733227607" MODIFIED="2010-10-29 17:20:36 +0100" MODIFIED_BY="[Empty name]" ORDER="654" SE="0.1" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.421388641393479"/>
<IV_DATA CI_END="1.0470706398770773" CI_START="0.7075150352498544" EFFECT_SIZE="0.8607079764250578" ESTIMABLE="YES" ESTIMATE="-0.15" LOG_CI_END="0.01997598203599783" LOG_CI_START="-0.15026432660697336" LOG_EFFECT_SIZE="-0.06514417228548777" MODIFIED="2010-10-29 17:20:35 +0100" MODIFIED_BY="[Empty name]" ORDER="660" SE="0.1" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.421388641393479"/>
<IV_DATA CI_END="1.068222869905267" CI_START="0.7218077870509788" EFFECT_SIZE="0.8780954309205613" ESTIMABLE="YES" ESTIMATE="-0.13" LOG_CI_END="0.028661871674062887" LOG_CI_START="-0.14157843696890832" LOG_EFFECT_SIZE="-0.05645828264742275" MODIFIED="2010-10-29 17:20:36 +0100" MODIFIED_BY="[Empty name]" ORDER="644" SE="0.1" STUDY_ID="STD-Fu-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.421388641393479"/>
<IV_DATA CI_END="0.8118760784229532" CI_START="0.3564389019826418" EFFECT_SIZE="0.5379444375946745" ESTIMABLE="YES" ESTIMATE="-0.62" LOG_CI_END="-0.09051025470489639" LOG_CI_START="-0.4480149028551359" LOG_EFFECT_SIZE="-0.26926257878001614" MODIFIED="2010-10-29 17:20:37 +0100" MODIFIED_BY="[Empty name]" ORDER="661" SE="0.21" STUDY_ID="STD-Ghoshal-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.14361005593394"/>
<IV_DATA CI_END="2.144257882982554" CI_START="1.0588744271627701" EFFECT_SIZE="1.5068177851128535" ESTIMABLE="YES" ESTIMATE="0.41" LOG_CI_END="0.33127701535900733" LOG_CI_START="0.024844459801659193" LOG_EFFECT_SIZE="0.17806073758033322" MODIFIED="2010-10-29 17:20:37 +0100" MODIFIED_BY="[Empty name]" ORDER="652" SE="0.18" STUDY_ID="STD-Olmi-2003" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.266318723507261"/>
<IV_DATA CI_END="1.1438445007895752" CI_START="0.6607399353094076" EFFECT_SIZE="0.8693582353988059" ESTIMABLE="YES" ESTIMATE="-0.14" LOG_CI_END="0.058366988583624595" LOG_CI_START="-0.17996944351653507" LOG_EFFECT_SIZE="-0.060801227466455235" MODIFIED="2010-09-01 16:13:07 +0100" MODIFIED_BY="[Empty name]" ORDER="649" SE="0.14" STUDY_ID="STD-Poulsen-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="11.859392672921041"/>
<IV_DATA CI_END="1.3289457436718481" CI_START="0.2881177713976399" EFFECT_SIZE="0.6187833918061408" ESTIMABLE="YES" ESTIMATE="-0.48" LOG_CI_END="0.12350725054023295" LOG_CI_START="-0.5404299531673546" LOG_EFFECT_SIZE="-0.2084613513135609" MODIFIED="2010-10-29 17:20:38 +0100" MODIFIED_BY="[Empty name]" ORDER="659" SE="0.39" STUDY_ID="STD-Sanguineti-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.550276342584428"/>
<IV_DATA CI_END="0.5323738217059241" CI_START="0.1921285430372605" EFFECT_SIZE="0.31981902181630395" ESTIMABLE="YES" ESTIMATE="-1.14" LOG_CI_END="-0.2737833081338445" LOG_CI_START="-0.7164081106055696" LOG_EFFECT_SIZE="-0.49509570936970704" MODIFIED="2010-10-29 17:20:38 +0100" MODIFIED_BY="[Empty name]" ORDER="656" SE="0.26" STUDY_ID="STD-Skladowski-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="7.496903378411504"/>
<IV_DATA CI_END="1.3948592543123164" CI_START="0.688807445039324" EFFECT_SIZE="0.9801986733067553" ESTIMABLE="YES" ESTIMATE="-0.02" LOG_CI_END="0.14453038814060906" LOG_CI_START="-0.16190216741673907" LOG_EFFECT_SIZE="-0.008685889638065058" MODIFIED="2010-10-29 17:20:39 +0100" MODIFIED_BY="[Empty name]" ORDER="657" SE="0.18" STUDY_ID="STD-Weissberg-1983" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.266318723507261"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-11-04 12:18:30 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Neutron therapy</NAME>
<IV_OUTCOME CHI2="0.3353559589821339" CI_END="1.2744014804595052" CI_START="0.961650034505302" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="1.107035784271444" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.10530626730894163" LOG_CI_START="-0.0169829484775141" LOG_DATA="YES" LOG_EFFECT_SIZE="0.044161659415713775" MODIFIED="2010-09-09 14:41:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9532474288037469" P_Q="0.9048745514261245" P_Z="0.15689765800021063" Q="0.014281665329121673" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.4155829096732124">
<NAME>Total mortality</NAME>
<GROUP_LABEL_1>Neutron</GROUP_LABEL_1>
<GROUP_LABEL_2>Photon</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours neutron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours photon</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="1.357977415720963" CI_START="0.9175975359839302" DF="0" EFFECT_SIZE="1.1162780704588713" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.1328925473308433" LOG_CI_START="-0.03734776131212788" LOG_EFFECT_SIZE="0.04777239300935769" MODIFIED="2010-08-18 09:44:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.27133213922522215" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="51.6002165197828" Z="1.0999999999999999">
<NAME>Mixed beam (neutron/photon) versus photon</NAME>
<IV_DATA CI_END="1.357977415720963" CI_START="0.9175975359839302" EFFECT_SIZE="1.1162780704588713" ESTIMABLE="YES" ESTIMATE="0.11" LOG_CI_END="0.1328925473308433" LOG_CI_START="-0.03734776131212788" LOG_EFFECT_SIZE="0.04777239300935769" MODIFIED="2010-08-18 09:44:24 +0100" MODIFIED_BY="[Empty name]" ORDER="172" SE="0.1" STUDY_ID="STD-Griffin-1989" TOTAL_1="0" TOTAL_2="0" WEIGHT="51.6002165197828"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.3210742936530122" CI_END="1.3433882864980575" CI_START="0.8962368061734971" DF="2" EFFECT_SIZE="1.0972666163434965" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.12820155720412432" LOG_CI_START="-0.047577224683386904" LOG_EFFECT_SIZE="0.04031216626036871" MODIFIED="2010-09-09 14:41:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8516862062680782" P_Z="0.36866581258067044" STUDIES="3" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="48.399783480217195" Z="0.8989753275190593">
<NAME>Neutron versus photon</NAME>
<IV_DATA CI_END="2.350871978763452" CI_START="0.5300487401456933" EFFECT_SIZE="1.1162780704588713" ESTIMABLE="YES" ESTIMATE="0.11" LOG_CI_END="0.37122897943100297" LOG_CI_START="-0.27568419341228756" LOG_EFFECT_SIZE="0.04777239300935769" MODIFIED="2010-09-01 14:37:17 +0100" MODIFIED_BY="[Empty name]" ORDER="176" SE="0.38" STUDY_ID="STD-Griffin-1984" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.573422196660859"/>
<IV_DATA CI_END="1.7374059318740906" CI_START="0.8249824570440187" EFFECT_SIZE="1.1972173631218102" ESTIMABLE="YES" ESTIMATE="0.18" LOG_CI_END="0.23990129995340798" LOG_CI_START="-0.08355528646823732" LOG_EFFECT_SIZE="0.07817300674258533" MODIFIED="2010-09-01 14:36:01 +0100" MODIFIED_BY="[Empty name]" ORDER="175" SE="0.19" STUDY_ID="STD-Maor-1986" TOTAL_1="0" TOTAL_2="0" WEIGHT="14.293688786643436"/>
<IV_DATA CI_END="1.3563473546898503" CI_START="0.8148140771272872" EFFECT_SIZE="1.0512710963760241" ESTIMABLE="YES" ESTIMATE="0.05" LOG_CI_END="0.13237092471309383" LOG_CI_START="-0.08894147652276865" LOG_EFFECT_SIZE="0.021714724095162622" MODIFIED="2010-09-01 14:35:53 +0100" MODIFIED_BY="[Empty name]" ORDER="174" SE="0.13" STUDY_ID="STD-Maor-1995" TOTAL_1="0" TOTAL_2="0" WEIGHT="30.532672496912898"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-11-10 12:43:45 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-11-10 12:43:45 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATEAAARuCAIAAAA055e6AAA6zElEQVR42u2dv25US/a2WyIhcEDA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-11-05 17:10:38 +0000" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-002.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: Summary analyses for altered fractionation versus conventional radiotherapy, outcome: Total mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAs0AAAFgCAMAAAB3+7QeAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-11-05 17:25:43 +0000" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-002.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: Summary analyses for altered fractionation versus conventional radiotherapy, outcome: Locoregional control.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAs0AAAFACAMAAABwV7EoAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2010-11-05 17:11:15 +0000" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-002.03" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: Summary analyses for altered fractionation versus conventional radiotherapy, outcome: Disease free survival.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAs0AAAEQCAMAAAB82bnfAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-11-05 17:21:54 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-11-05 17:20:48 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-11-05 17:12:20 +0000" MODIFIED_BY="[Empty name]">Search strategy for MEDLINE via OVID</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-05 17:20:48 +0000" MODIFIED_BY="[Empty name]">
<P>1.         "Head and Neck Neoplasms"/                              <BR/>2.         "Mouth Neoplasms"/                                  <BR/>3.         "Gingival Neoplasms"/                               <BR/>4.         "Palatal Neoplasms"/                                 <BR/>5.         "Tongue Neoplasms"/                                <BR/>6.         ((cancer$ or tumour$ or tumor$ or neoplas$ or malignan$ or carcinoma$ or metatasta$) adj5 (oral$ or intra-oral$ or intraoral$ or "intra oral$" or gingiva$ or oropharyn$ or mouth$ or tongue$ or cheek$ or gum$ or palatal$ or palate$ or "head and neck")).mp.               <BR/>7.         or/1-6                         <BR/>8.         exp Radiotherapy/                          <BR/>9.         (radiotherap$ or chemotherap$ or chemoradiotherap$ or chemo-radiotherap$ or "radiation therap$" or bracytherap$ or irradiat$).ti,ab.<BR/>10.       (adjuvant or neo-adjuvant or "neo adjuvant").ti,ab.                              <BR/>11.       (hyperfractionate$ or hyper-fractionate$).mp.                          <BR/>12.       exp Surgical Procedures, Operative/                               <BR/>13.       (dissect$ adj2 neck$).ti,ab.                                    <BR/>14.       (excision or excise or resect$).ti,ab.                                 <BR/>15.       Lymph Node Excision/                              <BR/>16.       (lymphadenectom$ or glossectom$).ti,ab.                                 <BR/>17.       exp Antineoplastic agents/                                    <BR/>18.       (antineoplast$ or antitumor$ or anti-tumor$ or anti-neoplast$ or antitumour$ or anti-tumour$).mp.  <BR/>19.       Antineoplastic combined chemotherapy protocols/                             <BR/>20.       exp Combined Modality Therapy/                                    <BR/>21.       or/8-20                                   <BR/>22.       7 and 21</P>
<P>The above subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in MEDLINE: sensitivity maximising version (2009 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of the<I> Cochrane Handbook for Systematic Reviews of Interventions, v</I>ersion 5.0.2 (updated September 2009):</P>
<P>1. randomized controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomized.ab.<BR/>4. placebo.ab.<BR/>5. drug therapy.fs.<BR/>6. randomly.ab.<BR/>7. trial.ab.<BR/>8. groups.ab.<BR/>9. or/1-8<BR/>10. exp animals/ not humans.sh.<BR/>11. 9 not 10</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-11-05 17:20:59 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-11-05 17:20:59 +0000" MODIFIED_BY="[Empty name]">Cochrane Oral Health Group's Trials Register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-08-16 10:23:47 +0100" MODIFIED_BY="Anne Littlewood">
<P>((mouth or oral or intraoral or intra-oral or gingiva* or oropharyn* or cheek* or gum* or palat* or lip or tongue or &#8220;head and neck&#8221;) AND (tumour* or tumor* or cancer* or carcinoma* or neoplas* or malignan*))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-11-05 17:21:17 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-11-05 17:21:17 +0000" MODIFIED_BY="[Empty name]">Cochrane Central Register of Controlled Trials (CENTRAL) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-04 13:08:07 +0000" MODIFIED_BY="Anne Littlewood">
<P>#1        MeSH descriptor Head and Neck Neoplasms this term only  <BR/>#2        MeSH descriptor Mouth neoplasms this term only       <BR/>#3        MeSH descriptor Gingival Neoplasms this term only<BR/>#4        MeSH descriptor Palatal neoplasms this term only<BR/>#5        MeSH descriptor Tongue neoplasms this term only    <BR/>#6        ((cancer* near/5 oral*) or (cancer* near/5 intra-oral*) or (cancer* near/5 intraoral*) or (cancer* near/5 &#8220;intra) and oral&#8221;*) or (cancer* near/5 gingiva*) or (cancer* near/5 oropharyn*) or (cancer* near/5 mouth*) or (cancer* near/5 tongue*) or (cancer* near/5 cheek*) or (cancer* near/5 gum*) or (cancer* near/5 palatal*) or (cancer* near/5 palate*) or (cancer* near/5 "head and neck"))<BR/>#7        ((tumour* near/5 oral*) or (tumour* near/5 intra-oral*) or (tumour* near/5 intraoral*) or (tumour* near/5 &#8220;intra) and oral&#8221;*) or (tumour* near/5 gingiva*) or (tumour* near/5 oropharyn*) or (tumour* near/5 mouth*) or (tumour* near/5 tongue*) or (tumour* near/5 cheek*) or (tumour* near/5 gum*) or (tumour* near/5 palatal*) or (tumour* near/5 palate*) or (tumour* near/5 "head and neck"))<BR/>#8        ((tumor* near/5 oral*) or (tumor* near/5 intra-oral*) or (tumor* near/5 intraoral*) or (tumor* near/5 &#8220;intra) and oral&#8221;*) or (tumor* near/5 gingiva*) or (tumor* near/5 oropharyn*) or (tumor* near/5 mouth*) or (tumor* near/5 tongue*) or (tumor* near/5 cheek*) or (tumor* near/5 gum*) or (tumor* near/5 palatal*) or (tumor* near/5 palate*) or (tumor* near/5 "head and neck"))<BR/>#9        ((neoplas* near/5 oral*) or (neoplas*  near/5 intra-oral*) or (neoplas* near/5 intraoral*) or (neoplas* near/5 &#8220;intra) and oral&#8221;*) or (neoplas* near/5 gingiva*) or (neoplas* near/5 oropharyn*) or (neoplas* near/5 mouth*) or (neoplas* near/5 tongue*) or (neoplas* near/5 cheek*) or (neoplas* near/5 gum*) or (neoplas* near/5 palatal*) or (neoplas* near/5 palate*) or (neoplas* near/5 "head and neck"))<BR/>#10     ((malignan* near/5 oral*) or (malignan*  near/5 intra-oral*) or (malignan* near/5 intraoral*) or (malignan* near/5 &#8220;intra) and oral&#8221;*) or (malignan* near/5 gingiva*) or (malignan* near/5 oropharyn*) or (malignan* near/5 mouth*) or (malignan* near/5 tongue*) or (malignan* near/5 cheek*) or (malignan* near/5 gum*) or (malignan* near/5 palatal*) or (malignan* near/5 palate*) or (malignan* near/5 "head and neck"))<BR/>#11     ((carcinoma* near/5 oral*) or (carcinoma*  near/5 intra-oral*) or (carcinoma* near/5 intraoral*) or (carcinoma* near/5 &#8220;intra) and oral&#8221;*) or (carcinoma* near/5 gingiva*) or (carcinoma* near/5 oropharyn*) or (carcinoma* near/5 mouth*) or (carcinoma* near/5 tongue*) or (carcinoma* near/5 cheek*) or (carcinoma* near/5 gum*) or (carcinoma* near/5 palatal*) or (carcinoma* near/5 palate*) or (carcinoma* near/5 "head and neck"))<BR/>#12     ((metatasta* near/5 oral*) or (metatasta* near/5 intra-oral*) or (metatasta* near/5 intraoral*) or (metatasta* near/5 &#8220;intra) and oral&#8221;*) or (metatasta* near/5 gingiva*) or (metatasta* near/5 oropharyn*) or (metatasta* near/5 mouth*) or (metatasta* near/5 tongue*) or (metatasta* near/5 cheek*) or (metatasta* near/5 gum*) or (metatasta* near/5 palatal*) or (metatasta* near/5 palate*) or (metatasta* near/5 "head and neck"))<BR/>#13     (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12)<BR/>#14     MeSH descriptor Radiotherapy explode all trees          <BR/>#15     (radiotherap* or chemotherap* or chemoradiotherap* or chemo-radiotherap* or "radiation therap*" or bracytherap* or irradiat*)<BR/>#16     (adjuvant or neo-adjuvant or "neo adjuvant&#8221;)<BR/>#17     (hyperfractionate* or hyper-fractionate*)<BR/>#18     MeSH descriptor Surgical Procedures, Operative explode all trees<BR/>#19     (dissect* near/2 neck*)<BR/>#20     (excision or excise* or resect*)<BR/>#21     MeSH descriptor Lymph node excision this term only                        <BR/>#22     (lymphadenectom* or glossectom*)<BR/>#23     MeSH descriptor Antineoplastic agents explode all trees       <BR/>#24     (antineoplast* or antitumor* or anti-tumor* or anti-neoplast* or antitumour* or anti-tumour*)<BR/>#25     MeSH descriptor antineoplastic combined chemotherapy protocols this term only<BR/>#26     MeSH descriptor combined modality therapy explode all trees<BR/>#27     (#14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26)<BR/>#28     (#13 and #27)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2010-11-05 17:21:54 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-08-16 10:27:55 +0100" MODIFIED_BY="Anne Littlewood">EMBASE via OVID search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-05 17:21:54 +0000" MODIFIED_BY="[Empty name]">
<P>1.         "Head and Neck Neoplasms"/                              <BR/>2.         "Mouth Neoplasms"/                                  <BR/>3.         "Gingival Neoplasms"/                               <BR/>4.         "Palatal Neoplasms"/                                 <BR/>5.         "Tongue Neoplasms"/                                <BR/>6.         ((cancer$ or tumour$ or tumor$ or neoplas$ or malignan$ or carcinoma$ or metatasta$) adj5 (oral$ or intra-oral$ or intraoral$ or "intra oral$" or gingiva$ or oropharyn$ or mouth$ or tongue$ or cheek$ or gum$ or palatal$ or palate$ or "head and neck")).mp.               <BR/>7.         or/1-6                         <BR/>8.         exp Radiotherapy/                          <BR/>9.         (radiotherap$ or chemotherap$ or chemoradiotherap$ or chemo-radiotherap$ or "radiation therap$" or bracytherap$ or irradiat$).ti,ab.<BR/>10.       (adjuvant or neo-adjuvant or "neo adjuvant").ti,ab.                              <BR/>11.       (hyperfractionate$ or hyper-fractionate$).mp.                   <BR/>12.       exp Surgical Procedures, Operative/                               <BR/>13.       (dissect$ adj2 neck$).ti,ab.                                    <BR/>14.       (excision or excise or resect$).ti,ab.                                 <BR/>15.       Lymph Node Excision/                              <BR/>16.       (lymphadenectom$ or glossectom$).ti,ab.                                 <BR/>17.       exp Antineoplastic agents/                                    <BR/>18.       (antineoplast$ or antitumor$ or anti-tumor$ or anti-neoplast$).mp.  <BR/>19.       Antineoplastic combined chemotherapy protocols/                             <BR/>20.       exp Combined Modality Therapy/                                    <BR/>21.       or/8-20                                   <BR/>22.       7 and 21</P>
<P>The above subject search was linked to the Cochrane Oral Health Group filter for EMBASE via OVID:</P>
<P>1. random$.ti,ab.<BR/>2. factorial$.ti,ab.<BR/>3. (crossover$ or cross over$ or cross-over$).ti,ab.<BR/>4. placebo$.ti,ab.<BR/>5. (doubl$ adj blind$).ti,ab.<BR/>6. (singl$ adj blind$).ti,ab.<BR/>7. assign$.ti,ab.<BR/>8. allocat$.ti,ab.<BR/>9. volunteer$.ti,ab.<BR/>10. CROSSOVER PROCEDURE.sh.<BR/>11. DOUBLE-BLIND PROCEDURE.sh.<BR/>12. RANDOMIZED CONTROLLED TRIAL.sh.<BR/>13. SINGLE BLIND PROCEDURE.sh.<BR/>14. or/1-13<BR/>15. ANIMAL/ or NONHUMAN/ or ANIMAL EXPERIMENT/<BR/>16. HUMAN/<BR/>17. 16 and 15<BR/>18. 15 not 17<BR/>19. 14 not 18</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>